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Abstract
Vaccinia virus (VACV) produces two morphologically distinct mature 
virions: enveloped virus (EV) and intracellular mature virus (IMV). EV is 
produced first in the replication cycle and is required for virus dissemination. 
IMV is thought to be produced by default, when the cellular membranes that 
wrap EV become exhausted and as the more robust particle, is involved in host- 
to-host transmission.
The aim of this study was to examine the hypothesis that IMV production 
is not a default, but is an active process mediated by the IMV-specific protein, 
A26. Two recombinant VACVs were constructed: vldA26L and vldA26L.neo, in 
which the A26L gene was deleted or inactivated. One-step growth curves 
demonstrated a reduction in virus yields for these viruses. Examination of the 
kinetics of EV and IMV production by the A26L deletion mutants did not 
demonstrate a reduction in IMV as expected, yet the production of single- 
membraned virus was perturbed when compared to wild-type VACV IHD-J and 
a revertant virus. Constitutive expression of A26 from a synthetic early/late 
promoter did not affect virus yields and did not result in increased production of 
IMV in favour of EV.
Treatment of virions with membrane perturbing agents demonstrated 
increased susceptibility of EV to inactivation when compared to IMV, suggesting 
that the EV pre-cursor and mature IMV are different particles. Mutant IMV from 
A26L' VACV cultures demonstrated increased sensitivity to the detergent 
Tween-20 when compared to wild-type IMV, behaving similarly to stripped EV. 
This suggests resistance might be attributable to the presence of IMV-specific 
proteins that are not found on stripped EV.
This study provides evidence that IMV is a true end-stage product of 
VACV morphogenesis, and that OPVs employ a mechanism to actively 
differentiate particles towards IMV, thus preventing maturation of a subset of 
virions as EV. This results in two non-interchangeable isoforms of mature 
infectious virions that are produced to perform their individual functions in the 
virus life-cycle.
© Crown Copyright 2010.
Declaration
Unless stated otherwise, the results and data presented in this thesis is 
soley the work of Rachel Dean. This work has not been submitted anywhere else 
for a higher degree. Where other sources of information have been used they 
have been acknowledged. The recombination cassettes for the vldA26L.rev, 
vldA26L.neo and vldA26L.EL were constructed by GeneArt AG (Germany). Virus 
preparations were embedded and sectioned for transmission electron 
microscopy by Dr Simon Smith. Dr Tom Laws and Dr David Ulaeto assisted with 
statistical analyses. Polyclonal sera were kindly provided by Dr David Ulaeto, Dr 
Amanda Gates and Amanda Phelps.
Acknowledgements
I would like to thank Dr David Ulaeto for his guidance, continued patience 
and support throughout this epic journey, even when I felt there was no way that I 
could complete this, and for finding the time to help in the lab and review this 
thesis. I would also like to thank Dr Amanda Gates and Dr Diane Williamson for 
their guidance and support, and much appreciated review and proof reading of 
this thesis!
There are several people that I would also like to thank who have helped 
throughout this project: Dr Tom Laws for statistical advice, Dr Amanda Gates, 
Amanda Phelps for the mouse sera and help with virus titrations, Lin Eastaugh 
for help with tissue culture. I would also like to thank Dr Michelle Nelson, Dr 
Matthew Jackson and Dr Tim Milne for giving up their time to buddy me in the lab 
at the weekends.
To all my friends in Salisbury -  a massive thank you. I know you must all 
feel like this has taken me years -  and it has! But thank you so much for keeping 
me going, taking me out for drinks and cheering me up when it was much 
needed!
Finally, thank you to Phil and my parents for believing in me -  I would not 
have been able to do this without your support and encouragement through the 
dark times!
Publications
Data in this thesis has been presented as follows:
1. Rachel Dean and David Ulaeto. The Effect of Disruption of the Vaccinia Virus 
A26L Gene on Maturation of IMV Particles. Poster presented at the XVth 
International Poxvirus and Iridovirus conference, Oxford, 2004.
2. Rachel Dean and David Ulaeto. The Effect of Disruption of the Vaccinia Virus 
A26L Gene on Maturation of IMV Particles. Poster presented at International Union 
of Microbiological Societies conference, San Francisco, 2005.
3. Rachel Dean and David Ulaeto. The Effect of Disruption of the Vaccinia Virus 
A26L Gene on Maturation of IMV Particles. Poster presented at the Society for 
General Microbiology conference, Edinburgh, 2005.
4. Rachel Dean and David Ulaeto. The Effect of Disruption of the Vaccinia Virus 
A26L Gene on Maturation of IMV Particles. Poster presented at the XVIIth 
International Poxvirus and Iridovirus Conference, Grainau, Germany, 2008.
Contents
Abstract........................................................ .......................................................... i
Declaration............................ .................................................................................ii
Acknowledgements....................................................... ....................................... iii
Publications........................................................................................................... iv
Contents................ ..............................................................................................v
List of Figures................................ ....................................................................... xi
List of Tables......................................................................................................... xv
Abbreviations.............................................................. .......................................... xvi
1 Introduction........................................................................................ 1
1.1 Smallpox, a Historical Disease............................................................1
1.1.1 Smallpox, the Disease.........................................................................2
1.1.2 Clinical Manifestation of Disease........................................................ 2
1.1.3 Infectivity and Transmission.................................................................3
1.2 Poxvirus B io logy.................................................................................4
1.2.1 Taxonomy.............................................................................................4
1.2.2 Vaccinia Virus (VACV).........................................................................5
1.2.2.1 The Structure of VACV.....................................................................5
1.2.2.2 Chemical Composition.................................................................... 7
1.2.2.3 The VACV Genome..........................................................................7
1.2.2.4 VACV Gene Transcription.................................................................8
1.2.2.4.1 Early Phase.............................................................. ;....................9
1.2.2.4.2 Intermediate Phase........................................................................ 10
1.2.2.4.3 Late Phase......................................................................................11
1.2.2.5 VACV DNA Replication..................................................................... 13
1.2.2.6 VACV Replicative Cycle....................................................................15
1.2.2.6.1 VACV Entry into Host Cells............................................................16
1.2.2.6.2 VACV Morphogenesis....................................................................17
1.2.2.6.3 EV-specific Proteins.......................................................................23
1.2.2.6.4 IMV-specific Proteins.....................................................................26
1.2.2.5.5 Host-Derived Proteins....................................................................29
1.2.2.6.6 Immunomodulatory Proteins........................................................ 30
V
1.3 Prevention and Treatment of Poxvirus Infections......................... 31
1.3.1 Vaccines.............................................................................................. 31
1.3.1.1 Live Vaccines...............................  31
1.3.1.2 Complications of Live Smallpox Vaccines....................................   32
1.3.1.3 Next Generation Smallpox Vaccines.........................................  33
1.3.1.4 Attenuated, Replication Competent Vaccines................................. 33
1.3.1.5 Attenuated, Replication-Defective Vaccines................................... 34
1.3.1.6 Sub-unit Vaccines ........................................................... 35
1.3.2 Antiviral Therapies.............................................................................36
1.5 Aims of Project................................................................................... 38
2 Materials and Methods......................................................................39
2.1 Materials.................................................................................................39
2.1.1 Oligonucleotide Primers...................................................................... 39
2.1.2 Plasmid DNA.....................................  39
2.1.3 General Reagents................................................................................39
2.2 Microbiological Methods....................................................................39
2.2.1 Preparation of Culture Media.............................................................. 39
2.2.2 Media Supplements.............................................................................40
2.2.3 Maintenance of E.coli Strains............................................................. 40
2.3 DNA Manipulation and Cloning................................ 41
2.3.1 Agarose Gel Electrophoresis.............................................................. 41
2.3.2 Digestion of DNA.................................................................................41
2.3.3 Polymerase Chain Reaction (PCR)....................................................42
2.3.4 Purification of DNA...............................................................................42
2.3.5 Polishing of PCR Products.................................................................. 46
2.3.6 Estimation of Concentration of DNA...........................  46
2.3.7 Ligation of DNA...................................................  47
2.3.8 Transformation of Recombinant Plasmids into E. co li.......................49
2.3.9 Plasmid Minipreparation .................................................................... 49
2.3.10 Digestion of DNA Fragments with S1 Nuclease............................... 50
2.3.11 Sequencing of DNA............................................................... 51
2.4 Cell Culture............................................................................................ 51
2.4.1 Maintenance of Mammalian Cell Lines...............................................51
2.4.2Transfection of Mammalian Cell Lines.................................................53
2.5 Manipulation of VACV..........................................................................54
2.5.1 Infection of Mammalian Cells with VACV............................................54
2.5.2 Purification of VACV....................  54
vi
2.5.3 Quantification of Virus by Plaque Titration..........................................55
2.5.4 Quantification of Virus by Metabolic Labelling....................................58
2.5.5 Extraction of Viral DNA........................................................................59
2.5.6 Inhibition of EEV Production in Recombinant VACV Cultures...........61
2.5.7 Effect of Antimicrobial Peptides (AMPs) on VACV Particles..............61
2.5.8 Preparation of Virus for Transmission Electron Microscopy (TEM)... 63
2.6. Generation of Recombinant VACV................................................... 64
2.6.1 Selection of Recombinant VACV....................................................... 64
2.6.2 Plaque purification of Recombinant VACV.........................................65
2.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 67
2.7.1 Isolation of Messenger Ribonucleic Acid (mRNA)............................. 67
2.7.2 Removal of Genomic DNA from Extracted RNA................................ 68
2.7.3 Quantification of RNA..........................................................................69
2.7.4 One-step Real-Time PCR....................................................................70
2.8 Protein Techniques.............................................................................. 71
2.8.1 SDS-PAGE..........................................................................................71
2.8.2 Western blot Analysis.........................................................................71
2.9 Statistical Analyses............................................................................. 72
3 Construction of an A26L gene deletion mutant Vaccinia Virus .78
3.1 Introduction...........................................................................................74
3.1.1 Aims of This Study.............................................................................. 75
3.2 Results..................................................................................................76
3.2.1 Design of the A26L Gene Deletion Cassette......................................76
3.2.2 Construction of the Deletion Cassette by PCR.................................. 76
3.2.3 Cloning of the Deletion Cassette into pCAPs Plasmid Vector   80
3.2.4 Construction of an A26L Deletion VACV by Homologous 
Recombination........................................................................................84
3.2.5 Selection of Recombinant Virus for Mycophenolic Acid (MPA) 
Resistance.............................................................................................84
3.2.6 Genotypic Analysis of Recombinant Virus..........................................85
3.2.7 Plaque Purification of Recombinant Virus...........................................87
3.2.8 Propagation of vldA26L......................................................................91
3.2.9 Characterisation of vldA26L................................................................91
3.2.9.1 Comparative Growth Kinetics of vldA26L and VACV IHD-J in
vitro......................................................................................................... 91
3.2.9.2 Analysis of IMV and EV Produced in vitro by Plaque Titration 94
3.2.9.3 Analysis of IMV and EV Produced in vitro by Radioactive
Labelling of Virions in Lipid-Enriched Cultures.....................................105
3.2.9.4 Production of EEV in Brefeldin A-treated Cultures......................... 114
3.3 Discussion 115
4 Construction of Secondary Recombinant VACV using 
Reverse Guanine Phosphoribosyl Transferase (GPT)
Selection............................................................................................. 122
4.1 Introduction............................................................................................122
4.1.1 Aims of This Study............................................................................... 127
4.2 Results....................................................................................................128
4.2.1 Design and Construction of VACV Secondary Recombination 
Cassettes................................................................................................128
4.2.1.1 Null Recombination Cassette........................................................... 128
4.2.1.2 Revertant Recombination Cassette................................................. 129
4.2.1.3 Early/late Recombination Cassette................................................. 129
4.2.1.4 Early, Late and F13L Recombination Cassettes............................. 131
4.2.2 Construction and Selection of Secondary Recombinant EcoGPT- 
negative VACV by Homologous Recombination....................................132
4.2.2.1 Isolation of Secondary Recombinant VACV.....................................133
4.2.2.2 Screening of Secondary Recombinant VACV DNA by PCR 133
4.2.3 Repeat Plaque Purification of vldA26L1.1.1.1.1................................ 137
4.2.3.1 MPA Inhibits Replication of wt VACV IHD-J.....................................137
4.2.3.2 Culture of New Clones Derived from vldA26L1.1.1.1.1. in MPA
and 6-TG...........................................................................................  143
4.3 Discussion..............................................................................................149
5 Generation of Secondary Recombinant Viruses using a 
Positive Selection Method: neomycin resistance......................... 154
5.1 Introduction............................................................................................154
5.1.1 Aims of This Study............................................................................... 155
5.2 Results.................................................................................................. 156
5.2.1 Design of Recombination Cassettes................................................... 156
5.2.2 Construction of Recombination Cassettes ............................... 159
5.2.3 Construction and Selection of Recombinant Viruses......................... 160
5.2.4 Plaque Purification of the Revertant VACV.........................................161
5.2.5 Plaque Purification of the Secondary A26L mutant............................ 161
5.2.6 Plaque Purification of vldA26L.EL...................................................... 167
5.2.6.1 Growth of Putative vldA26L.EL in Different Cell Lines to
Increase Virus Replication ...........................................................................167
5.2.7 Plaque Purification of vldA26L.EL from a Repeat Transfection 168
5.2.8 Confirming the Isolation of Recombinant VACVs............................... 170
5.3 Discussion 173
6 Characterisation of Secondary Recombinant VACVs.................... 177
6.1 Introduction................................................  177
6.1.1 Aims of This Study................................................................................178
6.2 Results...................................................................................................178
6.2.1 Comparative Growth Kinetics of Recombinant VACVs...................... 178
6.2.2 Effect of Deletion of A26L on Maturation of IMV and EV ................... 182
6.2.2.1 Comet Formation..........................................  182
6.2.2.2 Kinetics of IMV and EV Production in BSC40 cells....................182
6.2.2.3 Kinetics of IMV and EV Production in RK13 cells (I)..................187
6.2.2.4 Kinetics of IMV and EV Production in RK13 cells (II) .... 197
6.2.2.5 Examination of the Kinetics of IMV and EV Production in
RK13 cells of Varying Passage History.................................................205
6.2.3 Effect of Overexpression of A26L on Maturation of IMV and E V  209
6.2.3.1 Kinetics in BSC40 cells.....................................................................213
6.2.3.2 Kinetics in RK13 cells (I)...................................................................216
6.2.3.3 Kinetics in RK13 cells (II)..................................................................216
6.2.4 Quantification of IMV Produced in VACV Cultures when A26L
was Modified............................................................................................221
6.2.5 Transmission Electron Microscopy (TEM)........................................ 223
6.2.6 Expression Kinetics in VACV Cultures................................................223
6.2.6.1 Expression of A26L in vldA26L.EL Cultures................................... 228
6.2.6.2 Expression Kinetics of the A26L, A27L and F13L Genes in 
Recombinant VACV Cultures Throughout Infection in RK13 cells 229
6.3 Discussion..............................................................................................234
7 E ffe c t o f  A n tim ic ro b ia l P ep tide s  on  V A C V ......................................... 246
7.1 Introduction............................................................................................246
7.1.1 Aims of This Study............................................................................... 249
7.2 Results....................................................................................................249
7.2.2 Effect of AMPs on EEV Membrane..................................................... 249
7.2.3 Effect of Detergent on the EEV Membrane.........................................250
7.2.4 Effect of Detergent on the IMV Membrane..........................................258
7.2.5 Stability of VACV When A26 is Deleted..............................................262
7.3 Discussion 262
8 Final Discussion 269
8.1 VACV as a Live Smallpox Vaccine........................................................ 269
8.2 Role of A26 in IMV Maturation............................................................... 270
8.3 IMV as a True End-stage Product of VACV Morphogenesis.................272
8.4 Active Differentiation of Virions in OPVs................................................273
8.5 Future Work................................................................................... 278
Appendix.................................................................................................282
Reference List........................................................................................ 293
X
List of Figures
Chapter 1
Figure 1.1 VACV Morphogenesis ..................................................... 21
Figure 1.2 Organisation of the ATI Locus in Different Poxviruses..............28
Chapter 3
Figure 3.1 Schematic of a VACV Recombination Cassette for Deleting
the A26L Gene............................................................................... 77
Figure 3.2 PCR Amplification of A26L Gene Deletion Cassette..................79
Figure 3.3 Screening for the EcoGPT Gene in pCAPs Constructs..............81
Figure 3.4 Screening for the EcoGPT Gene in pCAPs Construct Clone
3 from Large Scale Isolation.......................................................... 83
Figure 3.5 Genotypic Analysis of Recombinant Virus Following Serial
Passage in Selection Medium....................................................... 86
Figure 3.6 PCR Screening of Viral DNA Extracted from Recombinant
VACV Clones from Round 5 of purification.................................. 90
Figure 3.7 Western Blot Analysis of Purified VACV IHD-J and vldA26l___92
Figure 3.8 One-step Growth Curves for VACV IHD-J and vldA26L............93
Figure 3.9 Mean Absorbance at 570 nm of RK13 Cell Monolayers 
Infected with CsCI Gradient Fractions of vldA26L at 6 Hours
p.i.............. .....................................................................................97
Figure 3.10 Mean Absorbance at 570 nm of RK13 Cell Monolayers 
Infected with CsCI Gradient Fractions of VACV IHD-J at 6
Hours p.i ....................................................  100
Figure 3.11 Titres of CsCI Fractions of VACV IHD-J and vldA26L
Cultures at Various Times p.i......................................................... 101
Figure 3.12 Repeat Titration of CsCI Fractions of VACV IHD-J and
vldA26L Cultures at 8 Hours p.i..................................................... 104
Figure 3.13 Analysis of IMV and EV by Radioactive Labelling of
Virions in VACV IHD-J and vldA26L Cultures.............................. 108
Figure 3.14 Analysis of IMV and EV by Radioactive Labelling of
Virions in VACV IHD-J and vldA26L Cultures.............................. 110
Figure 3.15 Analysis of IMV and EV by Radioactive Labelling of
Virions in VACV IHD-J and vldA26L Cultures.............................. 112
Figure 3.16 Effect of BFA on EEV Production in VACV IHD-J and
vldA26L Cultures............................................................................ 116
Chapter 4
Figure 4.1 Schematic of Secondary VACV Recombination Cassettes
for Modulating Expression of A26L............................................... 123
Figure 4.2 Synthesis of Secondary Recombination Cassettes................... 130
Figure 4.3 Screening of the Null Secondary Recombinant by PCR............134
Figure 4.4 Screening of Extracted DNA from vldA26L1.1.1.1.1 Stock
by PCR................................................................................................ 136
xi
Figure 4.5 Screening by PCR of Extracted Viral DNA from Repeat
Plaque Purified Clones Derived from vldA26L1.1.1.1.1...................138
Figure 4.6 Detection of A26 by Immunoblotting in Repeat Plaque
Purified Clones Derived from vldA26L1.1.1.1.1 .......................... 140
Figure 4.7 Titration of vldA26L1.1.1.1.1 in the Presence of MPA in
RK13 cells.......................................................................................... 141
Figure 4.8 Titration of VACV IHD-J in the Presence of MPA in RK13
cells.................................................................................................144
Figure 4.9 Absorbance (570 nm) of Differential Titrations of
vldA26L1.1.1.1.1 and VACV IHD-J...............................................146
Figure 4.10 Screening by PCR of Repeat Plaque Purified Clones 
Derived from vldA26L1.1.1.1.1 Following 3 Rounds of 
Reverse EcoGPT Selection in STO cells + 0.1 mM 6-TG............150
Chapter 5
Figure 5.1 Schematic of Secondary VACV Recombination Cassettes
for Modulating Expression of A26L...............................................157
Figure 5.2 Flow Diagram Representing Process of Isolation of
Revertant VACV.............................................................................162
Figure 5.3 Screening of Revertant Clones vldA26L.rev2.2.3.1,
vldA26L.rev2.2.3.2 and vldA26L.rev2.2.3.3 by PCR.................... 163
Figure 5.4 Flow Diagram Representing Process of Isolation of
Secondary A26L Deletion VACV..................................................164
Figure 5.5 Screening of Putative vldA26L.neo Clones by PCR..................165
Figure 5.6 Screening of Putative vldA26L.EL Cultured in RK13 Cells
and BSC40 Cells by PCR.............................................................. 169
Figure 5.7 Flow Diagram Representing Process of Isolation of
vldA26L.EL..................................................................................... 171
Figure 5.8 Screening of Putative vldA26L.EL Clones from Plaque
Purification 4 by PCR.....................................................................172
Figure 5.9 Immunoblotting for A26 Protein..................................................174
Chapter 6
Figure 6.1 One-step Growth Curves for Recombinant VACVs...................180
Figure 6.2 Transformation of Data from One-step Growth Curves for
Recombinant VACVs.....................................................................181
Figure 6.3 Comet Formation in Recombinant VACV Strains...................... 183
Figure 6.4 Analysis of IMV and EV by Radioactive Labelling of Virions
in IHD-J and vldA26L Cultures...................................................... 185
Figure 6.5 Analysis of IMV and EV by Radioactive Labelling of Virions
in vldA26L.rev and vldA26L.neo Cultures.................................... 186
Figure 6.6 Analysis of IMV and EV by Radioactive Labelling of Virions
in IHD-J and COP Cultures....................................... 188
Figure 6.7 Analysis of IMV and EV by Radioactive Labelling of Virions
in IHD-J and vldA26L Cultures...................................................... 191
Figure 6.8 Analysis of IMV and EV by Radioactive Labelling of Virions
in vldA26L.rev and vldA26L.neo Cultures.....................................193
Figure 6.9 Analysis of IMV and EV by Radioactive Labelling of Virions
in IHD-J and COP Cultures............................................................195
Figure 6.10 Analysis of IMV and EV by Radioactive Labelling of
Virions in IHD-J and vldA26L Cultures.......................................... 198
Figure 6.11 Analysis of IMV and EV by Radioactive Labelling of
Virions in vldA26L.rev and vldA26L.neo Cultures........................ 201
Figure 6.12 Analysis of IMV and EV by Radioactive Labelling of
Virions in IHD-J and COP Cultures............................................... 203
Figure 6.13 Examination of Progeny in RK13 cells of Varying Passage
Number...........................................................................................207
Figure 6.14 Examination of Progeny in RK13 cells of Varying Passage
Number...........................................................................................208
Figure 6.15 Examination of Progeny in RK13 cells at Passage 2 ...............210
Figure 6.16 Analysis of IMV and EV by Radioactive Labelling of
Virions in IHD-J and vldA26L.EL Cultures....................................211
Figure 6.17 Analysis of IMV and EV by Radioactive Labelling of
Virions in vldA26L.rev and vldA26L.EL Cultures.......................... 215
Figure 6.18 Analysis of IMV and EV by Radioactive Labelling of
Virions in vldA26L.rev and vldA26L.EL Cultures.......................... 217
Figure 6.19 Analysis of IMV and EV by Radioactive Labelling of
Virions in vldA26L.rev and vldA26L.EL Cultures ...................220
Figure 6.20 Proportion of IMV Produced in Cultures When A26L was
Deleted or Overexpressed............................................................ 222
Figure 6.21 Transmission Electron Micrographs of Recombinant
VACVs in RK13 cells......................................................................224
Figure 6.22 Amplification Efficiencies of TaqMan® Assays......................... 227
Figure 6.23 Expression Kinetics in vldA26L.EL Cultures Throughout
the Infectious Cycle........................................................................230
Figure 6.24 Expression Kinetics Throughout the Infectious Cycle in
Recombinant VACV Cultures........................................................ 231
Figure 6.25 Expression Kinetics Throughout the Infectious Cycle in
Recombinant VACV Cultures........................................................ 233
Chapter 7
Figure 7.1 Effect of AMPs on the EEV Membrane ( I) ................................. 251
Figure 7.2 Effect of AMPs on the EEV Membrane (II) ................................ 252
Figure 7.3 Effect of AMPs on EEV-enriched Cultures................................. 253
Figure 7.4 Effect of Tween-20 on the EEV Membrane (I)........................... 255
Figure 7.5 Effect of Tween-20 on the EEV Membrane (II).......................... 256
Figure 7.6 Effect of Tween-20 on EEV-enriched Cultures.......................... 257
Figure 7.7 Effect of Tween-20 on the IMV Membrane (I)..... 259
Figure 7.8 Effect of Tween-20 on the IMV Membrane (II)........................... 260
Figure 7.9 Effect of Tween-20 on IMV-enriched Cultures .......................... 261
Figure 7.10 Effect of LL-37 and Detergents on Infectivity of IMV-
enriched Cultures of Recombinant VACV.....................................263
xiii
Chapter 8
Figure 8.1 Proposed VACV Morphogenesis where Two Non-
Interchangeable Isoforms of Infectious Virus are Produced 274
Appendix
Figure A1 vldA26L Recombination Cassette Sequence............................. 283
Figure A2 Revertant Construct for Reverse GPT Selection........................ 284
Figure A3 EL construct for Reverse GPT Selection.................................... 285
Figure A4 Null Construct for Reverse GPT Selection................................. 286
Figure A5 Early Construct for Reverse GPT Selection............................... 287
Figure A6 Late Construct for Reverse GPT Selection................................. 288
Figure A7 F13L Construct for Reverse GPT Selection............................... 289
Figure A8 Revertant Recombination Cassette Sequence ................290
Figure A9 vldA26L.neo Recombination Cassette Sequence......................291
Figure A10 vldA26L.EL Recombination Cassette Sequence......................292
xiv
List of Tables
Chapter 2
Table 2.1 Oligonucleotide Primers Used Throughout This Study for
Construction of Recombination Cassettes ..........................44
Table 2.2 Oligonucleotide Primers Used Throughout This Study for
Screening and Sequencing of Recombinant VACV.....................52
Chapter 3
Table 3.1 Differential Titres of Recombinant Virus from Each Round of
Plaque Purification.............................................................. .........88
Chapter 4
Table 4.1 Virus Titres of Repeat Plaque Purified Clones Derived from
vldA26L1.1.1.1.1................................... 147
Chapter 6
Table 6.1 Primer and Probe Sequences in TaqMan® Assay....................... 226
XV
<
Abbreviations
% percent
A delta
°C Degrees Celsius
3H tritium
6-TG 6-thioguanine
A absorbance
A.D. anno domini
ABS adult bovine serum
ANOVA analysis of variance
ATI A-type inclusion
B.C. before Christ
BFA Brefeldin A
bp base pair
c centi
CAM chorioallantoic membrane
CD cluster of differentiation
CEV cell-associated enveloped virus
CMLV camelpoxvirus
CPE cytopathic effect
cpm counts per million
CPXV cowpoxvirus
CsCI caesium chloride
Ct cycle threshold
Da Daltons
DF downstream flank
DMEM Dulbecco’s minimal essential medium
DNA deoxyribonucleic acid
dNTPs deoxynucleotides
Dstl Defence Science and Technology Laboratory
ECL enhanced chemiluminescence
EcoGPT Escherichia coli guanosine phosphoribosyltransferase
ECTV ectromelia virus
EDTA ethylenediaminetetra acetic acid
EEV extracellular enveloped virus
ELISA enzyme-linked immunosorbent assay
EV enveloped virus
FCS fetal calf serum
FPXV fowlpoxvirus
g grams
GAG glycosaminoglycans
h hours
HAT hypoxanthine, aminopterin and thymidine
HIV human immunodeficiency virus
HRP horseradish peroxidise
HSV Herpes simplex virus
IEV intracellular enveloped virus
IHD-J International Health Department-J
IMV
IND
IV
k
I
M
m
mAb
MHC
MOI
MPA
MPXV
MRV
MT
MVA
Mwt
n
neo
NV
NYCBH
OD
OPV
ORF
P
P-i-
PAGE
PCR
pfu
pH
RNA
rpm
RT
SDS
SEM
SFV
SMP
STE
t
TCID
TE
TEM
TGN
TK
U
UF
UV
V
intracellular mature virus
investigational new drug
immature virion
kilo
litres
molar
mili or metre
monoclonal antibody
major histocompatibility complex
multiplicity of infection
mycophenolic acid
monkeypoxvirus
malignant rabbit fibroma virus
microtubule
modified vaccinia Ankara 
molecular weight 
nano
neomycin/G418/Geneticin® 
nascent virus
New York City Board of Health
optical density
orthopoxvirus
open reading frame
pico or probability or plasmid
post-infection
polyacrylamide gel electrophoresis 
polymerase chain reaction 
plaque-forming units
potential of hydrogen-measure of hydrogen ions associated with
acidity
resistance
ribonucleic acid
revolutions per minute
reverse transcription/reverse transcriptase
sodium dodecyl sulphate
standard error of the mean
shope fibroma virus
skimmed milk powder
surface tubule element
time
tissue-culture infectious dose 
trypsin EDTA
transmission electron microscopy 
trans-Golgi network 
thymidine kinase 
units
upstream flank
ultraviolet
volts
xvii
v volume
VACV vaccinia virus
VARV variola virus
w weight
WR Western Reserve
wt wild-type
www world wide web
x g  x gravity
a alpha or anti-
p micro
1 Introduction
1.1 Smallpox, a Historical Disease
Smallpox is now considered a historical disease by the World Health 
Organisation since its certified eradication in 1980. The first cases of smallpox are 
thought to have appeared around 10,000 BC in early agricultural settlers in 
Northeastern Africa (1), at a time when the population density was thought to have 
reached a minimum required for the disease to be maintained without re- 
introduction. The first evidence for the disease was in ancient Egypt approximately 
1580 years BC on scarred mummified remains. Ramses V, who reigned for only 5 
years from 1157 BC, is one of the most famous figures thought to have died of 
smallpox. The disease was likely to have been spread from Egypt and Northern 
Africa by Egyptian traders to India and the Far East, but it was not until 400 AD that 
the disease was first documented in China (2).
In the fifth and sixth centuries AD smallpox reached Europe, where several 
epidemics occurred during the Middle Ages. It was around this time that the term 
variola, derived from the Latin words varius (spotted), and varus (pimple), was first 
used by the Swiss Bishop Marius of Avenches (3). Henry V lll’s fourth wife Anne of 
Cleves, Mary II, and Elizabeth I of England were all famous survivors of the 
disease. The word poc or pocca, of Anglo-Saxon origin, meaning bag or pouch, 
was used to describe the disease and in the fifteenth century writers began to refer 
to the disease as small pockes, to distinguish it from syphilis, the great pockes (3).
Smallpox was introduced to the Americas by the Spanish and Portuguese 
conquistadors in the early sixteenth century and was a major cause in the fall of
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Aztec and Inca Empires. It is speculated that in 1763 Lord Jeffrey Amherst, 
General of the British forces during the French-lndian war, presented two blankets 
and a handkerchief seeded with smallpox scabs to the Native Americans as an 
attempt at biological warfare.
By the middle of the eighteenth century smallpox had become epidemic in 
Northern America and Europe, leading to 400,000 deaths annually in Europe, and 
was endemic in Africa and India (3).
1.1.1 Smallpox, the Disease
Smallpox is caused by variola virus (VARV), a member of the Poxviridae 
family. There are two species of VARV, variola major which causes classical 
smallpox and variola minor which results in a milder form of the disease. The case 
fatality rate of variola major infection was reported as 30-40 %, whereas that of 
variola minor was generally 1 % or less (3). Variola minor was first described by 
Korte in 1904 as a very mild smallpox-like disease that had occurred in South 
Africa, and subsequently was identified in North and South America, Europe and 
Australia. In the 1950s, virological studies confirmed that these milder outbreaks 
were in fact mild varieties of smallpox caused by VARV.
1.1.2 Clinical Manifestation of Disease
The incubation period of smallpox is approximately 12-14 days and during 
this time the patient will feel healthy and is non-infectious. Illness begins with 
sudden onset of flu-like symptoms such as fever, headaches, malaise, back pain,
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and in some cases abdominal pain and vomiting. After 2-3 days these symptoms 
subside and the characteristic rash appears first on the oral mucosa, and then 
approximately 24 hours later on the skin. The distribution of the lesions is 
centrifugal, with more lesions occurring on the extremities such as the head and 
limbs, and less on the trunk. Lesions also appear on the palmar and plantar 
surfaces. The rash develops from macules to papules to vesicles to pustules, 
which in survivors eventually scab and fall off 8-14 days after the onset of 
symptoms, sometimes leaving depressed depigmented scars. Lesions may differ in 
size, however all are at the same developmental stage throughout the course of 
the disease. The distribution of the lesions, and the fact that they exhibit the same 
developmental stage, are the main clinical signs for differential diagnosis of 
smallpox compared to chickenpox.
1.1.3 Infectivity and Transmission
VARV is highly contagious, although an infected person is unable to infect 
others during the incubation period. Following onset of fever and during the first 
week of rash, the virus is released via the respiratory tract where face-to-face 
contact results in the highest frequency of infection. The disease can also be 
transmitted by contaminated clothes and bedding, although the risk of infection is 
much lower by this route. Patients infected with variola major were generally 
bedridden early, i.e. before they became infectious and so transmission was limited 
to those in close contact. Variola minor was less severe and sufferers frequently 
remained ambulatory throughout the course of disease, thus infection was more
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frequently transmitted. Patients continued to be infectious until the final stages of 
disease where the remaining virus-containing scabs were shed. Additionally, 
vaccinees could still be infected but typically would manifest a modified, less 
severe disease. Vaccinees who contracted variola major were more likely to be 
ambulatory, and thus to spread infection more widely. However, the potency of the 
vaccine was such that overt smallpox was rare in vaccinees (3;4). There is no 
known animal reservoir and the virus is not known to have been transmitted by 
insect vectors.
1.2 Poxvirus Biology
1.2.1 Taxonomy
As the causative agent of smallpox, VARV is the most infamous of the 
Poxviridae family, however, since its eradication research has continued using 
other poxviruses to increase understanding of virus-host relationships. The 
Poxviridae are divided into 2 main subfamilies: Chordopoxvirinae and 
Entomopoxvirinae, which infect vertebrates and insects, respectively. The 
Chordopoxvirinae consist of 8 genera that infect a wide range of birds, mammals 
and reptiles, and the viruses are genetically, antigenically and morphologically 
similar. Four genera have members which infect humans: orthopox, parapox, 
yatapox and molluscipox, where molluscipox and some members of orthopox are 
obligate human pathogens. Only 3 genera have been identified in the 
Entomopoxvirinae subfamily, based on the insect host.
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1.2.2 Vaccinia Virus (VACV)
Due its extensive use in research, VACV is the prototypic orthopoxvirus 
(OPV) used in laboratories to study poxviruses. It was the first animal virus to be 
seen microscopically, to be grown in tissue culture, accurately titred, physically 
purified and chemically analysed (5). VACV has no known natural host and its 
origin is not known, although there are several theories about its emergence: a) the 
virus evolved from variola virus as a result of continual passage through humans; 
b) the virus was derived from cowpox by continual passage through animals; c) or 
the natural host is now extinct (3). Indeed, the emergence of other OPVs such as 
buffalopox, are thought to be VACV that escaped during mass smallpox 
vaccinations, although there is a possibility that these are naturally occurring. It 
may also be that the virus causes a largely occult infection in their natural hosts, 
thereby limiting the opportunity for transmission to acutely susceptible hosts.
1.2.2.1 The Structure of VACV
VACV is the largest known DNA virus, measuring 310 x 240 x 140 nm with a 
smooth brick- or pillow-shaped particle (6-8). There is some uncertainty about the 
size of the virus particle as atomic force microscopy suggests a slightly flattened 
ellipsoidal shaped particle with dimensions of 350 x 300 x 265 nm (9), whereas 
cryo-electron tomography suggests a barrel-shaped particle of dimensions 360 x 
270 x 250 nm (10). It would appear that the size of the particle is dependent on the 
method by which the virus is viewed and prepared, as demonstrated by Malkin et 
al. (2003) who found that air dried particles shrunk more than two-fold along the
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shortest axis (9). The surface of the mature virion is smooth when negatively 
stained and viewed by cryo-electron microscopy (11 ;12). In contrast to this, virus 
preparations viewed by negative staining-, metal shadowing-, deep etch- or freeze 
etch- electron microscopy, or atomic force microscopy revealed randomly arranged 
surface ridges denoted “surface tubule elements” (STEs) (9;13-15). Dubochet et 
al. (1994) suggest that the STEs are artefacts, and are a result of osmotic stress 
during negative staining, however the biochemical evidence presented by Wilton et 
al. (1995), together with the reports of surface ridges by numerous research groups 
suggests that they are not artefactual, and it is more likely that the insensitivity of 
the cryo-electron microscopy fails to identify the fine surface detail of the virus 
particle (9;11;15).
Thin sections of non-enveloped mature virus particles reveal a membrane 
which surrounds the entire particle (note: at least one additional lipid membrane 
surrounds the enveloped forms), and a core wall which surrounds a homogenous 
core. The membrane consists of two layers approximately 1-20 nm thick: the outer 
domain is 3-9 nm thick, and the inner domain 5-6 nm thick. The outer core wall is 
estimated to be 8-17 nm thick, with a striated appearance and is referred to as the 
“palisade layer”. The inner core wall is 5-8 nm thick, and is known as the “smooth 
layer”. The inner membrane surface and outer core remain tightly apposed at the 
top and bottom of the particle however separation of the core wall and the 
membrane along the longer axis results in a characteristic dumb-bell shaped core. 
Two central bilateral concavities are formed between the core and membrane and 
within these reside two “lateral bodies”. The core contains a tube-like structure
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which is visualised when sectioned parallel to and bisecting the broadest plane of 
the virus (16).
1.2.2.2 Chemical Composition
The principal components of the mature virus particle are protein (90 %), 
lipid (5 %) and DNA (3.2 %) of the dry weight (17). The lipid components of mature 
virus are similar to that of the host cell with the exception of one third less 
phosphatidyl ethanolamine than the host cell and three to four times the amount of 
acyl bis(monoacylglycero)phosphate than found in host cells (18;19). Insignificant 
amounts of RNA have been reported, and trace amounts of spermine and 
spermidine may play a role in viral DNA core condensation (20).
1.2.2.3 The VACV Genome
Poxviruses have linear, double-stranded DNA genomes, which in the case 
of VACV is -200 kb encoding approximately 200 genes. At each end of the DNA 
strand are identical but oppositely orientated inverted terminal repeats (ITRs); the 
lengths of ITRs can be variable even within a genus (5). These ITRs may contain 
coding regions, which results in two copies of some genes at each end of the 
genome. In OPVs, these regions are hypervariable resulting in terminal regions 
with transpositions and deletions (5). The central portion of the genome is highly 
conserved and contains genes that are essential for virus replication. The terminal 
regions are more variable, encoding non-essential genes required for virulence, 
host-range and modulation of the host immune response (5). The two strands of
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DNA are connected by hairpin loops to form a covalently continuous polynucleotide 
chain. VACV mRNAs are not spliced, as replication occurs in the cytoplasm and 
therefore VACV DNA does not contain introns. Genes are closely spaced in the 
genome and appear to be expressed from their own promoter. The genome 
sequences of VACV and VARV are similar, and comparative analyses have 
demonstrated more than 90 % sequence identity (21-23).
It has been proposed that the viral genome exists in the core complexed 
with viral proteins in a helical structure: disruption of the core can release 30-40 nm 
diameter tubules that possess an apparently helical substructure (6;9). It is unclear 
if these tubules are the same as those described by Peters and Mueller in 1963 
(16). Treatment of the core with detergents and denaturing agents resulted in the 
identification of DNA-protein complexes which were named “nucleoids” and 
“subnucleoids” (24-27).
1.2.2.4 VACV Gene Transcription
The mechanisms of VACV gene expression have been well documented 
(28), where transcription proceeds in three phases: early, intermediate and late. 
Each phase is controlled by distinct promoters and, in most cases, virally-encoded 
transcription factors. Approximately 25 virus-encoded factors have been identified, 
and each of these are encoded primarily by genes of the preceding gene class, 
thus gene regulation in poxviruses may be described as a “cascade.” Viral RNA 
synthesis is carried out by a virus-encoded multi-sub-unit eukaryotic-like RNA 
polymerase that is encoded by at least 8 genes (5;29;30).
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1.2.2.4.1 Early Phase
The early transcriptional phase occurs after virus entry and early class 
mRNA can be detected within minutes. The enzymes and other proteins required 
for this are packaged within the virion along with the genome. Approximately half of 
the VACV encoded genes are considered early class (31 ;32) and encode proteins 
participating in DNA replication (33-35), nucleotide synthesis (36;37) and 
intermediate gene transcription (34;38). In addition, some early genes encode 
virulence factors for modulation of host responses (39;40). Characteristically, early 
promoter sequences are defined by a critical core region from -13 to -27 that is 
A/T-rich with a G residue at -21 or -22 (41). Initiation of transcription occurs with a 
purine residue, usually 12-17 nucleotides downstream of the core region (41) and 
requires a single transcription factor, the vaccinia early transcription factor (VETF) 
(42) and RNA polymerase-associated early specificity factor RAP94 (43;44). VETF 
is a heterodimer of the D6R and A7L gene products (45;46) that interacts with two 
regions upstream and downstream of the transcriptional start site (45;47), and is 
thought to recruit the RNA polymerase to the transcriptional start site. Initiation also 
requires ATP hydrolysis to induce accelerated dissociation of the VETF-promoter 
complex (45). RAP94 is required for transcription initiation and formation of a 
stable complex with an early promoter template (48) and perhaps also for the 
targeting of the transcription complex of assembling virions (49). Termination of 
most early class genes occurs 20-50 bp downstream of the termination signal 
TTTTTNT, situated at the 3’-end of the gene on the non-template strand (50), and 
is thought to involve the capping enzyme (51) and nucleoside phosphohydrolase I
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(NPH I) (52;53). It is proposed that as the mRNA is extruded from the RNA 
polymerase, it makes contact with the capping enzyme which signals NPH I to 
drive the release of the transcript through hydrolysis of ATP (53).
1.2.2.4.2 Intermediate Phase
Intermediate phase genes are expressed earlier than late phase genes and 
require the onset of DNA replication to occur prior to expression. In addition, their 
promoters lack the TAAATG motif characteristic of late promoters (54). 
Intermediate promoters have two important regions: a 14 bp A/T-rich core region 
situated 10-11 bp upstream of the initiator element, and the initiator element that 
has the minimal sequence of TAAAT/A at -1 to +4 relative to the first A in the motif 
(reviewed in (5);(55)).
Several proteins have been reported to be involved in intermediate 
transcription such as YinYangl (YY1) that is thought to bind within the initiator 
element and facilitate RNA polymerase binding (56). The vaccinia intermediate 
transcription factors (VITF) have been identified by Vos and colleagues where 
VITF-A is thought to have promoter DNA-melting activity and VITF-B is the capping 
enzyme (57;58). Further studies have identified VITF-1, VITF-2 and VITF-3: VITF-1 
is the 30 kDa subunit of the viral RNA polymerase (59); VITF-2 is a host nuclear 
protein that is thought to have a tethering role linking one of the other factors to the 
RNA polymerase (60); and VITF-3 has been identified as a heterodimer of A8L and 
A23R gene products (61).
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Intermediate gene expression of VACV is also thought to require de novo 
synthesis of viral RNA polymerase (28), and as all characterised RNA polymerase 
sub-unit genes have early promoters, it is therefore likely that intermediate gene 
expression requires newly synthesised RNA polymerase.
1.2.2.4.3 Late Phase
Late gene expression occurs approximately 2 hours post-infection, where 
transcripts were detected after 140 minutes in synchronously infected HeLa cells, 
and continued for up to 48 hours (62). Late genes tend to produce structural 
proteins involved in virion morphogenesis, and enzymes and factors that are 
required for early gene expression in the subsequent round of infection, that will be 
packaged into the mature virion (42;46;63). As in intermediate promoters, late 
promoters have two important regions with an A/T-rich region upstream of a 
transcription initiator element (64). The initiator element contains the highly 
conserved TAAAT motif, usually followed by a G or A residue, where the G would 
form part of the ATG initiation codon; this would overlap the transcription initiation 
sequence. The core sequence is situated about -16 to -11 from the initiator 
element with consecutive T or A residues (28).
Late mRNAs have a 5’- capped heterogeneous-length poly(A) sequence 
that has been shown to be synthesised by RNA polymerase slippage. These 
poly(A) leader sequences are also found in those early and intermediate transcripts 
that contain the TAAAT initiator element, suggesting that strand slippage is an 
intrinsic feature of VACV RNA polymerase (65-67).
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Up to five transcription factors have been described for late VACV gene 
expression. G8R (VLTF-1), A1L (VLTF-2) and A2L (VLTF-3) described by Keck et 
al. (1990), have been identified as the minimal gene set that are required for late 
promoter activity (68), however the functions of these gene products have yet to be 
assigned. A fourth transcription factor, encoded by H5R, belongs to an early class 
of genes and associates with the site of viral replication in the cytoplasm (69). More 
recent studies have demonstrated that the encoded proteins interact, and can 
further interact with the host cell factors A2/B1 or RBM3 (70). The fifth late 
transcription factor, VLTF-X, is host-derived (71) and thought to be responsible for 
targeting late VACV promoters as sites of initiation (28).
VACV RNA polymerase (RNAP) does not appear to respond to specific 
termination signals in intermediate and late genes, resulting in extremely 
heterogeneous 3’-terminal sequences (72). Yet, the gene products of G2R, J3R 
and A18R appear to affect transcript length (72-75) suggesting roles in promoting 
transcription elongation and termination.
Unusually for late genes, the A-type inclusion (ATI) protein transcript in 
cowpoxvirus (CPXV) terminates at a precise location after the ORF (76) by site- 
specific riboendonucleolytic cleavage; the 3’-end is then polyadenylated. This 
region is also found in the VACV orthologue, suggesting that this cleavage site is 
conserved in poxviruses (77). More recently, site-specific cleavage of VACV F17R 
transcripts has been reported, and the evidence suggests that cleavage is 
mediated by the same factor as for ATI transcripts (78). It is not known whether
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RNA 3’-end processing is common in VACV however this indicates poxviruses 
employ at least two mechanisms to modify the 3’-ends of mRNA.
1.2.2.5 VACV DNA Replication
The onset of DNA replication during infection differs between poxviruses 
(79;80). DNA replication in VACV begins approximately 1-2 hours p.i., resulting in 
the synthesis of more than 10,000 genome copies per cell (81 ;82). Poxviruses 
exclusively replicate in the cytoplasm of infected cells which dictates that most, if 
not all, of the genes required for DNA replication must be virally-encoded (83). In 
support of this, virus replication has also been reported in enucleated cells (84;85).
Several poxvirus genes encode enzymes that are able to synthesise DNA 
pre-cursors, such as deoxyuridine 5’- triphosphatase (dUTPase) (86), thymidylate 
kinase (36), thymidine kinase (37;87;88) and ribonucleotide reductase (89;90). 
These pre-cursors may be at levels within the host cell that are sub-optimal for 
virus replication. Studies have shown that the virulence of poxviruses was reduced 
in animals when the thymidine kinase or ribonucleotide reductase genes were 
deleted, but these mutant strains were not attenuated when cultured in vitro 
(91 ;92).
The mechanism for DNA replication is largely undefined in poxviruses. 
Several proteins have been identified to be involved including a DNA polymerase 
(E9); (93), an essential and stoichiometric component of the processive 
polymerase (A20); (94), a single-strand DNA-binding protein (13); (95), a type I 
topoisomerase (H6); (96;97), uracil DNA glycosylase (D4); (98), nucleic acid
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independent nucleoside triphosphatase (D5); (99;100), serine/threonine kinase 
(B1); (101) and a bacterial-type Holliday junction resolvase (A22); (102). Unusually, 
an origin of replication has not yet been defined, although c/s-acting sequences 
found within the telomeric 200 bp have been implicated as being necessary and 
sufficient for minichromosome replication (103). The existing model of poxvirus 
DNA replication suggests that DNA replication is initiated from a nick at either end 
of the hairpin termini to expose a 3’-OH group. The exposed 3’ terminus serves as 
a site for the processive polymerase (A20) to perform strand-displacement primer 
extension. The nascent strand and the template are self-complementary and can 
isomerize to fold back on itself. Extension of the nascent strand occurs by copying 
the remainder of the genome resulting in the formation of concatemeric 
intermediates, where a concatemer junction forms by replication of the hairpin. The 
onset of late transcription (104; 105), and the synthesis of Holliday junction 
resolvase (A22) and type 1 topoisomerase (H6) (106; 107) are required for the 
resolution of concatemer structures to produce mature, monomeric genomes.
The ability of poxviruses to undergo recombination was first demonstrated 
over 50 years ago (108), occurring at high rates within infected cells. The process 
may be an important source of genetic variation among the Poxviridae and may 
occur as a result of DNA replication and concatemer resolution (109) but the 
proteins involved have yet to be elucidated. It is likely that many poxvirus genes, 
such as immunomodulatory proteins, have been acquired in this way, entering 
poxvirus genomes via genetic recombination from their host or possibly other 
viruses (110). There is strong evidence to suggest that recombination can occur
14
between poxvirus genomes during natural host transmission. For example, 
malignant rabbit fibroma virus (MRV) is derived from genetic recombination of the 
leporipoxviruses shope fibroma virus (SFV) and myxoma virus (111-113). 
Recombination also readily occurs between viral genomes and transfected DNA 
(114). This property, together with the large size of poxvirus genomes that are able 
to accept large portions of foreign DNA, has been exploited to try to further 
understand poxvirus biology by the construction of mutant viruses (115).
1.2.2.6 VACV Replicative Cycle
VACV infection yields two types of mature virion: enveloped virus (EV) and 
intracellular mature virus (IMV). EV is produced first in the replicative cycle (116), 
accounting for -25 % of the total progeny and IMV is produced later (116) 
accumulating in the cell to make up the majority of progeny virions. The 
mechanism of both IMV and EV production has not been fully elucidated, however, 
the presence of proteins unique to each type of virion suggests that they are 
structurally, antigenically and functionally different. EV is thought to play a role in 
viral dissemination as viruses that cannot produce EV do not spread in tissue 
culture and are attenuated in vivo (117-120). This suggests that EV is required for 
dissemination within the host. In addition, EV is more resistant to neutralising 
antibody and complement as the membranes are host-derived, enabling long- 
range spread within a host. IMV is thought to be the more robust particle although 
is less resistant than EV to host defences, and is presumed to be involved in host- 
to-host spread.
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1.2.2.6.1 VACV Entry into Host Cells
The mechanisms of entry for IMV and EV are thought to differ due to the 
different numbers of viral membranes and different surface proteins present (121). 
The fragility of the additional membrane has precluded extensive studies of EV 
binding, however, proteins present on the surface of non-enveloped single- 
membraned virions have been shown to be important for entry of both forms of the 
virus (122-124). Two models have been proposed: 1) direct fusion of a single- 
membraned virion with the plasma membrane allowing release of the core into the 
cytoplasm (125) and 2) endocytosis of a single-membraned virion into vesicles 
followed by fusion of the membrane with the vesicular membrane resulting in the 
release of the core into the cytoplasm (126). These mechanisms are not 
necessarily mutually exclusive but have been shown to require low pH (126; 127) 
and may be influenced by the virus strain and cell-type used in the studies reported 
(128). How the EV additional membrane is lost during entry has only recently been 
demonstrated, where the EV membrane was shown to be disrupted at the point of 
cell contact after binding by a process that requires B5 and A34 (123). This 
resulted in a single-membraned virion that was able to enter the cell as described 
above. Recent studies by Mercer et al. (2008) have demonstrated that virions can 
also enter cells by macropinocytosis, where virions induce cell-surface blebbing 
that is characteristic of apoptosis (129).
Binding of single-membraned virions to the cell surface has been shown to 
involve the viral proteins H3, A27 and D8, which bind to glycosaminoglycans
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(GAGs) (130-133), A26 which binds to the cellular matrix protein laminin (134) and 
L1 to an unknown cell surface receptor, independent of GAGs (135).
Binding of the EV particle, however, appears more complicated to delineate. 
Studies by Vanderplasschen and Smith (1997) demonstrate that non-enveloped 
and enveloped virus bind to different cell surface receptors (121), but no EV- 
specific proteins have been identified in EV attachment. It has been suggested that 
A34 may be involved as mutation of the A34R gene results in a reduction in 
infectivity of EV (136), however, this is likely due to the requirement for A34 for 
disruption of the EV membrane upon binding (123).
Unlike many other enveloped viruses that require only 1 protein, fusion of 
the VACV membrane and entry of the core into the cytoplasm is mediated by a 
complex of multiple proteins: A16, A21, A28, F9, G3, G9, H2, 12, J5, L1, L5 and 03 
(122;124;137-146). Each of these proteins are essential for fusion but not binding, 
and have common features including membrane-anchored domains, situated at 
either their N- or C-terminus, and invariant cysteine residues. Many of these are 
conserved in all sequenced poxviruses (146;147) suggesting a common entry 
mechanism that is largely unchanged between species. The entry fusion complex 
(EFC) proteins have also been shown to be required for cell-to-cell fusion triggered 
by low pH or mutation of the A56 or K2 proteins (124;148;149).
1.2.2.6.2 VACV Morphogenesis
The synthesis of progeny virions begins in the cytoplasm of infected cells, in 
areas known as “virus factories”. Few, if any, cellular organelles associate with
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virus factories, although sometimes they are surrounded by endoplasmic reticulum 
(ER) derived cisternae (150). The onset of early viral transcription (151) and viral 
DNA replication (150) is followed by the appearance of viral crescents, the earliest 
evidence of virus assembly. These crescent structures are made up of lipid and 
protein and grow to form a closed, spherical structure that encases the viral DNA 
and core components to form an immature virion (IV). The structure of the crescent 
lipid bilayer is still under debate and several models have been proposed: 1) a 
single-membrane bilayer (152;153); 2) a double-membrane bilayer (154); and 3) 
folded cisternae (6; 155). Although evidence has been provided for each of these 
models, there are several aspects of the VACV replication cycle that favour the 
single-membrane model. For example, two membranes would present problems 
with viral entry into cells compared to the more obvious single-membraned entry by 
simple fusion with the plasma membrane to release the viral core into the 
cytoplasm. In addition, clear images using freeze-fracture microscopy after 
treatment of cultures with rifampicin demonstrated a single lipid bilayer that was 
covered by a “spicule” layer composed of D13 scaffold protein (13;156). However, 
the origin of the lipid membrane is an enigma as it is believed, by some, that 
membranes are formed de novo, as they are dissimilar to intracellular membranes 
in structure and composition, although no plausible mechanism has been proposed 
for this (152).
Four viral proteins F10, H5, G5 and A11 are implicated in the formation of 
viral membranes as determined by mutagenesis experiments, as deletion of any 
one of these results in the disruption of virus assembly at the earliest stages of
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morphogenesis (157-161). Of these, H5 is reported as the most abundant and has 
been implicated with additional roles in DNA replication due to its association with 
A20 and in late transcriptional regulation (69;162-164). F10, H5 and A11 are all 
phosphorylated, suggesting a role for phosphorylation in virus maturation (159;165- 
167) and F10 possesses intrinsic kinase activity (160;161 ;168).
The A14L and A17L gene products have been shown to be involved in 
membrane biogenesis and are critical for the diversion of ER membranes to virus 
factories and the formation of the viral membrane (169-171). Mutation of these 
genes results in the formation of crescents that do not make contact with the virus 
factories, however, it is not yet clear whether the absence of these proteins leads 
to stalling of the morphogenesis process or instability of viral membranes (172- 
177). Interactions between A14 and A17 have been reported to be mediated by the 
N-terminal region of A17 to form a lattice structure that is thought to sustain viral 
integrity and serves to anchor other viral proteins such as A27, to the membrane 
(170;178;179).
Following proteolytic cleavage of core proteins and condensation of DNA, 
the I Vs transform into the characteristic brick-shaped single-membraned virion. A 
portion of these virions will become wrapped in host-derived membranes to form 
intracellular enveloped virus (IEV). These are exported to the cell surface to either 
remain bound as cell-associated enveloped virus (CEV), which are then moved 
towards neighbouring cells by polymerizing actin tails in the underlying cytoplasm, 
or are released from the surface into the extracellular milieu as extracellular 
enveloped virus (EEV). The proportion of enveloped virus that remains bound as
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CEV or released as EEV varies between strains and is dependent on the host cell 
type (120;180;181). The formation of IEV using intracellular membranes and 
subsequent release of EEV appears to be unique to OPVs, however, there are 
reports of the budding of single-membraned virions through the plasma membrane 
to become EEV. This has been documented for the WR, IHD-J and MVA strains of 
VACV (182), and is analogous to the major route of release for fowlpoxvirus 
(FPXV) (183). It is unclear whether these membranes are similar in composition to 
EV produced as a result of intracellular wrapping. The majority of virions remain 
unwrapped within the cell until lysis, and there is much debate as to whether these 
particles are pre-cursors of EV that accumulate within the cell by default due to 
depletion of intracellular membranes, or are a true end-stage product of OPV 
maturation (116) (Figure 1.1).
In some poxviruses such as canarypoxvirus (CNPXV) and FPXV and in the 
OPVs ectromelia (ECTV) and CPXV, but not VACV or VARV, IMVs are occluded 
within A-type inclusion (ATI) bodies (184-187). It is thought that ATIs protect virions 
and increase their stability in the environment, aiding transmission. Occlusion of 
virions is not a passive process, requiring not only the ATI protein but also the 4c 
protein (A26) (188). Viruses with a truncated ATI, together with A26 are unable to 
occlude IMV within ATI bodies (188). This would suggest important additional roles 
for these proteins.
2 0
EEV IMV
i
MT
\
Virus factory
\
EEV
CEV
CEV /
□
□ Actin tail
IEV
%
\
\
D I
Non-enveloped
virus
Nucleus
21
Figure 1.1 VACV Morphogenesis
1 EEV or IMV bind to the cell and enter following the loss of one or more membranes. The naked 
viral core is released into the cytoplasm. 2 The core is transported via microtubules (MT) where the 
formation of viral factories occurs within the cell. 3 Transcription of the early mRNAs leads to core 
uncoating. DNA replication and viral crescent formation begins. 4 DNA is packaged and immature 
virions (IV) assemble. Concomitant with proteolytic cleavage of viral core proteins IV are processed 
to form single-membraned virions. 5 Some virions are transported via microtubules to intracellular 
membranes for envelopment. 6 Particles are wrapped by a Golgi- or trans-Golgi network (TGN)- 
derived double membrane to form triple-membraned IEV and are then transported to the cell 
surface via microtubules. 7 To exit the cell, the outer IEV membrane fuses with the cell membrane 
to expose a CEV at the cell surface. Actin polymerisation beneath the CEV forms an actin tail that 
drives the virus toward a neighbouring cell, or the virus is released as an EEV.
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1.2.2.6.3 EV-specific Proteins
The wrapping of virions to become EV is a complex process and has been 
shown to require a multitude of virus-encoded proteins (reviewed in (189)). Up to 
10 proteins are known to be unique to the EV membrane, with the first identified by 
Payne et al. (1978, 1979): A56 (89K/haemagglutinin), B5 (42K), F13 (37K), A33 
and A34 (representing 5 proteins ranging from 20-23K, depending on the degree of 
glycosylation), and two proteins of 21 OK and 11 OK respectively that have yet to be 
identified but may be complexes of the other proteins (181; 190-197). F12 and A36 
have been more recently identified as unique to IEV, being absent from EEV and 
CEV, and are thought to be lost during fusion with the plasma membrane during 
exit from the cell (198-201).
All of these EV proteins are glycosylated, with the exception of A36, F12 
and F13 which are acylated; the A33, A56, and B5 proteins are acylated in addition 
to being glycosylated (195;202). These modifications allow the proper folding of 
these proteins and may facilitate their association with or localisation in the lipid 
membranes.
Wrapping is dependent on F13 and B5, as deletion of these genes in VACV 
results in reduced IEV (117-119). The role of F13 is not fully understood: F13 has 
limited amino acid similarity to phospholipase D (PLD) (203;204) suggesting a role 
in signalling or membrane trafficking, however no PLD activity has been 
demonstrated for F13 when expressed in cell culture (205). Others have reported 
that F13 has broad lipase activity (206) and therefore suggest that F13 regulates 
vesicular budding (207;208). Studies by Husain and Moss (2001) provide evidence
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for this by showing F13 localises to the Golgi and causes redistribution of B5 from 
the trans-Golgi network (TGN) to endosomal membranes (209). Overexpression of 
F13 causes a reduction in EEV, suggesting that the correct level of F13 production 
is critical (210). B5 is proteolytically processed to remove the N-terminal signal 
peptide (211) and exists as a viral membrane protein; it is also cleaved near the 
transmembrane domain to produce a 35 kDa secreted protein (212). This protein is 
highly acylated (195) and forms high molecular mass complexes (192) which are 
most likely due to B5-A34 (213), B5-F13 (195) and B5-A33 (214) interactions. It is 
suggested that the signals necessary for targeting to the Golgi reside in the 
transmembrane/cytoplasmic tails (215-217), and these may also be involved in 
retrieval of B5 from the plasma membrane (217). The amino acid sequence 
suggests 4 short consensus repeats (SCR) that are characteristic of complement 
activation, and which have been demonstrated to be important in wrapping 
(118;218). The SCR domain has also been shown to be a target for anti-VACV 
neutralising antibodies (219).
Deletion of other EV specific proteins does not appear to affect wrapping but 
has varying effects on plaque size and EEV production (189). It is therefore more 
likely that these proteins are involved in the transport of IEV to the cell surface and 
in facilitating egress. Deletion of F12L leads to a reduction in CEV/EEV as IEV 
accumulates within the cell, presumably by preventing IEV transport, implicating 
F12 in microtubule-mediated transport to the plasma membrane (198). In addition, 
the association of F12 with IEV has been shown to be via an interaction with A36, 
which is critical for the function of F12 during egress (220). More recently however,
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Dodding et al. (2009) have reported that F12 is not essential for microtubule 
transport, but directly interacts with the viral protein E2 to form a complex that is 
involved in IEV wrapping (221). Thus the function of F12 remains unclear.
Deletion of A36 also results in a reduction in EEV, yet the levels of CEV 
remain normal. This suggests that A36 is involved in release of CEV from the cell 
surface and studies have demonstrated that actin tail formation requires A36 where 
the protein concentrates on the cytosolic face of the plasma membrane beneath 
CEV at the point of actin tail formation (222). It has been shown that recruitment of 
A36 requires A33 as a chaperone, to allow tyrosine phosphorylation of A36 thus 
inducing actin-tail formation. Deletion of A36 also results in the loss of kinesin-1 
recruitment and therefore a loss in efficient transport of IEV to the cell periphery, 
suggesting a further role for A36 in microtubule-mediated transport (223).
The production of EEV was actually enhanced when A33R or A34R were 
deleted, although a reduction in infectivity was also observed in the case of the 
latter (136;191 ;224). Tyrosine phosphorylation of A36 is also reduced in the 
absence of A34 or F13, and inhibited in the absence of A33, suggesting a role in 
the control of modification of A36 to allow release of CEV (225).
Interestingly, the only EV-specific protein not to impact on EV 
morphogenesis and release is A56, although its deletion results in syncitial plaque 
formation (226). A56R encodes a haemagglutinin, which is found both on the 
surface of infected cells and on EEV (197;227). Not all strains of VACV express 
A56R, for example, the IHD-W strain does not. Its role appears to be to prevent 
cell-to-cell fusion (227) and reduce the entry of superinfecting virus, when
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complexed with the virally-encoded K2 protein (228), through interaction with the 
EFC (229;230). Inhibition of synctial fusion may be required for the infection of 
uninfected neighbouring cells with CEV.
1.2.2.6.4 IMV-specific Proteins
It is assumed that the end-stage product of OPV morphogenesis is an 
enveloped virion, and it has been shown that enveloped virus is required for the 
dissemination of disease throughout the host: EV knockout viruses do not 
disseminate in vitro and are avirulent in vivo (reviewed in (189)). As previously 
described in this chapter, there are several proteins that are unique to the surface 
of EV that are necessary for its formation and function (section 1.2.2.6.3). This may 
also be the case for IMV as there are proteins that are unique to the surface of IMV 
that are produced late in the infectious cycle: A26 (4c) and A25 (ATI) (116). It has 
not yet been determined whether IMV is also a true end-stage product of 
morphogenesis, however its role in transmission between hosts has been 
considered. Both A26 and the ATI proteins have been shown to be necessary for 
the occlusion of virions within ATIs (188). The ancestral function of ATIs was 
thought toc be to protect virions from environmental degradation during transmission 
between hosts, similar to occlusion bodies observed in entomopoxviruses (231) 
and baculoviruses (232). Comparative genomic analysis of sequenced OPV 
genomes demonstrates that both A26 and ATI gene sequences are highly 
conserved in most, if not all, OPVs yet the ATI gene is truncated in many of these 
for example in VACV and VARV (Figure 1.2B-E), and also in camelpoxvirus
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(CMLV) and monkeypoxvirus (MPXV) (188;233). A truncated ATI renders the virus 
occlusion negative. The full length version of the ATI gene in CPXV and the 
atypically truncated version in ectromelia virus (ECTV) are approximately 60 % 
longer than the highly conserved truncate (233). Interestingly the approximate point 
of mutation is similar in all ATI truncate-OPVs, preserving the truncate COOH- 
terminal region which is immunodominant for antibody responses in mice (77). This 
would suggest an additional role in immunomodulation, perhaps to aid infection of 
phagocytic cells, such as a macrophage, that would be capable of ingesting the 
large ATI and degrading the ATI matrix, or perhaps the establishment of infection 
in an immune host (116). Interestingly, the ATI and A26L genes are completely 
absent in yatapoxviruses, leporipoxviruses, suipoxviruses and capripoxviruses 
(Figure 1.2F) (234;235).
The role of A26 is unlikely to be only as an occlusion factor as the truncated 
gene is retained in most OPVs and, as a result, additional roles for A26 have been 
suggested: Stern and Dales (1976) proposed that A26 was a component of the 
STEs that were visualised by electron microscopy (236;237), although viruses 
lacking A26 have also been shown to possess STEs (238;239). This is somewhat 
marred by the lack of confirmation of STEs by cryo-electron microscopy. More 
recently, Ulaeto et al. (1996) demonstrated a switch in production to IMV from EV 
late in the infectious cycle that was concomitant with detection of A26 in virus 
cultures (116). This has led to the suggestion that A26 is a differentiation switch, 
resulting in maturation of IMV instead of EV. This would be a unique mechanism by
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Figure 1.2 Organisation of the ATI Locus in Different Poxviruses
Genomes were examined for homologues of the A24R and A29L genes to locate the ATI locus for
A CPX CPR06 (Accession no. D00319 and X06343); B VACV WR (Accession no. M37415 and
M61187); C VACV Cop (Accession no. M35027); D VACV MVA (Accession no. U94848); E VARV 
Bangladesh-1975 (Accession no. L22579); F Yaba-like disease virus (YLDV) (Accession no.
AJ293568); G FWPV (Accession no. AF198100); H MCV I (Accession no. U60315). YLDV is also 
representative of leporipoxvirus, suipoxvirus and capripox which do not contain homologues of the 
A25L or A26L genes.Genes are represented as blocks and are transcribed in a rightward direction 
when featured above the line or in a leftward direction when featured below the line. Filled blocks of 
the same colour represent equivalence where those bound by black lines have been described in 
the literature and those bound by coloured line have been identified from available sequence data.
Disrupted genes are represented as smaller blocks and overlaps represent frameshifts. Red lines 
represent deletions in the genomes of VACV Cop and MVA and open-ended blocks represent gene 
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which OPVs direct the differentiation of virions to produce two functionally distinct, 
non-interchangeable mature particles: EV in the earlier stages of infection to 
facilitate dissemination within the host and IMV later to facilitate host-to-host 
spread.
1.2.2.6.5 Host-Derived Proteins
Interestingly, several host cell proteins have been found associated with 
purified virions (240;241). All are present in low abundance and many of these 
have been reported as components of other viruses such as HIV-1 and human T- 
cell leukaemia/lymphoma virus (242-245).
Many of these are associated with EEV and are found on the outer envelope 
such as CD46, CD59, CD29, CD71, CD81 and MHC-1 (246;247), conferring 
resistance to complement. Advantageously, progeny virus will always carry 
complement regulators that are adapted to the complement of its most recent host, 
which may be important in OPVs that have a broad natural host-range.
Studies by Chung et al. (2006) have identified 23 host proteins associated 
with purified IMV particles that were present in low abundance (240). Many of 
these are not surprising as they are cytoskeleton proteins and protein 
transport/vesicular trafficking proteins that may be utilised during the virus life 
cycle. Several of these, such as cyclophilin A, fi-actin and ubiquitin have been 
previously found in IMV particles (241 ;248;249), and others such as 60S acidic 
ribosomal proteins, thioredoxin and peroxiredoxin 1 were uniquely identified in 
VACV (240), although their roles in VACV biology have not been established.
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It is possible that some of these proteins are incorporated into the particle 
non-specifically or adhere to the particle during purification (250), however 
incorporation of cyclophilin A into viral cores, where inhibition of cyclophilin A by 
cyclosporine results in inhibition of VACV replication, may indicate that VACV 
requires this protein as part of the replicative cycle (248).
1.2.2.6.6 Immunomodulatory Proteins
Poxviruses encode proteins with immunomodulatory functions involving 
inhibition of apoptosis, production of cytokines and chemokines, the activity of 
immune cells such as NK (natural killer) cells and cytotoxic T cells, and the activity 
of complement and antibodies (reviewed in (251)). This enables them to elude 
detection and destruction by the host immune system. These proteins can be 
classified as virostealth, viromimicry and virotransduction.
Virostealth is a mechanism employed by many viruses to enable viral 
infections to remain undetected by subversion of discriminatory pathways by 
preventing presentation of viral antigens and/or downregulating recognition 
receptors (252;253). Viromimicry involves the production of virokines or 
viroreceptors that act as mimics of the host immune system to disrupt antiviral 
pathways. For example, viroreceptors resemble their cellular counterparts and act 
to sequester cytokines such as interferons (IFNs) and tumour necrosis factor (TNF) 
(254-257). The virokine vaccinia complement control protein (VCP) acts on C3 
convertase, directly or indirectly causing its decay thus inhibiting the complement 
pathways (258). Virotransduction counteracts the deleterious effects of the pro-
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inflammatory response thereby producing an environment that is conducive to viral 
replication. This is primarily by the production of anti-apoptotic proteins that 
interfere with caspases or disrupt intracellular signalling cascades (259;260).
The origins of poxvirus immunomodulatory proteins are unknown, however it 
is likely that some of these that are similar to their cellular counterparts may have 
originated from their host either by ancestral retrotranscription or acquired from 
other viruses via homologous recombination, and these viruses have co-evolved 
immunomodulatory strategies with their host.
1.3 Prevention and Treatment of Poxvirus Infections
Although smallpox was officially declared eradicated in 1980, the threat of a 
deliberate or accidental release of VARV, or a fully emergent human MPXV 
outbreak, has renewed interest in poxvirus research. The increasing knowledge of 
poxvirus biology has been used to provide further information about existing 
vaccines, identify ways in which poxviruses can be genetically manipulated to 
generate safer, more efficacious vaccines and develop novel drug therapies.
1.3.1 Vaccines
1.3.1.1 Live Vaccines
The traditional smallpox vaccine was VACV produced from the 
chorioallantoic membrane (CAM) of chicken embryos, or the exudates from the 
infected skin of domestic animals. During the smallpox eradication programme, 
Dryvax™ (New York City Board of Health (NYCBH) strain) was primarily used in
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the USA and South America, and the Lister/Elstree strain was primarily used in 
Europe, Africa and Asia. The vaccine was administered by scarification using a 
bifurcated needle, and immunisation was deemed successful on the appearance of 
a ‘take’ (a vaccinial pustule or lesion) 7-9 days later (3).
1.3.1.2 Complications of Live Smallpox Vaccines
Although these vaccines were efficacious, as proven by the global 
eradication of smallpox, there was a high incidence of adverse events as a result of 
smallpox vaccination. These ranged from fever, myalgia, malaise and headaches, 
to more severe life-threatening effects such as generalised vaccinia, eczema 
vaccinatum, encephalitis and the almost always fatal progressive or necrotising 
vaccinia (3). Myopericarditis is a more recently described side-effect that may have 
occurred historically but has only been recognised in the past decade (261-263). 
Live smallpox vaccines cannot be administered to contraindicated individuals such 
as HIV patients, or patients undergoing immunosuppressive therapy or 
chemotherapy. In addition, complications can arise in patients who have skin 
disorders such as eczema, atopic dermatitis and psoriasis, in pregnant women, or 
anyone with these conditions who comes into contact with a recent vaccinee who 
is shedding virus. This is likely to represent a significant proportion of the UK 
population and as a result, efforts are being made to improve the safety of 
smallpox vaccines that could be used in a mass vaccination campaign.
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1.3.1.3 Next Generation Smallpox Vaccines
Sometimes described as second generation smallpox vaccines, new 
smallpox vaccines have been developed that are produced in cell culture to 
generate safer, sterile vaccines that have reduced hazards from adventitious 
agents and transmissible spongiform encephalopathies. ACAM2000 (Acambis Pic) 
is based on Dryvax™ and is propagated in Vero cells. This vaccine has been 
demonstrated to induce similar cutaneous reactogenicity and immunogenicity to 
Dryvax™ in clinical trials (264;265). Other vaccines include Elstree-BN (Bavarian- 
Nordic) based on the Lister/Elstree strain and the cell-cultured smallpox vaccine 
(CCSV) developed by DynPort (a derivative of the NYCBH strain propagated in 
MRC-5 cells) all of which have similar reactogenic and immunogenic profiles to 
their parent strains (www.bavarian-nordic.com; (266)). However, the virulence of 
these live next generation vaccines remains similar to the parent strains with 
identical contra-indications (264;267), therefore new approaches are needed to try 
to produce vaccines that are not only safe for use but also maintain the efficacy of 
the original smallpox vaccines.
1.3.1.4 Attenuated, Replication Competent Vaccines
The generation of a live-attenuated replication-competent smallpox vaccine 
was achieved in Japan with LC16m8, produced by serial passage of the Lister 
strain in primary rabbit kidney cells at low temperature. The LC16m8 clone was 
selected for its ability to form small pocks on CAMs (268). This vaccine was shown 
to be safer than the Lister parent and was less neurovirulent, yet remained
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immunogenic (269;270) as demonstrated by its protective efficacy in animals (271- 
273). Analysis of the genome sequence demonstrated a disruption of the B5R 
gene, necessary for the production of EV, suggesting the attenuation is due to 
reduced viral dissemination (270). Interestingly, B5 is a major target for EV- 
neutralising antibodies in poxvirus infection (274;275) and induces a robust 
immune response (275-277), which would suggest its importance in protection. 
LC16m8 however produces an 8 kDa truncate of B5, and yet is still able to confer 
protection and induce EV-neutralising antibodies (272). This vaccine is currently 
licensed for use in Japan and has investigational new drug (IND) status in the 
USA.
1.3.1.5 Attenuated, Replication-Defective Vaccines
Vaccine strains that are replication-defective are often referred to as third 
generation vaccines. The most successful example is the modified vaccinia Ankara 
(MVA) strain developed by Mayr et al. (1975) (278), subsequently developed for 
licensure by Acambis Pic (MVA3000) and Bavarian-Nordic (IMVA-MUNE). MVA 
was derived from the Ankara strain of VACV after >500 passages in chick embryo 
fibroblasts. The virus has lost -15 % of the wild-type genome and is unable to 
replicate in most mammalian cells, including human cells (279). This has resulted 
in a safer vaccine that has been shown to have no serious adverse effects, but 
remains efficacious in animal models. Originally, this vaccine strain was considered 
for use only as a primary immunisation to protect against adverse events prior to 
vaccination with a traditional replicating vaccine strain. Studies have shown that
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MVA can induce a protective immune response when administered alone, albeit 
with much higher doses than are required for traditional and next generation 
vaccines (280-284), but MVA was not able to protect mice against infection with 
VACV WR when administered post-exposure (285). The safety profile of MVA is 
promising (286) and currently this strain is in clinical trials for use as a stand alone 
smallpox vaccine candidate. In addition, recombinant MVA is being investigated as 
a vaccine vector against a variety of diseases (287;288). Studies have generated 
recombinant MVA as candidate vaccines against infectious diseases such as 
malaria (289;290), influenza A (291 ;292), tuberculosis (293) and HIV-1 (294-296). 
In addition, recombinant MVA viruses are being used as cancer vaccines (297- 
299).
1.3.1.6 Sub-unit Vaccines
Using recombinant proteins or using DNA vaccines encoding proteins that 
are abundant on either the IMV or EEV surface, or ideally both, has been the 
approach taken by many to create a smallpox sub-unit vaccine. Antigens such as 
L1, A27, B5 and A33 have been successfully used to protect against lethal disease 
in animal models (300-306). Although using a panel of antigens as a sub-unit 
vaccine is regarded as a safe alternative to a replicating smallpox vaccine, the 
limited repertoire of antigens that are displayed to the immune system could result 
in a less efficacious vaccine.
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1.3.2 Antiviral Therapies
Currently there are no licensed therapies for smallpox, although some that 
showed efficacy in vitro were tested during the smallpox eradication programme in 
India, such as metisazone and thiosemicarbazone (3). However, nausea and 
vomiting were a common side-effect of treatment and as a result they were not 
considered further.
Novel drug therapies target parts of the poxvirus replicative process, or 
interfere with the release of virus thus preventing spread (reviewed in (307). A 
promising candidate is an acyclic nucleoside phosphonate, cidofovir (CDV), that is 
a potent inhibitor of poxvirus-encoded DNA polymerase (308;309). Its activity relies 
on several phosphorylation steps for conversion to 5’-nucleotides. Two adjacent 
incorporations of the active moiety into the elongating DNA strand are required to 
inhibit the viral DNA polymerase and induce chain termination thereby inhibiting 
viral replication. CDV, which is also a potent inhibitor of herpesvirus DNA 
polymerase (310), was first licensed for the treatment of cytomegalovirus retinitis in 
HIV patients, and has since been awarded IND status for emergency treatment of 
smallpox. However, the route of delivery may hinder its use; CDV is poorly 
absorbed when administered orally therefore administration is intravenous (i.v.) 
and probenecid, a competitive inhibitor of organic anion transport, must be co­
administered to reduce nephrotoxicity. More recently a CDV derivative, CMX001 
has been developed that incorporates a lipid group thereby increasing the antiviral 
activity by -1000-fold and increasing the oral bioavailability to the extent that the 
drug can be administered orally (311 ;312). In addition, this derivative has been
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shown to have a reduced nephrotoxic effect and is consequently much safer than 
the CDV parent. Once taken up into the cell, CMX001 is cleaved to yield free CDV, 
therefore the mechanism of action is the same. IND status has also been given to 
CMX001 and clinical trials have begun (reviewed in (313)). Resistance to CDV and 
its derivatives has arisen in viruses repeatedly passaged in the presence of the 
drug, and has been mapped to mutations in the virally encoded DNA polymerase 
(314).
Another anti-poxviral candidate drug is ST-246, a potent virus egress 
inhibitor developed by Siga Technologies Inc. (315). ST-246 targets the F13 
protein, preventing wrapping of virions and subsequent egress from the infected 
cell (316). The exact mechanism of action is unclear, however, different OPVs 
demonstrate differing sensitivities to the drug; CPXV and CMLV are less sensitive 
than VACV, which may be due to their differing dependencies on the enveloped 
form for propagation (317). ST-246 has high oral bioavailability and does not 
appear to be toxic, although clinical trials are currently underway to investigate this.
Other antiviral therapies that have potential to be developed for the 
treatment of poxvirus infection include the nucleoside analogues ribavirin, adefovir 
and S-adenosylhomocysteine (SAH) hydrolase inhibitors, and kinase inhibitors 
such as Gleevac (318-322). Inhibitors of the virally-encoded topoisomerase 1B 
(vTOPO) enzyme such as novobiocin and coumermycin are effective at reducing 
replication and, interestingly, fluoroquinolones have been shown to have a similar 
effect. This suggests the possibility of a generic medical countermeasure that is 
effective against both bacteria and viruses (323-325).
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1.4 Aims of the Project
The aim of this study is to investigate the role of the membrane protein A26 
as a putative differentiation switch in IMV/EV maturation in VACV, the prototype 
OPV, by generating a defined A26L deletion mutant. This will provide insight into 
the complex process of OPV morphogenesis and examine the possibility that 
OPVs direct an active process of differentiation in progeny virions. In the event that 
the preliminary studies successfully generate the required mutants, the effects of 
modulation of A26L expression on the kinetics of IMV and EEV production by 
altering its attendant promoter will be investigated, with the overall aim of providing 
a rationale for developing a next generation live attenuated smallpox vaccine.
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2 Materials and Methods
2.1 Materials
2.1.1 Oligonucleotide Primers
Oligonucleotide primers used in this study were synthesised by Eurogentec 
Inc. and Sigma-Genosys, UK.
2.1.2 Plasmid DNA
Plasmid DNA constructs used in this study were pCAPs vector from the PCR 
cloning kit (blunt-end) supplied by Roche Diagnostics Ltd. (West Sussex, UK) and 
pCR®-XL-TOPO® supplied by Invitrogen Ltd. (Paisley, UK). The deletion plasmid 
p1107 was used to amplify the EcoGPT gene (326). Recombination cassettes 
described in Chapter 6 were synthesised by GeneArt AG (Germany).
2.1.3 General Reagents
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich 
(Dorset, UK) and molecular biological reagents from Roche Diagnostics Ltd. Sterile 
H20  and phosphate-buffered saline (PBS) were purchased from Gibco BRL, a 
division of Invitrogen Ltd.
2.2 Microbiological Methods
2.2.1 Preparation of Culture Media
Luria-Broth (L-broth) was prepared for the routine culture of Escherichia coli 
strains. 10 g of bacto-tryptone was added to 5 g of bacto-yeast extract and 10 g of
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NaCI. The constituents were dissolved in 800 ml sterile H2O and adjusted to pH 7 
with NaOH. The final volume was corrected to 1 litre with sterile water and the 
medium was sterilised by autoclaving and stored at 4 °C.
Luria-agar (L-agar) was prepared for the routine culture of E.coli strains by 
the addition of 10 g of bacto-tryptone to 5 g bacto-yeast extract plus 15 g bacto- 
agar and 10 g NaCI. The constituents were dissolved in 800 ml sterile water and 
adjusted to pH 7 with NaOH. The final volume was corrected to 1 litre with sterile 
H2O and the medium was sterilised by autoclaving and stored at 4 °C.
2.2.2 Media Supplements
Ampicillin or kanamycin (Sigma-Aldrich) were added to growth media where 
appropriate. To 200 ml L-broth or molten L-agar, 200 pi ampicillin (100 mg/ml) or 
100 pi kanamycin (100 mg/ml) were added to give final concentrations of 100 
pg/ml and 50 pg/ml respectively.
2.2.3 Maintenance of E.coli Strains
Strains were stored at -80 °C in L-broth containing the appropriate antibiotic 
supplemented with 30 % (v/v) glycerol, or streaked on L-agar plates containing the 
appropriate antibiotic and stored at 4 °C for approximately 1-2 weeks.
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2.3 DNA Manipulation and Cloning
2.3.1 Agarose Gel Electrophoresis
Agarose gels were used to separate DNA following manipulation and 
cloning steps. In the first instance, 1 % agarose gels were prepared in 1 x TAE 
buffer with 0.5 pg/ml ethidium bromide. TAE buffer consists of 0.04 M Tris-acetate 
and 0.001 M EDTA at pH 8.0. After some time, the laboratory switched to use of 
pre-cast 1.2 % E-Gels® (Invitrogen Ltd.). These are bufferless self-contained 
agarose gels pre-equilibrated with ethidium bromide.
DNA samples were mixed with 4x sample loading buffer (300 pi glycerol, 
700 pi distilled H2O and 100 pg tartarazine) to a final volume of 20 pi and loaded 
onto the agarose gels alongside 20 pi of molecular weight marker at a 
concentration of 125 pg/ml. Poured agarose gels were electrophoresed for 30 
minutes at 100 volts in 1x TAE buffer, and E-Gels® were electrophoresed for 30 
minutes using a proprietary dedicated powerpack according to the manufacturer’s 
instructions. DNA was visualised under ultraviolet (UV) light and photographed 
using a Syngene Gene Genius Biolmaging System (Cambridge, UK).
2.3.2 Digestion of DNA
DNA was digested using restriction endonucleases supplied by Roche 
Diagnostics Ltd. (West Sussex, UK) according to the manufacturer’s instructions. 
Briefly, a 20 pi reaction contained 1-2 pg DNA, 10 U enzyme, and 2 pi reaction 
buffer (10x) with the remaining volume made up to 20 pi with distilled H2 O.
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Reactions were incubated for 2 hours at the manufacturer’s recommended
temperature.
2.3.3 Polymerase Chain Reaction (PCR)
PCR was used to amplify DNA using primers to target specific regions of the 
VACV genome (Table 2.1). Typically, each reaction contained 250 ng template 
DNA, 1 pi of each primer (10 pmol), 2.5 pi reaction buffer (1 Ox), 1 pi dNTP mixture 
(10 mM each), 1 pi Taq polymerase (5 U) and made up to a final volume of 25 pi 
with distilled H2O.
DNA was denatured for 3 minutes at 94 °C and then amplified during a 
reaction of 25 cycles (typically 1 minute at 94 °C for denaturing, 30 seconds at 55 
°C for annealing, 1 minute at 72 °C for extension of the amplicon). Extension times 
were adjusted to give approximately 30 seconds/500 bp of predicted product. This 
was followed by a final period of extension at 72 °C for 10 minutes. Reactions were 
performed either in a GeneAmp 2400 (Applied Biosystems, UK) or a PTC-200 DNA 
Engine Thermal Cycler (MJ Research, USA).
2.3.4 Purification of DNA
Following a PCR or digestion, the DNA fragment of interest was purified to 
remove buffers, primers, nucleotides and enzymes. This was carried out either by 
excision of the DNA from an agarose gel, or directly from the reaction mix using a 
QIAquick PCR purification kit (Qiagen) or a MinElute PCR purification kit (Qiagen). 
These protocols are designed to purify single- or double-stranded DNA fragments
42
£
c =*«■ •*->=  0  ^
S oO
c  Q- —
5  E<  <D
a>(/>
3
h-
ior-
h-
£/3 ^
"q. »-
<uS 
c  £ r£> EO) o 
\ r  C l
o  B 
o _2o Or- Uj
n  ro °  0
.<2 o 
if) '4= 0 0
C C>  >, 
0  if)
Oh-
0 0 3 C
Q- &O) 
2 - 1 
O )^
H ^
CL O
cd ^
O c  o  0 Lu 5=
*♦- P o £
0 0 0 . t  
0 if) sz c.
II0 "O
h-
COCM
<
O 0
= i 
a I
E 0 0
S> re 
1? >
0
0
o
0
M"
CD
CDCM<
O
i _
0
O
E
os—Q.
0
i—3 -*—> 
0 C
C
o
Jt; 0"D C -Q 0 
0  GDI
IDID
4*
s’ !
O) o
I  -C 0 
0 ■ >
E 2 
0 j§
£  °- Q. 0 
=3 c  
m-  0 O CT> 
C _l O CD E  CM
T3 <
"S s
LD
0 *4—»O
E
o
i _Q.
i_
0
0
O
^  CM £  CD C >  0 
if) C n- 0O D)| 
G _l O CD E  CM T5 <
^  o
LDLD
CD >.0k_ 0
O) 0
d o
4—> 0)L_ r(U 4—'>4—c
E >1if)
0 if)
0 o4—>
if) CL
CL 0=3 c
M— 0o CD
c _lo CO4—>CM
-O <
■O0 O
LD
0  ^
TO ^  CM 
> . 0 0
TO 0  
0 C
■a £
0 _l 
£  CD 
C CM > .<  
W O 
O u_ 
C 0) 
.2 O
~  E
S sTO Q.
IDID
Co
CD
0
0c TO5= C
<- >* E 0
$ 1/5 0 _o
V) Q-Q. 0 3 C14- 0O O) 
C _l O CD E  CM ~o <
0
O
E
oi—
CL
0 •4—>
0
-  TJ CD 0 ~G CM 
0 0 <
M"CD
0 -♦—*O
E
o
i—Q.
0 -*—>
0
gU—'
CD ^  x= ^
- f—• 1C CM >00 
if)■*- 0  
o  c
c <•>O ^
CO
LD
0o
c
0
=3
cr
0
c/)
i—
0
E
0) 0
E £ ■- 0
0- z
oo
<  
cd
<  
< r CD 
5  CD
•”  O 
O O
i= <CDP q
<<<
o
CD
CDI-
<
CD
CD
O
<
O
CD
H
<
e E 
<
O 
CD 
CD O
O 
CD 
O <  
CD Q
<
CD
CD CD 
CD
O
3I-
<I-
<
O
CD
CD
CD CD
CD
<
<
CD I— 
CD
O  CD 
O .
<
o
<
I- o
I—o
<
<
I-I-
HQ_
CD
I-f—
I— 
CD h-
S
O
o
oH
CDI-I-
<
<
O
CDI-
O
CD
O
O
CD
h-
O
I-
M  
1  
s >
O
CD O  
I-  <
oo I— 
CL 
CD
CM< CD
O  CD
<<
<I-
<
f-H<
O
<
CD CD 
CD CD HCD
I -  CD<  h-<  <
O
CM
o
43
o>
e
To
0
c
c
<
<Dk.
3«*-<
<0 ^
E
<1)
o-CDi
ID
IDLD LDLD LDID
<D
</>
D
0
C
o
03 fit0 is
" 5
c  
05= c
c- > •E 0
SS «°2 5
to  Q-Q. 03 C
M— 0O 0) 
C _l O CD ■E CM "O <
'S 3
0 -*—»
o
E
o
i _
Q.
_ lCO
0
O
E
o
L_CL
0C
0
0^
TD CD 
~0 CM 0 <
c
o
0 )
0i _
0 )C
c
— I
CO
l_L
0>
0C
03
Q.
0C00)
_J 0
CD oCM
< EoO i—Q.
L -(D
E
i _
Q.
00
0>0
_ lCD 0CM
< 03
■0 ■00 -0C 00) i—
0 LD0 O'■0 •4—>i 00 L3
0
^0
0  0
75 -o
1 g
§ > £  
—  0  O 0
1 | C -* 
0 0) 
- t  C0  C
Jl> CO
g  c  
.E  o  w o
00o CM
c  <  0  3
cr 4 :
0 o  
O) sZ'
_ 0 
^  c
S  E
p  -c  Q _00! _
00c
£o
TJ
0
O
0
1 1  C CO
o  C  
03 J= 1= 0 O 0
! |  
C “ * 
0 0) 
i=  0  
w E
^  '0
.E  o  0  o
0
0O t-
c  <  0  Z]
o" 4r0 o  0 ■*-"
0) ^C 0 
^  C  
m 0£  E 
P  -C Q .
0
0l _
0
C
£o
■0
LL
Q.
E
0
CM<
0o
CL
E
0
CO
ID
0
o
c
0
3
0
0
COk_
0
E
0  0
If 0. z
o  
CD 
O <  
CD O
^ C D
S o
P|=
U <
<  rn
<  I- 
O  I -  
I— I— 
H  O
CD h- 
h— O
<  <
CD <
h-
<
O
<<
CD
O
CD
CD
CD<
<
\ -<
I -
O
<  ro 
CD j—
CD <  
I -  CD 
O  CD
<
CD <
O  
<  
CD 
I— 
CD 
O
CD
CD
CD
I -
O
I—
CD<
CD
O  <  
CD H  
CD < ' 
K O
O  o  I- o 
O  CD
CM
a
\ -
CD
I -
<
CD
<
<
O  h - 
I— I—I- o
CD I— 
I -  CD <  <
CD <  
I -  I—
O
I—
CD
<
CD
O  <
CD ^  K O
O  O  
I— O  
O  CD
CM
<
<
O
h
H
<  
O  
<  
I— 
CD 
CD
H  
I—
O
CD I— 
CD
<
CD
CD
CD CD 
CD b
CD <  CD
( j  CD CD 
< C ^ K
O  1_ <
<  cd <'
<  1— <  
O h h
$
I -
h - 
<  o
I- o
O'
LU
o
I—
o<
<
o
CD
I -
I -
I -  I—
CD
<<
CD
I -
O |— 
O  CD 
CD <
CM<
_JLL
<
CD
O
O<
CD<
CD
co<
<
O
O
I— 
O
o
<
CD
H
CD 
O  
\— 
I— 
CD 
CD
O'
<
44
ranging from 100 bp to 10 kbp from enzymatic reactions by adsorption to a silica 
membrane in the presence of high salt followed by elution in low salt (328).
According to the manufacturer’s instructions, 5 volumes of buffer PB were 
added to the PCR or digestion. This was mixed and placed in a QIAquick spin 
column. To bind the DNA, the column was centrifuged at 13,000 rpm for 1 minute 
and the flow through discarded. The column was washed with 750 pi buffer PE by 
centrifugation at 13,000 rpm for 1 minute. The flow through was discarded and the 
column was centrifuged for a further minute to dry. The column was placed into a 
fresh tube and 50 pi or 10 pi distilled H20  for the QIAquick or MinElute protocol, 
respectively, was applied to the centre of the membrane and left to stand for 1 
minute. The column was then centrifuged for 1 minute and the eluted DNA stored 
at -20 °C.
When necessary, DNA fragments were purified directly from an agarose gel 
to enable the selection of DNA fragments according to their size and separation on 
the gel. Purification of DNA was carried out using the QIAquick Gel Extraction kit 
(Qiagen) which is designed to extract and purify DNA of 70 bp to 10 kbp from 
standard or low-melting point agarose gels by adsorption to a silica membrane in 
the presence of high salt, followed by elution in low salt (328).
After excision of a DNA fragment, the gel slice was weighed and 3 volumes 
of buffer QG were added to 1 volume of gel. The sample was incubated at 50 °C 
for 10 minutes, or until the gel slice had completely dissolved. This was aided by 
vortexing the tube every 2 to 3 minutes. One gel volume of isopropanol was added 
to the sample and this was mixed and transferred to a QIAquick spin column. The
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column was centrifuged for 1 minute at 13,000 rpm and the flow through discarded. 
The column was washed with 500 pi buffer QG by centrifugation for 1 minute at
13,000 rpm to completely remove all traces of agarose, and the flow through 
discarded. The sample was washed with 750 pi of buffer PE and centrifuged for 1 
minute at 13,000 rpm. The flow through was discarded and the column was dried 
by centrifugation at 13,000 rpm for 1 minute. To elute the DNA, the spin column 
was placed in a fresh tube and 50 pi distilled H20  was applied to the centre of the 
QIAquick membrane and left to stand for 1 minute. The column was then 
centrifuged for 1 minute and the eluted DNA stored at -20 °C.
2.3.5 Polishing of PCR Products
To achieve blunt ends for cloning into the pCAPs vector, the PCR product 
was incubated with PfuTurbo DNA polymerase (Stratagene, California) to remove 
3’ overhangs which are produced during synthesis of the amplicon with Taq 
polymerase due to its terminal transferase activity. Briefly, to 20 pi of PCR product, 
1 pi of PfuTurbo DNA polymerase (2.5 U), 1.5 pi dNTPs and 2.5 pi of 10x reaction 
buffer were added. Reactions were incubated at 72 °C for 30 minutes. DNA was 
purified as described for PCR products in section 2.3 4.
2.3.6 Estimation of Concentration of DNA
To estimate the DNA concentration of plasmid preparations and PCR 
products, dilutions of DNA samples were electrophoresed through agarose gels
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and the intensity of ethidium bromide fluorescence under UV light compared by 
eye with a range of known standards (Roche Diagnostics Ltd.).
2.3.7 Ligation of DNA
Blunt-ended DNA fragments were sub-cloned into the pCAPs vector, a 
specially designed suicide vector that contains the lethal mutant gene of the 
catabolite activator protein (CAP). There are several advantages of using this 
positive selection cloning system. The pCAPs plasmid is linearised with the blunt- 
end cutting restriction enzyme /W/tvN1 in the coding region of the lethal CAP gene. 
Blunt-ended DNA fragments can be ligated into the vector and disrupt the lethal 
CAP gene. Only clones that contain recombinant vectors will survive as E.coli that 
contain the re-ligated vectors without an insert will not survive the transformation 
because they contain the active CAP gene. In addition, the vector contains the bla 
(p-lactamase) gene which confers ampicillin resistance, allowing clones that 
contain the recombinant pCAPs vector to grow on selective medium containing 
ampicillin (100 ug/ml).
Before ligation, the pCAPs vector was linearised by digestion with M/uN1. 
The reaction consisted of 2 pi of vector (10 ng), 1 pi SuRE/Cut buffer (10x), 1 pi of 
/W/uN1 (1 U) made up to 10 pi with 6 pi distilled H2O, and was incubated for 1 hour 
at 37 °C followed by 65 °C for 15 minutes to inactivate the enzyme.
Purified blunt-ended PCR products were ligated into the pCAPs vector as 
recommended by the manufacturer. Typically, reactions were set up containing 1 pi 
of linearised vector (1 ng), 10 pi ligation buffer (2x), up to 6 pi PCR product, 1 pi of
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T4 DNA ligase (5 U), 2 pi T4 DNA dilution buffer (10x) made up to a final volume of 
20 pi with distilled H2O. Varying ratios of vector:insert were set up to optimise the 
efficiency of ligation. The reaction was incubated at room temperature for 15 
minutes prior to transformation into XL1-Blue chemically competent cells 
(Stratagene) as described in section 2.3.8.
Alternatively, PCR products were sub-cloned directly into pCR®-XL-TOPO® 
(Invitrogen Ltd.). This vector is specifically designed for TA cloning of long PCR 
products (3-10 kb) and uses the lethal cccfB (control of cell death) gene to enable 
high efficiency cloning. This vector also has kanamycin and Zeocin™ resistance 
genes to aid the selection of transformants, and M13 forward and reverse priming 
sites for sequencing. The vector is supplied linearised, and has single overhanging 
3’ deoxythymidine residues. This allows ligation of PCR products synthesised by 
Taq polymerase which has terminal transferase activity to add a single 
deoxyadenosine residue to the 3’ ends of PCR products. TOPO® cloning utilises 
the VACV DNA topoisomerase I, which acts as a restriction enzyme and as a 
ligase, cleaving and re-joining DNA during replication. The topoisomerase I 
specifically recognises the pentameric sequence 5’-CCCTT-3’ and forms a 
covalent bond with the phosphate group of the 3’ thymidine. It cleaves one DNA 
strand, enabling the DNA to unwind. The enzyme then re-ligates the ends of the 
cleaved strand and releases itself from the DNA (Invitrogen Ltd.).
Briefly, 4 pi of PCR product was added to 1 pi of linearised vector and 
incubated for 5 minutes at room temperature. Up to 5 pi of this reaction was used 
to transform TOP10 cells (Invitrogen Ltd.) as described in section 2.3.8.
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2.3.8 Transformation of Recombinant Plasmids into E. coli
Plasmid DNA was transformed into chemically competent XL1-Blue cells 
(Stratagene) or TOP10 cells (Invitrogen Ltd.). According to the manufacturer’s 
instructions, cells were thawed on ice and up to 5 pi of ligation reaction added to 
the cells. These were incubated for 30 minutes on ice to allow association of 
plasmid DNA with the cells. Cells were heat shocked by incubation at 42 °C for 30- 
45 seconds, which causes permeabilisation of the bacterial membrane to DNA. 
Following this, 250 pi of room temperature SOC growth medium (20 g of bacto- 
tryptone, 5 g of Bacto-yeast extract, 10 ml 1 M NaCI and 2.5 ml 1 M KCI per litre) 
was added to the cells and incubated at 37 °C shaking for 1 hour. A small sample 
of the transformed cells (usually 50 pi) was spread onto L-agar containing the 
appropriate antibiotic in a 9 cm Petri dish and cultures were incubated at 37 °C 
overnight.
Single colonies were used to inoculate 5 ml L-broth containing the 
appropriate selective antibiotic and incubated for approximately 16 hours with 
shaking at 37 °C. Plasmid minipreparation was carried out as described in section 
2.3.9, and glycerol stocks prepared to maintain transformed E.coli strains at -80 °C 
as described in section 2.2.3.
2.3.9 Plasmid Minipreparation
Plasmid DNA from transformed E.coli strains was isolated using QIAprep 
Spin Plasmid Miniprep kit (Qiagen) according to the manufacturer’s instructions.
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The kit is designed to lyse bacterial cells by the alkaline lysis method of Birnboim 
and Doly (329) using the buffers provided.
Purification of plasmid DNA is by adsorption onto a silica membrane in the 
presence of high salt and elution in a low salt buffer. Briefly, transformed E.coli 
was cultured in 5 ml L-broth containing the appropriate antibiotic for approximately 
16 hours with shaking at 37 °C. Bacterial cells were harvested via centrifugation at
13,000 rpm for 3 minutes in a microcentrifuge. The supernate was removed and 
bacterial cells were resuspended in 250 pi buffer P1. To this, 250 pi of buffer P2 
was added and the tube was inverted to mix and incubated at room temperature 
for up to 5 minutes. After this time, 350 pi buffer N3 was added to precipitate 
cellular proteins, and the tube was inverted to mix immediately. The tube was 
centrifuged for 10 minutes at 13,000 rpm to remove the precipitate. The supernate 
was transferred to a QIAprep spin column and centrifuged for 1 minute at 13,000 
rpm to bind the DNA. The column was washed with 750 pi of buffer PE by 
centrifugation at 13,000 rpm for 1 minute. The membrane was dried by 
centrifugation at 13,000 rpm for 1 minute. The column was placed into a fresh tube 
and 50 pi of distilled H20  was applied to the centre of the QIAprep membrane and 
left to stand for 1 minute. The column was centrifuged for 1 minute and the eluted 
DNA stored at -20 °C.
2.3.10 Digestion of DNA Fragments with S1 Nuclease
The treatment of DNA fragments with S1 nuclease ensures that all single­
stranded and mispaired fragments are degraded. A typical reaction consisted of 8
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Ml of DNA, 1 m> of S1 nuclease, 0.1 |jl of NaCI (3 M) and 0.9 pi of reaction buffer 
(10x). Reactions were incubated for 1 hour at 37 °C. To check the integrity of the 
DNA, a small sample was examined using agarose gel electrophoresis.
2.3.11 Sequencing of DNA
Approximately 100 ng of DNA was required by Lark Technologies, Ltd. for 
single pass sequence reactions (up to 1 kbp). Inserts cloned into pCAPs vector 
(Roche Diagnostics Ltd.) were sequenced using primers GPT2 and GPT3 (Table 
2.1). Inserts cloned into the pCR®-XL-TOPO® vector were sequenced using 
universal primers M13F and M13R (Table 2.2) which anneal at either side of the 
cloning site and read into the insert from the opposite ends. Primers designed in 
house and synthesised by Lark Technologies, Ltd. were also used where specified 
to determine the sequence of larger inserts from a point of origin within the insert 
(Table 2.2). Sequences were analysed using DNASTAR Lasergene EditSeq and 
MegAlign programmes.
2.4 Cell Culture
2.4.1 Maintenance of Mammalian Cell Lines
RK13 (Rabbit kidney) and BSC40 (African Green Monkey kidney) cells 
kindly supplied by Dr D.O. Ulaeto (Dstl), and STO (mouse embryonic fibroblast) 
cells obtained from European Collection of Cell Cultures (ECACC, Porton Down, 
UK) were cultured in the growth medium D10 consisting of Dulbecco’s minimal 
essential medium (DMEM) (Sigma-Aldrich) supplemented with 2 mM L-glutamine
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(Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich), 100 pg/ml streptomycin 
(Sigma-Aldrich) and 10 % (v/v) foetal calf serum (FCS) (Sigma-Aldrich), at 37 °C in 
a 5 % (v/v) C02 humidified atmosphere. Cultures were maintained as sub-confluent 
monolayers, and passaged twice weekly following trypsinisation to remove the 
monolayer with TE (0.1 % (w/v) trypsin, 0.01 % (w/v) EDTA in Hanks balanced salt 
solution with phenol red) (Sigma-Aldrich). Cells were seeded into new flasks at a 
concentration of approximately 5 x 104 cells/cm2.
2.4.2 Transfection of Mammalian Cell Lines
Transfection of mammalian cell lines to deliver DNA into the cell was 
achieved using Lipofectamine™ Reagent (Invitrogen Ltd.), a 3:1 (w/w) liposome 
formulation of the polycationic lipid 2,3-dioleyloxy-N-[2(sperminecarboxamido)ethyl] 
-N,N-dimethyl-1-propanaminium trifluoroacetate (DOSPA) and the neutral lipid 
dioleoyl phosphatidylethanolamine (DOPE). DNA was combined with 
Lipofectamine™ Reagent to form a DNA-lipid complex which would fuse with the 
cell membrane and allow transport of DNA into the cell.
Cells were seeded into a 24-well tissue culture plate at a density of 
approximately 4 x 104 cells per well in 1 ml of growth media and incubated 
overnight at 37 °C in a humidified 5 % (v/v) C02 atmosphere. To increase 
transfection efficiency, cells were rinsed with 500 pi Opti-MEM® I Reduced Serum 
Medium (Invitrogen Ltd.) prior to transfection. Typically for each reaction, plasmid 
DNA was diluted to 0.2 - 0.4 pg in 25 pi Opti-MEM® I Reduced Serum Medium, and 
5 pi of Lipofectamine™ Reagent was diluted into 25 pi of Opti-MEM® I Reduced
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Serum Medium. These were combined and incubated for 45 minutes at room 
temperature to allow the DNA-lipid complexes to form. To each reaction, 150 pi of 
Opti-MEM® I Reduced Serum Medium was added and then the complexes were 
overlaid onto the cells. Cells were incubated for up to 5 hours then infected with 5 x 
105 pfu of VACV, and incubated for a further 24-48 hours at 37 °C in a humidified 5 
% (v/v) C02 atmosphere. In some cases, cultures were transfected then infected 
with VACV in selective medium (section 2.5.5).
2.5 Manipulation of VACV
2.5.1 Infection of Mammalian Cells with VACV
VACV was diluted to give the appropriate multiplicity of infection (MOI) in 
either PBS or D10. Cells were usually infected in a low volume and rocked slowly 
for 1 hour, prior to removal of the inoculum and replacement with tissue culture 
medium. Cells were incubated for up to 7 days at 37 °C in a humidified 5 % (v/v) 
C02 atmosphere.
In some experiments, cultures were supplemented with 10 pg/ml Blasticidin 
(Invitrogen Ltd.), 0.05 nM to 50 nM ST-246 (kindly provided by Dr D. Hruby, 
Oregon State University, USA) or 4 pg/ml Brefeldin A (BFA) (Sigma-Aldrich), or 
combinations thereof.
2.5.2 Purification of VACV
Virus was harvested from tissue culture vessels by carefully scraping the 
cells with a cell scraper or a pipette tip. Cells containing virus were then collected
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by centrifugation at 2,500 rpm for 10 minutes (Jouan Centrifuge C3i, France). Cells 
were lysed by dounce homogenisation or freeze-thaw (x3 cycles) and cellular 
debris removed by further centrifugation at 2,500 rpm for 10 minutes. Virus in the 
supernate was concentrated by ultracentrifugation at 20,000 rpm for 60 minutes 
and purified through a 36 % (w/v) sucrose cushion at 13,500 rpm for 80 minutes 
(Beckman L8-70M, USA).
To purify VACV EV and IMV, virus cultures were separated on CsCI 
gradients. CsCI gradients were prepared with premixed solutions of densities 1.20, 
1.25 and 1.30 g/ml, and virus purified through these gradients for approximately 18 
hours at 28,000 rpm (Beckman L8-70M, USA), at 15 °C. For quantification of EV 
and IMV, each gradient was collected into a 96-well tissue culture plate by 
mechanical fractionation either from the top of the gradient under the control of a 
syringe drive (5 ml/minute) or from the bottom of the tube under the control of a 
peristaltic pump.
2.5.3 Quantification of Virus by Plaque Titration
The Reed-Muench limiting dilution method used in this study calculates the 
50 % tissue culture infectious dose per ml (TCID50/ml) (330). The number of virus 
positive wells in a titration plate was input to a spreadsheet (courtesy of Dr D.O. 
Ulaeto) to calculate the TCID5o/ml. The following calculation was used:
Where the proportionate distance (pd) is calculated (always a negative value) and 
the dilution interval is 1/3:
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-pd
(% well infected at dilution next above 50%) - 50%
(% wells infected at dilution next above 50% - 
(% wells infected at dilution next below 50%)
x log dilution interval
log TCID50 = log dilution next to and above 50 % positives + (-pd)
TCID50 = 10(logTCID50)
TCID50/ml = (1/TCiD50)x (1/volume plated per well)
The resulting TCID50/ml can be used to estimate the number of plaque 
forming units per ml (pfu/ml) in a sample by applying the Poisson distribution. 
Where P(0) is the proportion of virus negative samples and m is the mean number 
of infectious units per unit volume (pfu/ml), therefore P(0) = e(-m). For any titre 
expressed as a TCID50, P(0) = 0.5. Thus e(-m) = 0.5 and m = -In 0.5 which is ~ 0.7 
(courtesy of ATCC). Therefore, in this study the conversion of TCID5o/ml into pfu/ml 
is achieved by a simple multiplication of 0.7. This has been validated for VACV by 
direct comparison of TCID50 titres with standard pfu titres (Dr. D.O. Ulaeto, 
personal communication).
Cells were seeded at a density of 5 x 104 per ml, in 100 pi volumes per well 
in a 96-well tissue culture plate and incubated overnight at 37 °C in a humidified 5 
% (v/v) CO2 atmosphere. Virus was diluted as appropriate in tissue culture medium 
prior to transferring 100 pi into each well of the first column of a 96-well tissue 
culture plate containing 200 pi tissue culture medium. Virus was diluted across the 
plate 1:3 to give a total of 8 wells per dilution. Fifty microlitres of each well was 
plated onto the corresponding wells of the 96-well tissue culture plate seeded with 
cells. Alternatively when large numbers of samples were to be quantified, a
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variation of this method was used. Briefly, up to 300 pi of sample was transferred 
to one well of the first column of a 96-well tissue culture plate. This was diluted 
across the plate 1:3 by transferring 95 pi of sample into wells pre-loaded with 190 
pi tissue culture medium. This would allow up to 8 samples to be diluted across a 
plate in parallel. Using a multi-stepper pipette, 15 pi of each dilution was plated per 
well down a column of a 96-well plate seeded with cells. In some cases, cultures 
were supplemented with selective agents to allow growth of recombinant virus, or 
in the presence of rabbit IMV-neutralising antibodies (1:800 dilution of neat sera) to 
quantify EEV in culture supernates. Plates were incubated for 5-7 days at 37 °C 
and 5 % (v/v) CO2 then fixed with formaldehyde (final concentration 1 % v/v) or 75 
% (v/v) ethanol. Monolayers were stained with crystal violet (1 % w/v) in 30 % or 75 
% ethanol and excess crystal violet rinsed off with tap water. The number of growth 
positive wells was determined visually and the TCID50/ml calculated.
To estimate the number of infectious units present in CsCI gradient 
fractions, a modified plaque titration method was used. Briefly, samples were 
diluted 1:100 in tissue culture medium. Then, 60 pi was transferred in triplicate to 
the first well of a column of a 96-well tissue culture plate containing 240 pi tissue 
culture medium per well. Samples were diluted 1:5 down the plate by transferring 
60 pi to the next row. This allowed the dilution of 4 samples in parallel per plate. 
Fifty microlitres of each dilution was transferred to the corresponding well of a 96- 
well plate seeded with RK13 cells. Plates were incubated for 7 days then fixed and 
stained as described previously. To calculate the virus titre, the mean absorbance 
at 570 nm was calculated using a Titretek Multiskan Plus spectrophotometer and
57
Ascent software 2.4.2 (Thermolab systems, UK). The presence of virus in each 
sample was indicated by a low absorbance reading and the absence of virus by a 
high absorbance. When the absorbance was plotted versus the dilution factor, the 
dilution at which 50 % of the wells were infected was determined using the 
regression analysis function in Microsoft Excel®. The reciprocal of this dilution 
allowed conversion to a virus titre, 50 %max-
2.5.4 Quantification of Virus by Metabolic Labelling
As an alternative method to quantify virions, in particular particles separated 
through a CsCI gradient, viruses were cultured in the presence of tritiated 
thymidine (3H thymidine) to metabolically label viral genomes, which can thus be 
quantitated using a scintillation counter.
BSC40 or RK13 cells were seeded at a density of 5 x 104 cells per well in a 
24-well tissue culture plate and incubated overnight at 37 °C in a humidified 5 % 
(v/v) C02 atmosphere. Cells were infected at MOI 10 as described in section 2.5.1 
and culture medium supplemented with 10 pCi 3H thymidine (Amersham) and 
returned to incubation at 37 °C in a humidified 5 % (v/v) C02 atmosphere. Virus 
replication was halted by freezing at -80 °C and virus liberated from the cells by 
freeze-thaw (x1 cycle) followed by dounce homogenisation with a steel 
homogeniser (x10 passes). Cultures were clarified by centrifugation at 13,000 rpm 
for 30 seconds or 2,100 rpm for 5 minutes. The supernates were layered onto CsCI 
gradients as described in section 2.5.2, and fractions collected from the bottom of 
the tube into a 96-well tissue culture plate. Virus was inactivated with formaldehyde
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(final concentration 1 % v/v) for 1 hour. In some cases, the density of each fraction 
was determined by weighing 100 |jl on a fine balance (HR-120, A and D 
Instruments). Virus particles were captured onto 96-well glass fibre GF/C Unifilter 
microplates (Perkin Elmer) using a Packard Filtermate 196 ceil harvester (Perkin 
Elmer) and left to dry at room temperature overnight. When dry, 20 pi of MicroScint 
O scintillation fluid (Perkin Elmer) was applied to each well and plates were 
subjected to counting on a TopCount liquid scintillation counter (Perkin Elmer).
2.5.5 Extraction of Viral DNA
Viruses were cultured in the appropriate cell line with or without selective 
agents for a minimum of 18 hours at 37 °C in a humidified 5 % (v/v) CO2 
atmosphere. Virus-containing cells were scraped from the bottom of the tissue 
culture flask or plate and 500 pi of the crude suspension transferred to a screw- 
capped Eppendorf tube. The sample was subjected to freeze-thaw (x3 cycles) to 
liberate intracellular virus, and cell debris removed by centrifugation at 2,100 rpm 
for 5 minutes. The supernate was transferred to a clean tube and 100 pi of lysis 
buffer (50 mM Tris-HCI, 10 mM EDTA, 1 % (v/v) SDS, 10 pg Proteinase K) added. 
Samples were heated at 80 °C for 1 hour. DNA was extracted by adding an equal 
volume of phenol:chloroform:isoamyl alcohol (25:24:1) (Sigma-Aldrich). After 
mixing, the sample was centrifuged at 13,000 rpm for 10 minutes. The DNA- 
containing top layer of the sample was transferred to a clean tube and the 
extraction repeated, twice. DNA was precipitated in 0.1 volume of ice-cold 100 % 
ethanol and incubated for 1 hour at -80 °C or overnight at -20 °C, and then pelleted
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by centrifugation at 13,000 rpm for 30 minutes. The DNA pellet was washed with 
200 pi 70 % (v/v) ice-cold ethanol and allowed to air dry. The pellet was 
resuspended in up to 1 ml nuclease-free H20  and stored in 100 pi aliquots at -20 
°C.
Alternatively, the QIAamp DNA blood mini kit (Qiagen) was used to purify 
viral DNA from the sample according to the manufacturer’s instructions for 
purification from blood and body fluids. The kit allows the purification of multiple 
DNA samples of up to 50 kb and removes PCR inhibitors such a divalent cations 
and proteins, using the same principles as the QIAprep spin kit and QIAquick DNA 
extraction kit (Qiagen). To lyse cells, 20 pi Triton X-100 (Sigma-Aldrich) was added 
and cultures incubated for 10 minutes at 37 °C. Each sample was pre-digested 
with 1 mg DNase-free RNase A (Sigma-Aldrich) for 10 minutes at 37 °C to prevent 
co-purification of RNA. To lyse viral particles, 2 pg of Proteinase K (Sigma-Aldrich) 
and 500 pi of buffer AL were added and the samples were heated at 80 °C for a 
minimum of 10 minutes. To bind the DNA to the silica-gel column, 525 pi of 100 % 
ethanol was added and the solutions run through the QIAamp column at 8,000 rpm 
for 1 minute. The columns were sequentially washed twice with 500 pi of buffer 
AW1 and AW2 by centrifugation at 8,000 rpm. Residual buffer was removed from 
the column by centrifugation at 13,000 rpm for 3 minutes. To elute the DNA, 200 pi 
of nuclease-free H20  pre-heated to 70 °C was added to each column and 
incubated for 5 minutes to increase efficiency of the elution. The columns were 
centrifuged at 13,000 rpm for 1 minute and the DNA collected in a microcentrifuge 
tube. DNA was stored at -20 °C until use.
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2.5.6 Inhibition of EEV Production in Recombinant VACV Cultures
RK13 cells were seeded at approximately 5 x 104 cells per well in 24-well 
tissue culture plates and incubated overnight at 37 °C in a humidified 5 % (v/v) C02 
atmosphere. Cells were infected at MOI 10 with the appropriate virus and incubated 
for 30 minutes to allow virus adsorption. The inoculum was removed and the cells 
rinsed with 1 ml PBS and the medium replaced with 0.5 ml tissue culture medium. 
For BFA experiments, a concentration of 4 pg/ml BFA (Sigma-Aldrich) was used 
and the medium was supplemented with 10 mM HEPES buffer (Sigma-Aldrich) to 
prevent changes in the pH that may affect the activity of BFA (331). Cultures were 
incubated for various times p.i. after which the culture supernate was removed and 
the cells rinsed twice with 1 ml PBS. Fresh tissue culture medium was applied to 
each culture with or without BFA (4 pg/ml) as appropriate and cultures incubated 
further to allow recovery of EEV. Cultures were sampled repeatedly over time by 
removing the culture supernate and replacing with fresh tissue culture medium. To 
quantify the amounts of secreted virus in each culture, the TCID50/ml was obtained 
for each sample using the Reed-Muench limiting dilution method as described in 
section 2.5.3.
2.5.7 Effect of Antimicrobial Peptides (AMPs) on VACV Particles
EEV was prepared fresh for each experiment to avoid damage to the lipid 
envelope by the freeze-thaw process. Briefly, RK13 cells were seeded at a density 
of approximately 5 x 104 cells per well of a 24-well tissue culture plate and 
incubated for a minimum of 6 hours at 37 °C in 5 % (v/v) C02. Cells were infected
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at an approximate MOI 10 of VACV IHD-J and cultures rocked slowly for 30 
minutes. The inoculum was removed and the cells rinsed with 1 ml PBS. To each 
well, 0.5 ml tissue culture medium was added supplemented with 10 pCi 3H 
thymidine as appropriate. Cultures were incubated for 15-20 hours at 37 °C in a 
humidified 5 % (v/v) CO2 atmosphere. The EEV-enriched culture supernate was 
harvested from each culture and clarified by centrifugation at 2,100 rpm for 5 
minutes to remove cellular debris.
IMV was prepared in RK13 cells as described above in tissue culture 
medium supplemented with 10 pCi 3H thymidine. Cultures were incubated for 24 
hours at 37 °C in 5 % (v/v) CO2 . To isolate IMV, the EEV-enriched culture 
supernate was discarded and the cells rinsed twice with 1 ml PBS. To remove CEV 
attached to the cell surface, cells were treated with 1 ml TE for 45 minutes at 37 
°C in a humidified 5 % (v/v) CO2 atmosphere. Cells were washed twice with 1 ml 
tissue culture medium with 10 % (v/v) FCS to inactivate the trypsin and collected 
by centrifugation at 2,100 rpm for 5 minutes to remove CEV. The pelleted cells 
were resuspended in 0.5 ml tissue culture medium and subjected to 2x freeze-thaw 
cycles to liberate IMV. IMV-enriched cultures were clarified by centrifugation at 
2,100 rpm for 5 minutes and diluted to 600 pi with tissue culture medium. Cultures 
were freshly prepared for each experiment however the remainder was stored at - 
20 °C or -80 °C for future use if necessary.
The effect of AMPs on EEV and IMV was examined by incubating 45 pi of 
EEV- or IMV-enriched culture prepared as described above. To each culture, 5 pi 
of LL-37 (final 100 pg/ml), Magainin II (final 100 pg/ml) or Tween-20 (final 0.5 %
62
(v/v)) was added and vortexed briefly. Cultures were incubated for 1.5 and 3 hours 
at 37 °C.
Experiments consisted of three replicates allowing for the quantitation of one 
sample by Reed-Muench limiting dilution analysis as described in section 2.5.3. 
For EEV-enriched cultures, samples were treated with 1:100 dilution of rabbit IMV- 
neutralising antibody (courtesy of Dr D.O. Ulaeto and Dr A. Gates) for 15 minutes 
at room temperature prior to titration on RK13 cells, to give a final dilution of 1:800 
of neutralising antibody. The remaining two replicates were subjected to 
ultracentrifugation at 28,000 rpm through CsCI gradients as described in sections
2.5.2 and 2.5.4 to separate virus particles by buoyant density. Gradients were 
fractionated and 100 pi of each fraction weighed prior to filtration onto glass fibre 
filter plates and scintillation counting.
2.5.8 Preparation of Virus for Transmission Electron Microscopy (TEM)
RK13 cells in a 24-well tissue culture plate were infected at MOI 10 with 
VACV and incubated for 24 hours at 37 °C in a humidified 5 % (v/v) C02 
atmosphere. The culture supernate was removed and the cells rinsed twice, with 1 
ml ice-cold PBS. The cells were scraped into 0.5 ml of 0.1 M cacodylate buffer and 
transferred to a screw-capped Eppendorf tube. Infected cells were collected by 
centrifugation at 2,100 rpm for 5 minutes, resuspended in 500 pi Karnovski fixative 
(2 % paraformaldehyde, 3 % glutaraldehyde in 0.1 M cacodylate buffer) and 
incubated for a minimum of 18 hours at 4 °C. Fixed cells were collected by 
centrifugation at 13,000 rpm for 30 seconds and post-fixed with osmium tetroxide
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(2 % v/v) in 0.1 M cacodylate buffer for 1-2 hours. Cells were washed in 0.1 M 
cacodylate buffer, then 70 % (v/v) ethanol and collected by centrifugation at 13,000 
rpm for 30 seconds. Samples were dehydrated in a graded ethanol series (30 
minutes per wash) of 70 %, 90 % and 95 % concluding with 3 final washes of 100 
% (v/v) ethanol for 30 minutes. After the final 100 % wash, cells were collected by 
centrifugation at 13,000 rpm for 30. seconds. Samples were infiltrated with LR 
White Resin (Agar Scientific, UK) and the resin polymerised by baking at 60 °C for 
18 hours in a gelatin capsule. Ultrathin (gold) sections were cut using a diamond 
knife on a LKB Ultramicrotome and sections were collected onto copper grids. 
Sections were stained with 2 % aqueous uranyl acetate (w/v) and 1 % lead citrate 
(w/v) for 20 and 5 minutes, respectively. Samples were viewed using a Philips 
CM 12 TEM operating at 80kV. Images were acquired using a SIS Keenview 1 
mega-pixel digital camera and were adjusted for brightness and contrast only.
2.6. Generation of Recombinant VACV
2.6.1 Selection of Recombinant VACV
Following transfection and subsequent infection of cells with VACV, progeny 
recombinant VACV was selected using the appropriate selective medium. For 
recombinant viruses engineered with the E. coli guanine phosphoribosyl 
transferase (EcoGPT) gene for resistance to mycophenolic acid, recombinant 
viruses were grown in RK13 or BSC40 cells with mycophenolic acid (25 pg/ml) 
added to the tissue culture medium, supplemented with xanthine (250 pg/ml) and 
hypoxanthine (15 pg/ml). For reverse selection of EcoGPT recombinant viruses, 
non-EcoGPT expressing viruses were selected in STO cells in the presence of 0.1
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mM 6-thioguanine (6-TG) (Sigma-Aldrich). Recombinant viruses engineered to 
contain the G418R gene for resistance to Geneticin®, were cultured in RK13 or 
BSC40 cells in the presence of 2 mg/ml Geneticin® (Invitrogen Ltd.)
All viruses were cultured for a minimum of 5 rounds of selection to enrich for 
recombinant virus and minimise the numbers of parental VACV prior to plaque 
purification.
2.6.2 Plaque Purification of Recombinant VACV
To isolate recombinant VACV such that a clonal population was achieved, 
virus was plaque purified either by limiting dilution or by plaque picking using 
agarose overlay. Using the agarose overlay method, BSC40 cells were seeded into 
6-well tissue culture plates at a density of 5 x 104 cells per ml in a volume of 5 ml, 
and incubated overnight at 37 °C in a humidified 5 % (v/v) CO2 atmosphere. 
Putative recombinant virus was dounce homogenised using a steel homogeniser 
and briefly treated in a sonicating water bath to disaggregate virus particles, prior 
to dilution to low MOI (approximately 10 pfu/well). Cells were infected in 500 pi of 
tissue culture medium and slowly rocked for 1 hour, before the inoculum was 
removed and replaced with 2 ml of low melting point agarose (final w/v 1 %) 
dissolved in DMEM supplemented with 2 mM L-glutamine plus 10 % FCS 
containing the appropriate selective agent and maintained molten at 37 °C until 
use. Once poured onto the cells, the agarose was allowed to set at room 
temperature before incubating for 24-72 hours at 37 °C in a humidified 5 % (v/v)
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CO2 atmosphere. Plaques were picked using a 1000 pi pipette tip and resuspended 
in 200 pi PBS. This process was generally repeated at least 3 times in succession.
Plaque purification by limiting dilution uses the Poisson distribution to 
calculate the number of growth positive wells that should ensure no more than 1 
pfu per well. For this method, a 96-well tissue culture plate was seeded with RK13 
cells at a density of 5 x 104 cells per ml in 100 pi volumes per well and incubated 
overnight at 37 °C in a humidified 5 % (v/v) CO2 atmosphere. Putative recombinant 
virus was dounce homogenised using a steel homogeniser and briefly treated in a 
sonicating water bath to disaggregate virus particles. Where the TCID5o/ml had 
been calculated, virus was diluted in 5 ml tissue culture medium to give 0.3 and 3 
TCID50 per well, which should result in -30 % and -100 % virus positive wells per 
plate, respectively, according to the Poisson distribution. Fifty microlitres of each 
dilution was added to each well of RK13 cells and incubated for 5-7 days at 37 °C 
in a humidified 5 % (v/v) C02 atmosphere. At each round of purification, the 
numbers of growth positive wells were monitored where no more than 30 virus 
positive wells indicated that less than 1 pfu was present per well. Where the 
TCID50/ml has not been calculated, virus was repeatedly diluted 3-fold into 1400 pi 
tissue culture medium and 100 pi of each dilution plated per well across a row of a 
96-well tissue culture plate of RK13 cells. Plates were incubated for 5-7 days at 37 
°C in a humidified 5 % (v/v) CO2 atmosphere. Using the Poisson distribution, 3 or 
less virus positive wells in a row indicates that the virus-positive wells in that row 
are likely to have arisen from no more than 1 pfu and the wells from this row were 
harvested for the next round of plaque purification. Plaque purification by limiting
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dilution was repeated for a minimum of 3 rounds. In some cases, a combination of 
agarose overlay and limiting dilution was used to plaque purify recombinant VACVs 
so as to utilise the advantages of both methods.
2.7 Reverse Transcription Polymerase Chain Reaction (RT-PCR)
The TaqMan® Gene Expression Assay contains forward and reverse 
sequence-specific primers and a dual-labelled probe that is specific to an internal 
region of the target sequence. This probe is labelled with a reporter fluorophore at 
the 5’- end and a quencher fluorophore at the 3’- end. During the amplification 
reaction, the probe anneals to the target sequence. In this state, the reporter and 
quencher fluorophore are in close proximity and the fluorescence intensity of the 
reaction is low. As the polymerase carries out extension of the forward and reverse 
primers and replicates the template to which the probe is bound, the 5’- 
exonuclease activity of the polymerase cleaves the probe. This releases the 
reporter away from the quencher and as a result the fluorescence intensity 
increases. Therefore, the increasing fluorescence correlates with the accumulation 
of PCR product in each cycle.
2.7.1 Isolation of Messenger Ribonucleic Acid (mRNA) from Virus Cultures
Viruses were cultured in RK13 cells at MOI 10 as described in section 2.5.1 
and incubated until various times p.i. The RNAqueous® kit (Ambion) was used for 
RNA extraction. The kit uses phenol-free, filter based technology to rapidly isolate 
RNA from tissues. Briefly, cells are disrupted using a high concentration
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guanidinium salt solution that also inactivates endogenous RNases (332). The 
sample is then passed through a glass fibre filter that binds the RNA and allows 
cellular components to run through (328;333;334). The RNA is washed several 
times before elution in a low ionic strength solution.
At the appropriate time p.i., the culture supernate was removed and 700 pi 
of lysis buffer was added to each well. Cells were gently pipetted up and down to 
lyse infected cells and liberate RNAs. Samples were transferred to nuclease-free 
tubes and stored at -80 °C until processing. To extract RNA, 700 pi of 64 % 
ethanol was added and each sample was gently mixed by inversion. The lysate 
was applied to a spin-filter column and was then centrifuged at 13,000 rpm for 1 
minute. The filtrate was discarded and the filter was washed with 700 pi wash 
solution #1 containing guanidinium salt solution to denature residual RNases. The 
filtrate was discarded and the column was washed twice with 500 pi of wash 
solution #2/3. The filtrate was discarded and the filter dried by centrifugation at
13,000 rpm for 1 minute. The filter was transferred to a fresh nuclease-free tube 
and the RNA eluted by centrifugation at 13,000 rpm for 30 seconds in 40 pi 
nuclease-free H20  (Ambion) pre-heated to 70 °C. To maximise RNA recovery, a 
second elution step of 10 pi pre-heated nuclease-free H20  was included. Extracted 
RNA was stored at -80 °C.
2.7.2 Removal of Genomic DNA from Extracted RNA
Prior to reverse transcription of mRNA to complementary DNA, (cDNA) 
contaminating genomic DNA (gDNA) was degraded using DNA-free TURBO
68
DNase™ (Ambion); this removes trace amounts of genomic DNA in RNA samples 
more efficiently than wild-type DNase I. Removal of the TURBO DNase™ uses an 
Inactivation Reagent therefore avoiding organic extraction or heating that may 
result in degradation of RNA or interfere with downstream reactions. Briefly, 5 pi 
reaction buffer (10x) and 1 pi TURBO DNase™ was added to a 50 pi sample. This 
was mixed gently and incubated for up to 30 minutes at 37 °C. To inactivate the 
nuclease, 5 pi Inactivation Reagent was added and incubated fo r 2 minutes at 
room temperature with occasional mixing. The sample was then centrifuged at
13,000 rpm for 1.5 minutes and the RNA-containing supernate transferred to a 
fresh nuclease-free tube.
2.7.3 Quantification of RNA
RNA was quantified using a NanoDrop® ND-1000 spectrophotometer 
(ThermoScientific). Briefly, 1.5 pi was applied to the NanoDrop electrode and the 
UV absorbance at 260 nm (A26o) and 280 nm (A28o) was recorded. The 
concentration of single-stranded RNA was calculated in pg/ml by:
A26o x dilution factor x 40 = pg RNA/ml
To determine the purity of each sample the ratio of A26o:A28o was calculated, 
where a value outside the range of 1.8 to 2.1 was indicative of protein 
contamination.
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2.7.4 One-step Real-Time PCR
For gene expression analysis, TaqMan® RNA-to-Ct 1-Sfep kit (Applied 
Biosystems, UK) was used. This kit allows the addition of RNA directly to the 
reaction where reverse transcription and real-time PCR are performed in one tube. 
A hot-start enzyme is included to prevent priming during reaction set up, an RNase 
inhibitor to prevent degradation of RNA template and the formula of enzymes 
provide high levels of sensitivity and quantitative discrimination (Applied 
Biosystems, UK). Typically reactions were performed in 20 pi volumes of 0.5 pi 
TaqMan® RT-Enzyme Mix (40x), 10 pi TaqMan® RT-PCR Mix (2x), 1 pi TaqMan® 
Gene Expression Assay (20x) and 8.5 pi template (~100 ng) in nuclease-free water 
(Ambion), using Applied Biosystems 7000 Real-Time PCR System. Reactions 
were dispensed into MicroAmp™ Optical 96-well reaction plates (Applied 
Biosystems) and the plate sealed with adhesive film. The cycling conditions used 
were 48 °C for 15 minutes; 95 °C for 10 minutes; followed by 40 cycles of 95 °C for 
15 seconds then 60 °C for 1 minute. At the end of the run, the cycle threshold (Ct) 
was determined for each gene using the ABI 7000 sequence detection system 
software (Applied Biosystems).
To determine the fold change, the delta delta cycle threshold (AACt) method 
of Livak and Schmittgen was used (335). For each sample, the average Ct value of 
triplicate wells was calculated. This was normalised using the 18s ribosomal RNA 
(rRNA) endogenous control gene to give the ACt (average Ct target gene - average 
Ct endogenous control). All ACt values throughout the infectious cycle were 
compared to the ACt value at t=0 for each gene tested to give the AACt (ACt target
70
gene - ACt at t=0). The fold change was calculated as 2'MCt. This analysis was 
performed for the A26L, A27L and F13L genes at several time points.
2.8 Protein Techniques
2.8.1 SDS-PAGE
Viral proteins were separated by polyacrylamide gel electrophoresis (PAGE) 
on Novex® 10 % Tricine gels (Invitrogen Ltd.) using an Xcell SureLock® Mini-Cell 
apparatus (Invitrogen Ltd.) according to the manufacturer’s instructions. Briefly, 8 
pi of purified virus (~107 pfu) was heated to 80 °C with 2 pi NuPage® Reducing 
agent and 10 pi Novex® Tricine SDS running buffer, all from Invitrogen Ltd. 
Samples were loaded onto the gel and separated for up to 1.5 hours at 125 volts in 
Tricine running buffer (Invitrogen Ltd). Gels were stained using SimpyBlue™ 
SafeStain (Invitrogen Ltd.) for 1 hour with agitation and washed three times in 
distilled H20  for up to 3 hours. Where required protein bands were excised from 
the gel with a sterile scalpel and stored at 4 °C until use.
2.8.2 Western blot Analysis
Protein from the SDS-PAGE gel was transferred to a nitrocellulose 
membrane by electroblotting using an XCell II® blot module at 25 volts for 2 hours 
in TrisGlycine transfer buffer plus 20 % methanol (all Invitrogen Ltd). All 
membranes, filter sponges and filter papers were pre-soaked in transfer buffer and, 
once assembled, air bubbles were removed from the transfer stack. After 
electroblotting, the membrane was incubated overnight at 4 °C in 5 % (w/v)
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skimmed milk powder in PBS (SMP). The membrane was washed three times in 
PBS, and incubated with a primary antibody probe diluted in SMP with 0.1 % 
Tween-20 as appropriate for 2 hours at room temperature with agitation. The 
membrane was washed three times in PBS and incubated with a secondary 
antibody conjugated to Horseradish peroxidise (HRP) (goat anti-mouse or goat 
anti-rabbit) (BioRad) diluted 1:1000 in SMP with 0.1 % Tween-20 for 1 hour. The 
membrane was washed three times and developed using 3,3’-diaminobenzidine 
tetrahydrochloride (DAB) (Sigma-Aldrich) according to the manufacturer’s 
instructions. Alternatively, for increased sensitivity, enhanced chemiluminescence 
(ECL) Western blotting detection reagents (Amersham Biosciences) were mixed at 
a ratio of 1:1 and applied to the membrane for 1 minute. An X-ray film was placed 
on the blot in the dark for ~1 minute and the film developed with Kodak solutions 
(Sigma-Aldrich).
2.9 Statistical Analyses
Statistical analyses were performed in consultation with Dr D.O. Ulaeto and 
Dr T. Laws using either Microsoft Excel® or GraphPad Prism version 5.0 
(GraphPad software). One-phase exponential non-linear regression analyses using 
the F-test statistic and/or two-way ANOVA with Bonferroni’s post tests were 
performed on one-step growth curve data. Repeated measures one-way ANOVA 
test was used to analyse the proportion of IMV produced in cultures. One-way 
ANOVA tests were used to analyse the recovery of EEV in BFA-treated cultures
72
and antimicrobial peptide experiments. Two-way ANOVA tests with Bonferroni’s 
post tests were used to analyse quantitative RT-PCR data.
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3 Construction of an A26L Gene Deletion Mutant Vaccinia Virus
3.1 Introduction
OPVs produce two types of mature virion: enveloped virus (EV) and 
intracellular mature virus (IMV). They are both fully infectious, yet differ in their 
structure and site of accumulation (222;336;337). EV is produced first in the 
replicative cycle (116) and is thought to be involved in dissemination of virus 
throughout the infected host to establish disease (120;338). The additional 
membrane serves to protect the virion from neutralisation by antibody and evade 
complement (247;339;340). IMV is produced later (116), presumably by default as 
a result of exhaustion of intracellular membranes, and as the more robust particle it 
is assumed to be involved in host-to-host spread. IMV is released from the 
cytoplasm upon cell lysis, and represents the majority of progeny virions. It is 
generally accepted that IMVs are pre-cursors of EVs, and may be an artefact 
produced in tissue culture systems, in which intracellular membranes are limiting 
compared to in vivo environments.
The A26 and A25 proteins have been identified as unique to the surface of 
IMV (116). A26 is thought to be the same protein described as 4c by Sarov and 
Joklik (341), and has been reported to have more than one role (15; 134; 188). 
These include A26 as a component of surface microtubules (15;236), acting on cell 
attachment by binding IMV to cell surface laminin (134), suppression of GAG- 
mediated cell fusion (342) and trafficking of IMVs to ATIs (188). Occlusion of 
virions occurs in some poxviruses such as CPXV, FPXV and ECTV, where both 
full-length ATI protein and A26 protein are produced, enabling virus particles to
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become embedded in inclusion bodies. Interestingly, a portion of the A26L gene is 
conserved in some viruses that produce a full-length ATI protein, but these viruses 
are occlusion negative, suggesting additional roles for A26 may exist.
Studies by Ulaeto et al. identified A26 (4c) as unique to the surface of IMV 
and reported that synthesis of A26 occurred at late times during the infectious 
cycle concurrent with maturation of IMV (116). It has been speculated that A26 
acts as a differentiation switch, resulting in maturation of particles to IMV instead of 
EV. This suggests that IMV may not be a pre-cursor of EV, and poxviruses have 
evolved mechanisms to control EV and IMV maturation enabling them to undertake 
their assumed roles in the poxvirus life-cycle.
3.1.1 Aims of this study
In order to examine the function of A26 in OPVs, an A26L gene deletion 
mutant was generated in VACV IHD-J. The intention was to use this particular 
strain of virus for its ability to produce elevated amounts of EEV in tissue culture 
(120; 181), which would be useful in future experiments where a reduction in EEV 
may be assessed. It was anticipated that analysis of the production of the different 
particles produced in vitro would help to determine the function of this protein, in 
the event that deletion of A26L prevents maturation of particles as IMV.
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3.2 Results
3.2.1 Design of the A26L Gene Deletion Cassette
The A26L gene is flanked upstream by A27L (also a late gene) which has 
been shown to play a role in virus penetration, cell fusion and envelopment of 
virions (170;343-346). The A25L gene (ATI gene) flanks A26L downstream, is 
truncated in VACV and is apparently non-functional. It was necessary to ensure the 
promoter and coding sequences of these genes were not disrupted as a result of 
genetic manipulation.
The VACV-WR A26L sequence (GenBank accession number YP_233031) 
was used to design the recombination cassette in this study as the genome 
sequence of the IHD-J strain was not available. To generate an A26L mutant, 1320 
bp out of the predicted 1503 bp sequence of A26L was deleted, replacing the 
deleted region with the E. coli xanthine guanine phosphoribosyl-transferase 
(EcoGPT) selection marker gene (GenBank accession number: X00222) (347;348) 
expressed from a synthetic early/late promoter (327) (Figure 3.1). The EcoGPT 
gene allowed for positive selection in the presence of mycophenolic acid (MPA) to 
increase the proportion of recombinant virus over the wild-type parent.
3.2.2 Construction of the Deletion Cassette by PCR
Using the primers GPT1, GPT2 and GPT3 (Table 2.1), the coding sequence 
of the EcoGPT gene was amplified by PCR utilising p1107 (326) as template in two 
stages, adding the appropriate sequences as tails to the 5’- end of each primer.
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Primer A
VACV IHD-J 
genome
140345-
140013
A27L
139963-138461 138416-136239
A26L
Primer E4
\  Primer GPT3 Primer GPT1
140062-139999 \ -------- ► — --------- ►
A25L
. ..........................
Recombination
cassette
UF region E/LP EcoGPT DF region
Primer GPT2
Figure 3.1 Schematic of VACV Recombination Cassette for Deleting the A26L Gene
The construct was synthesised by PCR and cloned into the pCAPs vector, a commercially available 
vector (Roche Diagnostics Ltd.) as described in section 3.2.3. Positions of primer binding sites used 
for PCR amplification and screening purposes are indictated.
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The first stage amplified the EcoGPT gene adding a synthetic early/late 
promoter (327) upstream of the initiation codon and VACV A26L downstream 
flanking sequence to the 3’- end. The second stage added VACV A26L upstream 
flanking sequence to the 5’- end of the early/late promoter sequence.
PCRs were optimised using Opti-Prime™ PCR Optimisation Kit 
(Stratagene) which contains a selection of buffers with varying MgCI2 and KCI 
concentrations. PCR amplification of product 1 using buffers #3, #4 and #10 
resulted in a product of 603 bp in each reaction. Using buffer #10 (product 1C) 
appeared to result in a single product whereas buffers #3 (product 1A) and #4 
(product 1B) resulted in a secondary product of ~1200 bp (Figure 3.2A). Prior to 
the second stage PCR, the 603 bp products were extracted from the agarose gel 
and purified using a QIAquick gel extraction kit (QIAGEN) to remove secondary 
PCR products and remaining primers, buffers and enzymes from the reaction. This 
prevented carry over of primer GPT1, which could have resulted in a repeat of 
reaction 1, preventing the addition of the upstream flank to the final product.
PCR amplification of product 2, using product 1 as template with primers 
GPT3 and GPT2 with buffers #2, #6, #10 and #12 resulted in a product of 657 bp 
in most of the reactions (Figure 3.2B). Product 2 was pooled from each reaction 
using buffers #2 and #12 (lanes 2, 5, 6, 9 and 13) except the reaction using 
template 1C (lane 10), and purified using a QIAquick gel extraction kit (QIAGEN). 
The DNA concentration was estimated as 50 ng/pl by comparing the band intensity 
to that of a known standard on an agarose gel (section 2.3.6).
78
B
1 2  3 4 1 2 3 4 5 6 7 8 9 1011 12 13
p1107
- 4 ^ " - 1 2 0 0  bp 
603 bp
(product 1)
l l i / l i  > ,
■  657 bp 
(product 2)
C
Primer GPT3 Primer GPT1
>  ►
UF region E/LP EcoGPT <—  DF region
Primer GPT2
Figure 3.2 PCR Amplification of A26L Gene Deletion Cassette
A Agarose (1 %) gel electrophoresis of PCR products using primers GPT1 and GPT2 with a 
selection of buffers from the Stratagene Opti-Prime™ PCR optimisation kit. Lane 1 -  100 bp ladder; 
lane 2 -  Stratagene buffer #3 (product 1A); lane 3 -  Stratagene buffer #4 (product 1B); lane 4 -  
Stratagene buffer #10 (product 1C).
B Agarose (1 %) gel electrophoresis of PCR using products 1A, 1B and 1C as templates and 
primers GPT3 and GPT2 with a selection of buffers from the Stratagene Opti-Prime™ PCR 
optimisation kit. Lane 1 -  100 bp ladder; lane 2 -  Stratagene buffer #2 (product 2A.2); lane 3 -  
Stratagene buffer #6 (product 2A.6); lane 4 -  Stratagene buffer #10 (product 2A.10); lane 5 -  
Stratagene buffer #12 (product 2A.12); lane 6 -  Stratagene buffer #2 (product 2B.2); lane 7 -  
Stratagene buffer #6 (product 2B.6); lane 8 -  Stratagene buffer #10 (product 2B.10); lane 9 -  
Stratagene buffer #12 (product 2B.12); lane 10 -  Stratagene buffer #2 (product 2C.2); lane 11 -  
Stratagene buffer #6 (product 2C.6); lane 12 -  Stratagene buffer #10 (product 2C.10); lane 13 -  
Stratagene buffer #12 (product 2C. 12).
C Schematic of recombination cassette. Arrows indicate primers.
79
3.2.3 Cloning of the Deletion Cassette into pCAPs Plasmid Vector
The PCR Cloning Kit (Blunt-end) supplied by Roche Diagnostics Ltd. was 
used to sub-clone purified product 2 so that the recombination cassette could be 
easily synthesised for future experiments. This cloning kit requires blunt-ended 
DNA fragments for the ligation reaction, therefore the ends of product 2 were 
polished to remove 3’ overhangs produced by Taq polymerase during the PCR 
reaction as described in section 2.3.5. The DNA fragment was purified using a 
QIAquick PCR purification kit (QIAGEN) to remove enzymes and buffers, and 
quantitated by comparing the band intensity to that of a known standard on an 
agarose gel (section 2.3.6). The concentration for each sample was estimated at 
32 ng/pl.
Blunt-ended ligation was carried out as described in section 2.3.7 where the 
recommended molar ratio of vectoninsert is 1:100 to 1:500. The ligation was 
performed using ratios of 1:100, 1:300 and 1:500 to increase the probability of 
success. A positive control reaction using the PCR control supplied with the kit and 
a negative control reaction using H20  were also performed. Each ligation reaction 
was transformed into XL-1 Blue chemically competent cells (Stratagene, California) 
as described in section 2.3.8. Transformants were selected for ampicillin resistance 
and inactivation of the CAP lethality gene.
To investigate the presence of the recombinant plasmid in transformants, 
plasmid DNA was isolated using a QIAprep Spin Plasmid Miniprep kit (QIAGEN) as 
described in section 2.3.9. Presence of pDNA was confirmed on an agarose gel 
(Figure 3.3A). Transformants 1, 2 and 3 all gave a band of similar mobility,
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Primer GPT3 Primer GPT1
>  ►
UF region E/LP EcoGPT m—  DF region
Primer GPT2
Figure 3.3 Screening for the EcoGPT Gene in pCAPs Constructs
A 5 pi of purified plasmid DNA was separated on a 1 % agarose gel. Lane 1 -  100 bp ladder; lane 2
-  transformant 1; lane 3 -  transformant 2; lane 4 -  transformant 3; lane 5 -  transformant 4; lane 6 -  
transformant 5.
B PCR for the EcoGPT gene (657 bp) in transformants 1-5 using primers GPT 3 and GPT 2. Lane 1
-  100 bp ladder; lane 2 -  transformant 1; lane 3 -  transformant 2; lane 4 -  transformant 3; lane 5 -  
transformant 4; lane 6 -  transformant 5.
C Schematic of recombination cassette. Arrows indicate primers.
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although clone 1 also had a slightly brighter band of apparent lower molecular 
weight. Transformant 4 also gave a single band of much higher molecular weight 
than the others, indicating that this transformant may contain multiple copies of the 
insert, or possibly is a concatemer of 2 or more plasmid molecules. Transformant 5 
gave a single band corresponding to the low molecular weight band in transformant 
1, suggesting that this band may represent re-ligated plasmid with no insert. This 
also suggests that transformant 1 may be a mixed “clone”, containing both a 
plasmid with insert and one without.
To screen for the presence of product 2 in the transformants, a PCR was 
undertaken using primers GPT3 and GPT2 (Figure 3.3B). Transformants 1, 2 and 
3 contained an insert of the correct size (657 bp) whereas the insert was not 
detected by PCR in transformants 4 and 5. Plasmid DNA from transformants 1, 2 
and 3 was sent to Lark Technologies, Ltd. for sequencing to check the sequence 
integrity. The sequencing results demonstrated that pDNA from transformants 1 
and 2 had several base substitutions within the EcoGPT gene, whereas the 
sequence from transformant 3 was correct. To obtain a high concentration stock of 
the deletion cassette, pDNA was isolated from a 250 ml culture of transformant 3 
using a QIAGEN plasmid maxi preparation kit (QIAGEN). The presence of the 
plasmid was confirmed on an agarose gel and the concentration of pDNA 
estimated at 7.6 pg/pl (Figure 3.4A) as described in section 2.3.6. A PCR using 
GPT 3 and GPT 2 confirmed the presence of the insert (Figure 3.4B). In addition to 
this, pDNA was sent to Lark Technologies, Ltd. to re-confirm the sequence 
integrity.
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Primer GPT3 Primer GPT 1
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UF region E/LP EcoGPT <—  DF region
Primer GPT2
Figure 3.4 Screening for the EcoGPT Gene in pCAPs Construct Transformant 3 from Large 
Scale Isolation
A Purified transformant 3 plasmid DNA was separated on a 1 % agarose gel. Lane 1 -  100 bp 
ladder; lane 2 — 1:20 dilution; lane 3 -  1:80 dilution; lane 4 - 1 :320 dilution.
B PCR for the EcoGPT gene (657 bp) in transformant 3 using primers GPT3 and GPT2. Lane 1 -  
100 bp ladder; lane 2 -  transformant 3.
C Schematic of recombination cassette. Arrows indicate primers.
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3.2.4 Construction of an A26L Deletion VACV by Homologous 
Recombination
The recombination cassette was introduced into the parental VAVC IHD-J 
genome via the upstream and downstream flanking regions that are homologous to 
the upstream and downstream regions of the A26L gene. This allows homologous 
recombination to take place, where the majority of the coding sequence of A26L 
was deleted and replaced by EcoGPT under the control of a synthetic early/late 
promoter. The resulting virus was amplified under positive selection conditions 
described in the next section.
3.2.5 Selection of Recombinant Virus for Mycophenolic Acid (MPA) 
Resistance
Following transfection of RK13 cells with pDNA from transformant 3, and 
subsequent infection with VACV IHD-J, newly generated recombinant virus was 
selected using MPA selective medium supplemented with xanthine and 
hypoxanthine in RK13 cells (sections 2.4.2 and 2.6.1). MPA inhibits the enzyme 
inosine monophosphate dehydrogenase preventing the formation of xanthine 
monophosphate (XMP) and in turn preventing the formation of guanine 
monophosphate (GMP) (347;348). This results in the intracellular depletion of 
purine nucleotides and an inhibition of cell growth, therefore inhibiting virus growth. 
In the presence of MPA, the GPT enzyme utilises the pre-cursors xanthine and 
hypoxanthine to synthesise purines via the salvage pathway. The mammalian 
hypoxanthine-guanine phosphoribosyl-transferase (HPRT) enzyme lacks the ability
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to utilise xanthine, therefore the salvage pathway, and ultimately progeny 
recombinant virus, can only be produced in those cells infected with recombinant 
virus expressing EcoGPT.
Transfections were carried out using a range of DNA concentrations (0.2, 
0.6, 2, 10 and 25 pg) to try to optimise the DNA:liposome ratios to increase the 
efficiency of delivering DNA into the cells (section 2.4.2). After 24 hours incubation, 
progeny virus was harvested and propagated in RK13 cells in MPA selection 
medium for 72 hours. A large plaque was found in the culture originating from the 
10 pg transfection. The putative recombinant virus was serially passaged 7 times in 
RK13 cells in the selection medium to enrich for recombinant virus and decrease 
wild-type virus. A small stock of putative recombinant virus from passage 7 was 
prepared by infecting a T25 tissue culture flask of RK13 cells in selection medium 
at low MOI, and 1 ml of this culture was used to prepare viral DNA.
3.2.6 Genotypic Analysis of Recombinant Virus
The putative recombinant was able to replicate in the presence of MPA 
indicating expression of EcoGPT, however to confirm the presence of the EcoGPT 
gene and absence of the A26L gene, a PCR was undertaken using extracted viral 
DNA, using dhhO as a negative control and either transformant 3 pDNA (for 
EcoGPT) or wild-type viral DNA (for A26L) as positive controls (Figure 3.5). The 
results demonstrated the presence of EcoGPT in the recombinant viral genome 
indicating a recombinant virus had been generated, however detection of the A26L 
gene indicated that wild-type virus was also present.
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VACV IHD-J 
genome A27L A26L
\  Primer GPT3 Primer GPU 
\  ►  ►
Primer E4 A25L
Recombination
cassette UF region E/LP EcoGPT <— DF region
Primer GPT2
Figure 3.5 Genotypic Analysis of Recombinant Virus Following Serial Passage in Selection 
Medium
PCRs were performed A for the EcoGPT gene (657 bp) using primers GPT 3 and GPT 2 and B for 
the A26L gene (1628 bp) using primers A and E4 Lane 1 -  100 bp ladder; lane 2 -  negative control; 
ane 3 -  recombinant virus; lane 4 -  positive control. C Schematic demonstrating primer binding 
sites.
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3.2.7 Plaque Purification of Recombinant Virus
To obtain pure clones, recombinant virus was plaque purified by limiting dilution as 
described in section 2.4.8. Virus was purified for a total of 5 rounds in the presence 
of MPA selection medium. At each round, differential titres were obtained in the 
presence and absence of MPA to monitor residual wild-type virus (Table 3.1). After 
the first round of purification for both vl6A26L1 and vl5A26L2, the virus titre was 
reduced by a third and by a half, respectively, in the presence of MPA medium. 
Both clones were subjected to a second round of purification which resulted in 3 
more clones, one of which (vl5A26L1.1) replicated equally well in the presence and 
absence of MPA, indicating high purity. The other 2 clones (vl6A26L1.2 and 
vl6A26L2.1) did not replicate well in the presence of MPA and passage of these 
viruses was discontinued.
Following the third round of purification, VI5A26L1.1.1 was quantitated in 
RK13 cells in the presence or absence of MPA medium, but also in STO cells in 
the presence or absence of 6-thioguanine (6-TG) (section 2.6.1). STO cells 
cultured in medium containing 6-TG are used in negative selection to inhibit the 
replication of virus expressing the EcoGPT gene (349), and are described in more 
detail in Chapter 4. Lack of replication in these culture conditions, compared to no 
selection, would indicate high purity of the clone. The titre of VI5A26L1.1.1 in STO 
cells in the presence of 6-TG was 6.0x102 TCID5o/ml compared to 2.37x104 
TCID5o/ml with no selection, and 3.9x104 TCID50/ml in MPA medium. This is a 2-log 
reduction under negative selection conditions indicating the majority of the virus is 
recombinant virus expressing EcoGPT. To increase the probability that the clone
87
MPA
(TCIDso/ml)
No selection 
(TCIDso/ml)
Differential
(%)
Round 1
VI5A26L1 1.69 x10b 2 .46x10“ 68.70
VI5A26L2 5.90 x10b 1.06 x 10“ 55.66
Round 2
VI6A26L1.1 6.68 x10 “ 6.45 x 10“ 103.57
VI6A26L1.2 3.93 x 10“ 6.30 x 104 6.24
VI5A26L2.1 6.24 x 10“ 3.53 x 104 17.68
Round 3
VI6A26L1.1.1 5.51 x 10" 7.98 x104 69.05
Round 4
VI5A26L1.1.1.1 1.86 x 10s 1.65 x 10“ 112.73
Round 5
VI5A26L1.1.1.1.1 2.83 x 10“ 1.27 x 10“ 222.83
VI5A26L1.1.1.1.2 2 .73x10“ 1.82 x 10“ 150.00
Table 3.1 Differential Titres of Recombinant Virus from Each Round of Plaque Purification
Virus was quantitated by Reed-Muench limiting dilution analysis in RK13 cells in the presence and 
absence of MPA selection. The differential is the titre in selection medium as a percentage of the 
titre in non-selective medium.
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represented a pure clone of recombinant virus, the plaque purification was 
repeated. The resulting clone from round 4, vl6A26L1.1.1.1, was quantitated in 
RK13 cells in the presence and absence of MPA medium, and in STO cells in the 
presence and absence of 6-TG. Differential titres in RK13 cells indicated that virus 
was able to replicate equally well in the presence and absence of MPA. In addition 
to this, recombinant virus was unable to replicate in STO cells in the presence of 6- 
TG indicating the absence of wild-type virus in this culture. To confirm replication of 
a non-EcoGPT expressing virus was not inhibited by 6-TG in STO cells, cells were 
infected with VACV IHD-J. The titres obtained for wild-type virus in the presence 
and absence of 6-TG were similar.
A final round of purification resulted in 2 clones vl6A26L1.1.1.1.1 and 
VI5A26L1.1.1.1.2. When quantified in RK13 cells in the presence and absence of 
MPA, the titres in the presence of MPA exceeded that in the absence of drug. A 
small stock of each cloned recombinant virus was prepared by infecting a T25 
tissue culture flask of RK13 cells in selection medium at low MOI and 1 ml of this 
culture was used to prepare viral DNA. The presence of EcoGPT gene and the 
absence of A26L in the 2 putative recombinant clones were confirmed by PCR 
(Figure 3.6). This demonstrated that the 5 rounds of plaque purification had 
reduced parental wild-type virus to undetectable levels.
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Figure 3.6 PCR Screening of Viral DNA Extracted from Recombinant VACV Clones from 
Round 5 of Purification
A PCR to detect EcoGPT (657 bp) using primers GPT3 and GPT2 (lanes 2-4) and A26L (1628 bp) 
using primers A and E4 (lanes 5-7) in VI5A26L1.1.1.11. Lane 1 -  100 bp ladder; lane 2 -  p1107; 
lane 3 -  recombinant vDNA; lane 4 -  wt vDNA; lane 5 -  wt vDNA; lane 6 -  recombinant vDNA; lane 
7 - d H 20.
B PCR to detect EcoGPT (657 bp) using primers GPT3 and GPT2 (lanes 2, 4 and 6) and A26L 
(1628 bp) using primers A and E4 (lane 3, 5 and 7) in vl5A26L1.1.1.1.2. Lane 1 -  100 bp ladder; 
lane 2 -  p1107; lane 3 -  wt vDNA; lane 4 -  wt vDNA; lane 5 -  dH20; lane 6 -  recombinant vDNA; 
lane 7 -  recombinant vDNA; lane 8 -  marker X (Roche Diagnostics, Ltd).
C Schematic demonstrating primers binding sites.
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3.2.8 Propagation of vl5A26L
For all future experiments, vl6A26L1.1.1.1.1 was used and future use of the 
name vl5A26L refers to this clone. A purified high titre stock of this was produced 
by infecting multiple T150 tissue culture flasks of RK13 cells in the presence of 
MPA medium at low MOI (section 2.5.2). The virus titre was quantified as 2.77x108 
TCID50/ml. This yield was lower than expected and this may have been due to a 
negative effect of the MPA medium on the cells.
Using virus from this stock, a Western blot was performed under reducing 
conditions to confirm the absence of A26 protein in VI5A26L (section 2.8). In VACV 
IHD-J, A26 resolved at approximately 60 kDa, however this band was absent in 
vl5A26L confirming the absence of the protein in the recombinant virus (Figure 
3.7).
3.2.9 Characterisation of VI5A26L
3.2.9.1 Comparative Growth Kinetics of vl5A26L and VACV IHD-J in vitro
To investigate the effects of deletion of A26L on the growth rate and virus 
yields, one-step growth curves were performed in RK13 cells. The experiment was 
performed in triplicate in 24-well tissue culture plates, infecting at high MOI to give 
a synchronous infection. Cultures were harvested at 6, 17, 24, 30 and 48 hours p.i. 
and virus quantitated by Reed-Muench limiting dilution analysis (Figure 3.8A). The 
results demonstrated that vl6A26L had a similar growth rate to the IHD-J parent, 
however the overall yield was reduced by approximately 0.5 log.
91
Figure 3.7 Western Blot Analysis of Purified VACV IHD-J and vl5A26L
Virus particles were heated to 85 °C for 2 minutes in Novex® Tricine SDS Sample Buffer with 
NuPAGE® Sample Reducing Agent and resolved in a Novex® 10 % Tricine Gel (Invitrogen Ltd). 
Proteins were then electroblotted onto nitrocellulose membrane and incubated with mono-specific 
rabbit antiserum for A26 protein. Lane 1 - SeeBlue®Plus2 Pre-stained standard; lane 2 - VACV IHD- 
J (~107 pfu); lane 3 - SeeBlue®Plus2 Pre-stained standard; lane 4 - vl5A26L (~107 pfu).
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Figure 3.8 One-step Growth Curves for VACV IHD-J and vl6A26L
Freshly confluent monolayers of RK13 cells in 24-well tissue culture plates were infected at MOI 20 
with wt VACV IHD-J (■) or vl5A26L (A). Cultures were maintained at 37 °C in a 5 % C 0 2 humidified 
atmosphere until the time of harvest. At the appropriate time p.i., replication was halted by freezing 
the cultures at -80 °C. Virus was liberated by three rounds of freeze-thaw followed by dounce 
homogenisation, prior to titration by Reed-Muench limiting dilution analysis. A Data is presented as 
mean TCID50/ml and SEM of triplicate wells. B To allow statistical analyses, data was log10 
transformed and fitted to a one-phase exponential association model.
93
To allow statistical analysis, the data was log™ transformed and fitted to a 
one phase exponential association model (Y=Ymax(1-exp(-KX))) where Ymax and 
K are changing variables (Figure 3.8B). Using an F-test to compare the total yield 
(Ymax), the wild-type virus was significantly different from vl5A26L (p<0.05), and 
there was no significant difference between the growth rates (K) of each virus.
The results of this experiment indicated deletion of A26L may affect the 
ability of VACV to replicate to high titres in vitro, which may be due to an effect on 
the recombinant virus ability to produce IMV. This issue was investigated further in 
this chapter. A second possible explanation may be due to a negative effect of the 
EcoGPT selection gene on the host cell or the virus. Importantly, the kinetics of 
growth for these viruses were similar and they reached their plateaux at similar 
times p.i. This was beneficial for subsequent work as viruses growing at different 
rates would have been problematic for kinetic experiments.
3.2.9.2 Analysis of IMV and EV Produced in vitro by Plaque Titration
Previous data have demonstrated detectable A26 protein from 9 hours p.i., 
and production of IMV after 15 hours p.i. (116). To investigate the production of 
IMV and EV throughout the replicative cycle and the hypothesis that A26 mediates 
IMV maturation, VI6A26L and wild-type virus were grown in RK13 cells infected at 
MOI 10 and the cultures harvested at 6, 8, 12, 17 and 22 hours p.i. A replicate 
culture was set up for the 22 hour timepoint, to control for the 17 hour culture which 
had to be initiated separately from the other time points for logistical reasons. At 
the earlier time points, it was anticipated that the majority of the progeny virus
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would be EV, followed by IMV after 8 hours p.i as A26 begins to be synthesised. 
These time points were chosen to facilitate observation of the predicted switch of 
particle maturation from EV to IMV in wild-type virus, and any differences that 
might be observed in VI5A26L.
Total progeny virions were subjected to ultracentrifugation through CsCI 
gradients to separate enveloped and non-enveloped particles due to their 
difference in buoyant densities. Approximately 80 fractions were collected 
mechanically from the top of the gradient into a 96-well microtitre plate in -200 pi 
volumes.
To determine the quantities of EV and IMV in each culture, plaque titrations 
of each fraction were undertaken. In an attempt to scale down the number of 
fractions to be tested, 10 pi of each fraction was diluted into 1 ml DMEM (to dilute 
the CsCI) and 50 pi of this used to infect corresponding wells of RK13 cells in a 96- 
well microtitre plate. This was used to indicate those fractions containing infectious 
virus simply by positive/negative screening for plaque formation. Plates were 
incubated for 4 days, then fixed and stained with crystal violet. The cell monolayers 
did not stain in any of the fractions tested, indicating cell death. This was 
unexpected but may indicate that infectious virus was present in each fraction or 
alternatively, may indicate cellular toxicity from residual CsCI.
To reduce the number of fractions to be tested, fractions were pooled into 
groups of 6 and the quantities of virus determined by a modified plaque titration 
method (section 2.5.3). Briefly, fractions were titrated in triplicate in a 96-well 
microtitre plate seeded with RK13 cells and incubated for up to 7 days. Following
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staining of the cell monolayers with crystal violet, the absorbance at 570 nm (A570) 
was determined. A high A57o indicated the absence of virus as the cell monolayer 
was still intact, and a low A57o indicated the presence of virus. The mean A570 for 
each fraction was plotted against the dilution factor in Microsoft Excel™ to give a 
curve, as shown in Figures 3.9 and 3.10 for 6 hours p.i. Using a regression 
analysis, these curves were used to calculate the dilution at which 50 % of the 
wells showed signs of infection (i.e. 50 % of the maximum A570 for the sample), in a 
manner analogous to calculation of TCID50. For each time point, this was used to 
estimate the virus titre of each fraction where the greater the dilution factor, the 
greater number of infectious units present. Therefore to obtain a virus titre, the 
reciprocal of the dilution factor was calculated for each fraction (Figure 3.11).
Titration of pooled fractions in this fashion demonstrated an apparent 
decrease in the ratio of IMV to EV particles at 8 hours p.i. (Figure 3.11B), although 
the EV and IMV ‘peaks’ were less distinguishable in these gradients. This may be 
due to the pooling of fractions masking the trough between the EV and IMV 
‘peaks’. To try to mitigate this, the titrations were repeated for the 8 hour fractions 
pooling only 4 fractions which would increase the chances of detecting a trough 
(Figure 3.12). Again, there was a decrease in the ratio of IMV to EV particles, 
although the EV and IMV ‘peaks’ were distinguishable only in VI6A26L. No 
differences in the ratio of IMV to EV were seen at the other time points (Figures 
3.11A, 3.11C, 3.11D, 3.11E and 3.11F).
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Figure 3.9 Mean Absorbance at 570 nm of RK13 Cell Monolayers Infected with CsCI Gradient 
Fractions of vl5A26L at 6 Hours p.i.
CsCI gradient fractions of vl5A26L cultures at 6 hours p.i. were titrated on RK13 cells for up to 7 
days and stained with crystal violet. The absorbance at 570 nm (A570) was determined for each well. 
A high A570 indicates the absence of virus, whereas a low absorbance indicates the presence of 
virus. ■ / ■ ■
A Fractions 1 (♦), 2 (□), 3 (A) and 4 (o) .  B Fractions 5 (♦), 6 (□), 7 (A) and 8 (o ) .  C Fractions 9 (♦), 
10 (□), 11 (A) and 12 (o) .  Data is presented as means of triplicate wells.
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Figure 3.10 Mean Absorbance at 570 nm of RK13 Cell Monolayers Infected with CsCI Gradient 
Fractions of VACV IHD-J at 6 Hours p.i.
CsCI gradient fractions of VACV IHD-J cultures at 6 hours p.i. were titrated on RK13 cells for up to 7 
days and stained with crystal violet. The absorbance at 570 nm (A570) was determined for each well. 
A high A570 indicates the absence of virus, whereas a low absorbance indicates the presence of virus. 
A Fractions 1 (♦), 2 (□), 3 (A ) and 4 (o). B Fractions 5 (♦), 6 (□), 7 (A ) and 8 (o). C Fractions 9 (♦),
10 (□), 11 (A), 12 (o) and 13 (•). Data is presented as means of triplicate wells.
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Figure 3.11 Titres of CsCI Fractions of VACV IHD-J and vl5A26L Cultures at Various Times 
p.i.
RK13 cells were infected at MOI 10 with wt VACV IHD-J (□) or VI6A26L (0) and cultured for 6 (A), 8 
(B), 12 (C), 17 (D), 22i (E) and 22ii (F) hours. Progeny virus was separated through CsCI gradients 
and fractionated from the top. Fractions were pooled in groups of 6, and virus in each pool was 
quantified in RK13 cells (section 2.5.3). Fractions 1-7 and 8-13 were assumed to represent EV and 
IMV, respectively.
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Figure 3.12 Repeat Titration of CsCI Fractions of VACV IHD-J and VI5A26L Cultures at 8 
Hours p.i.
RK13 cells were infected at MOI 10 with wt VACV IHD-J (□) or VI5A26L (0) and cultured for 8 hours. 
Progeny virus was separated through CsCI gradients and fractionated from the top of the gradient. 
Fractions were pooled in groups of 4, and virus in each pool was quantified in RK13 cells (section 
2.5.3). Fractions 1-9 and 10-18 were assumed to represent EV and IMV, respectively.
104
Measuring the presence of virus in this way resulted in a high throughput 
assay where the quantities of virus in hundreds of samples could be determined. 
One of the clear limitations of this experiment is the crude nature of the output 
data. The quantity of fractions precludes removal of CsCI by washing and 
centrifugation of each fraction, and even if removal of CsCI by dilution in a standard 
virus titration assay is possible, the number of fractions to titrate is prohibitive. 
Pooling of the fractions leads to a reduction in the sensitivity of the assay by failing 
to adequately separate IMV and EV ‘peaks’. Additionally, the effect of the absence 
of A26 protein on the characteristics and behaviour of IMV is unknown. 
Conceivably, its absence might cause IMV particles to be more (or less) likely to 
aggregate, confusing comparative analyses that are based on plaque forming 
units, which will quantify infectious units irrespective of the number of particles 
aggregated. This methodology may lead to an underestimate of the quantity of IMV 
in wild-type relative to recombinant virus. Consequently, it was decided to 
discontinue using this method for IMV and EV quantification, and to explore using 
tritiated thymidine to metabolically label virus particles.
3.2.9.3 Analysis of IMV and EV Produced in vitro by Radioactive Labelling of 
Virions in Lipid-Enriched Cultures
To address the limitations with the assay described in section 3.2.9.2, 
experiments were performed in which virus particles were metabolically labelled 
with a radioisotope (section 2.5.4). Viruses were cultured in medium containing 
tritiated thymidine (3H thymidine) to metabolically label viral DNA. This method
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enables estimation of relative numbers of viral genomes where it is assumed the 
3H thymidine is distributed evenly throughout the viral DNA. In addition, as cultures 
are separated through CsCI gradients, only 3H-labelled DNA that has been 
packaged into intact virus particles will be counted. Therefore, the amount of 
radiolabel in each given fraction will relate directly to the number of virions present 
irrespective of the particle/pfu ratio.
The quantities of lipids available for incorporation into intracellular 
membranes are assumed to be much less in an in vitro tissue culture system than 
in vivo, and therefore may be artefactually limiting for EV production in 
experimental systems. In an attempt to increase the intracellular lipids available for 
envelopment, cultures were supplemented with cholesterol-enriched adult bovine 
serum (ABS) (Sigma-Aldrich, UK). This may mimic in vivo conditions more closely 
than standard tissue culture conditions, where it is thought EV production is limited 
by the lack of intracellular membranes available. Preliminary experiments were 
performed to observe the effects of addition of the lipids at various timepoints on 
cells and virus replication.
RK13 cells were infected with wild-type or vl5A26L at MOI 5 in a 6-well 
tissue culture plate. Following 1 hour incubation, the medium was replaced with 
either DMEM + 10 % FCS or DMEM + 10 % ABS. Increased CPE and cell lysis 
was observed in wild-type and vl5A26L cultures supplemented with ABS after 24 
hours incubation suggesting that virus was able to replicate at a greater rate, than 
in FCS supplemented cultures. To speculate, an increased supply of lipids to the 
cells may have enhanced replication and envelopment of virions, which in turn
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could lead to increased cell-to-cell spread. This may account for the increased 
CPE observed after 24 hours.
To investigate this further, the production of EV in cultures supplemented 
with ABS, RK13 cells were infected at MOI 10 with wild-type or VI5A26L where the 
cells were supplemented with 10 % ABS 20 hours prior to infection (t=-20), with 10 
% ABS at the time of infection (t=0) or supplemented with 10 % FCS only, as 
described in standard protocols. To each culture, 10 pCi 3H thymidine was added 
at the time of infection and cultures were incubated for a further 24 hours. Total 
progeny virions were subjected to ultracentrifugation through CsCI gradients to 
separate the different particles due to their difference in buoyant densities. 
Approximately 60 fractions were collected mechanically from the bottom of the 
gradient into a 96-well microtitre plate in ~300 pi volumes. Virus particles were 
collected onto a UniFilter-96 GF/C glass fibre filter microplate (Perkin Elmer) using 
a Filtermate 196 cell harvester (Packard) and subjected to liquid scintillation 
counting on a TopCount 9904 liquid scintillation counter (Packard). This 
experiment was repeated in triplicate and the results are shown in Figures 3.13, 
3.14 and 3.15. In each culture condition there was a dramatic reduction in IMV 
production in vl5A26L compared to wild-type virus. To obtain a ratio of IMV:EV, the 
sum of CPM per peak was calculated, demonstrating a reduction in the ratio of 
IMV:EV. Unexpectedly, a concomitant increase in EV was not observed where the 
numbers of IMV had reduced. This may be due to the limitations of an in vitro 
tissue culture system where the supply of intracellular membranes is inadequate. 
Interestingly, the production of both types of virus particle in cultures supplemented
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Figure 3.13 Analysis of IMV and EV by Radioactive Labelling of Virions in VACV IHD-J and 
VI5A26L Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from wt (h) 
and vl5A26L (A ) virus grown in cultures supplemented with 10 % FCS (A), or 10 % ABS added at 
t=0 (B) or t=-20 h (C). Progeny virus was harvested at 24 hours p.i. and subjected to 
ultracentrifugation through CsCI gradients. Gradients were mechanically fractionated from the 
bottom of the gradient and individual fractions subjected to liquid scintillation counting.
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Figure 3.14 Analysis of IMV and EV by Radioactive Labelling of Virions in VACV IHD-J and 
vl5A26L Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from wt (■) 
and vl6A26L (A ) virus grown in cultures supplemented with 10 % FCS (A), or 10 % ABS added at 
t=0 (B) or t=-20 h (C). Progeny virus was harvested at 24 hours p.i. and subjected to 
ultracentrifugation through CsCI gradients. Gradients were mechanically fractionated from the 
bottom of the gradient and individual fractions subjected to liquid scintillation counting.
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Figure 3.15 Analysis of IMV and EV by Radioactive Labelling of Virions in VACV IHD-J and 
vl5A26L Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from wt (■) 
and vl5A26L (A ) virus grown in cultures supplemented with 10 % FCS (A), or 10 % ABS added at 
t=0 (B) or t=-20 h (C). Progeny virus was harvested at 24 hours p.i. and subjected to 
ultracentrifugation through CsCI gradients. Gradients were mechanically fractionated from the 
bottom of the gradient and individual fractions subjected to liquid scintillation counting. IMV:EV 
ratios were not calculated for samples where ABS was added at t=-20 h, because the counts were 
too low to reliably identify peaks.
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with ABS 20 hours prior to infection was particularly reduced compared to the other 
culture conditions indicating that extended incubation in cholesterol-enriched 
medium may be toxic to the cells. Possibly, several different fatty acids as opposed 
to cholesterol alone may be required for EV production to continue, or the timing 
and quantity of cholesterol requires optimisation.
These data suggest that deletion of the A26L gene in VACV IHD-J results in 
disruption of IMV production, therefore reducing the ratio of IMV.EV. Further 
investigation into the kinetics of virus maturation of VI6A26L, and restoration of the 
wild-type phenotype in a revertant virus will be described later in this study in 
Chapters 5 and 6.
3.2.9.4 Production of EEV in Brefeldin A-treated Cultures
The results in section 3.2.9.3 suggest that the A26L gene product is 
required for virus particles to mature as IMV. It may also be that once virions have 
acquired this marker they can no longer mature as EV, serving to negatively 
regulate wrapping. To investigate this further, EEV production in BFA-treated 
cultures was examined.
Incubation of infected cells with BFA specifically inhibits EV maturation, and 
removal of the drug results in the rapid recovery of EV (331). Previous studies 
have suggested that when removal of the drug is delayed beyond a certain point 
(i.e. after virions have had the opportunity to acquire IMV specific markers), EV 
recovery is reduced or abrogated (Dr D.O. Ulaeto, personal communication).
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In the absence of A26L, it was predicted that increased EEV would be 
recovered at later times p.i. in vlSA26L cultures than in wild-type cultures once BFA 
is washed out. Consequently, RK13 cells were infected at MOI 10 with wild-type 
virus or vl6A26L in the presence or absence of 4 pg/ml BFA (section 2.5.6). 
Cultures were incubated for 10, 20 and 24 hours after which time the BFA was 
washed out and replaced with tissue culture medium. Culture supernatants were 
harvested at 20, 24 and 28 hours and the secreted virus, assumed to be EEV, in 
each culture determined by Reed-Muench limiting dilution analysis. The recovery 
of EEV in BFA-treated cultures was calculated as a percentage of EEV recovered 
in untreated cultures (Figure 3.16). At each timepoint, the recovery of EEV was 
substantially greater in VI5A26L than wild-type virus indicating that vl5A26L has a 
greater ability to recover EEV following removal of the drug even at late times p.i. 
when compared to wild-type. This suggests that the absence of A26L allows EEV 
production even at late times p.i. in VI5A26L, suggesting that maturation to IMV 
had been disrupted.
3.3 Discussion
It has been known for some time that the EV particle of OPVs is an end- 
stage of virus maturation. However, this has not been clear for IMV particles and 
the possibility that IMV is not a structural pre-cursor of EV has not previously been 
excluded. One hypothesis for the formation of IMV is that it is virus left over when 
the supply of Golgi-derived membranes that are used to wrap EV becomes 
exhausted. This study was designed to investigate whether IMV is in fact produced
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Figure 3.16 Effect of BFA on EEV Production in VACV IHD-J and vl6A26L Cultures
RK13 cells were infected at MOI 10 with VACV IHD-J (■) or vl5A26L (■) and incubated in the 
presence or absence of 4 pg/ml BFA. BFA was washed out of the cultures and replaced with tissue 
culture medium at 10, 20 and 24 hours p.i. and the culture supernatant harvested at 20, 24 and 28 
hours p.i., respectively. Secreted virus was quantitated by Reed-Muench limiting dilution analysis. 
Data is presented as means and SEM of triplicate experiments, p-values were calculated using a 
one-way ANOVA.
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by a distinct maturation pathway resulting in a switch from EV to IMV formation, 
mediated by the IMV-specific protein A26.
To investigate the role of A26 in VACV morphogenesis, the A26L gene was 
successfully deleted from the IHD-J genome and replaced with the EcoGPT 
selection marker gene. This allowed selection of a pure, clonal recombinant virus in 
the presence of MPA as demonstrated by differential titrations in the presence and 
absence of selection. To further confirm the absence of wild-type virus in cultures, 
growth of recombinant virus was shown to be inhibited in STO cells in the presence 
of 6-TG, conditions previously described to inhibit growth of EcoGPT-expressing 
viruses (349). The use of differential titres may be a useful tool in future 
experiments to screen cultures for the presence of recombinant virus, and indicate 
their purity. In addition to this, the presence of the EcoGPT gene and absence of 
the A26L gene were demonstrated by PCR, and the absence of A26 protein was 
confirmed by Western blot.
One-step growth curves were performed to examine growth rates of 
vl6A26L in vitro. Although the growth rates of vl5A26L and wild-type virus were 
similar, there was a reduction in the overall yield of virus. There are two plausible 
explanations for this reduction: deletion of A26L has an effect on virus yields, or the 
expression of EcoGPT may have a negative effect on the host cell or the virus, 
resulting in a reduction in virus production. In future studies, it is necessary to 
determine whether the wild-type phenotype can be restored by re-introducing the 
A26L gene, therefore attributing the reduction in yields to the absence of A26L or 
by removing the selection marker gene to determine if the phenotype observed is
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due to the presence of EcoGPT. There was a slight delay in the onset of replication 
in vl6A26L cultures which may be attributed to a decrease in the rate of infectivity 
of this virus. It has been reported that VACV binds to host cells via an interaction 
with laminin mediated by A26 (134), by binding to GAGs via H3, A27 and D8 (130- 
133), and via L1 to an unknown receptor (135). It is possible that disruption of any 
one of these interactions may reduce the ability of the virus to enter cells, leading 
to a delay in the onset of replication as seen in cultures infected with the A26L 
deletion mutant.
Separation of virus particles through CsCI gradients and quantitation by 
plaque titration was used to examine the production of IMV and EV in vlSA26L. As 
expected at 6 hours p.i., where F13 is detectable and A26 is not (116), the 
quantities of EV exceeded that of IMV in both wild-type and vl5A26L cultures. At 8 
hours p.i., when A26 production begins (116) the ratio of IMV:EV increased in wild- 
type but not in VI5A26L, indicating that A26 may be necessary for maturation of 
IMV. Unexpectedly, a continuing reduction in the ratio of IMV:EV in VI5A26L 
compared to wild-type was not observed at the later time points. The reasons for 
this are unclear, although the limitations of the assay with respect to the logistics of 
directly quantitating the number of infectious particles have the effect of reducing 
its sensitivity, and the uncertainty over the possible phenotypic effect of the 
deletion of A26L on particle/pfu ratios for IMV are causes for concern.
Using 3H thymidine to metabolically label viral genomes was a more 
accurate method to enumerate virus particles following separation of virions 
through CsCI gradients. The results demonstrated a profound decrease in IMV in
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vl6A26L cultures. Interestingly, the data did not show a rise in the quantity of EV 
produced by vl5A26L concomitant with the apparent reduction in IMV. This 
suggests that failure to acquire the A26 protein by maturing virions does not 
automatically result in these virions undergoing envelopment. It may be that, just 
as IMV production appears to be controlled independently of EV production, so too 
EV production may be limited by a mechanism independent of IMV production. It 
has been previously suggested that EV production is limited by the availability of 
intracellular membranes for wrapping (350); and the presumed reduced pools of 
lipids in tissue culture systems may thus be artefactually limiting for EV production 
in this system. Supplementation of cultures with cholesterol-enriched serum to 
increase the pool of available lipids did not increase the production of EV, and in 
some cultures had an adverse effect on virus production. It is likely that this was a 
toxicity effect, and optimisation of concentrations and periods of incubation might 
improve EV yields. It may also be possible to increase the amounts of intracellular 
membranes available for wrapping by using an alternative cell line such as an 
adipocyte cell line that may have greater quantities of intracellular lipids.
There is no obvious explanation for the absence of large quantities of 
“undifferentiated” virions that would presumably sediment with the same density as 
IMV in CsCI gradients from vlSA26L cultures, however this may help to explain the 
reduction in overall progeny virus observed in one-step growth curves. Perhaps 
virus that is unable to differentiate as either IMV, due to the absence of A26, or EV 
due to lack of membranes, is unstable and does not withstand the purification 
process.
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Previous studies suggest that following the production of A26 at around 8 
hour p.i. the recovery of EV is reduced or abrogated when envelopment is delayed 
by treating cultures with BFA (Dr D.O. Ulaeto, personal communication). This 
suggests that an increasing proportion of non-enveloped particles that would 
normally have become EV may instead have matured as IMV. It is possible that 
these particles are no longer available for envelopment because they have already 
acquired the IMV-specific marker, A26. Further experiments with vl5A26L cultures 
treated with BFA demonstrate a greater recovery of EEV compared to VACV IHD- 
J. This suggests that the absence of A26L allows EEV production to continue at 
elevated levels at relatively late times p.i. in VI6A26L because differentiation to IMV 
does not occur.
The other functions for A26, previously discussed, do not explain why this 
gene, or at least a segment of it, is conserved in many OPVs such as VARV, 
MPXV and CPXV, most of which do not produce ATIs. More recent studies have 
demonstrated that A26 forms a complex with A27, anchored to the surface of the 
virion by association with A17 (351). A27 is required for EV formation (170), 
therefore binding of A26 may act to prevent wrapping of virions, leading them down 
a distinct maturation pathway.
During this study, attempts were made to generate hybridoma cell lines to 
produce monoclonal antibodies (mAbs) to A26, to use in place of polyclonal serum. 
Polyclonal sera contain a mixture of immunoglobulin molecules that recognise 
different epitopes of the same antigen and other non-target antigens. The 
specificity is therefore reduced and the polyclonal serum used in this study has
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been shown to cross-react with the 4b core protein (D.O. Ulaeto, personal 
communication); generation of mAbs specific to A26 was thus desirable. These 
mAbs would be a useful tool for the detection of A26 on the surface of IMV 
particles produced by the various recombinant VACVs generated during this 
project. The resulting hybridoma cultures produced antibodies that reacted with 
proteins of various sizes, yet none of these were of the size expected for A26. 
Therefore, the polyclonal serum was used for future experiments, as the specificity 
had been demonstrated for A26 with minimal cross-reactivity to 4b.
In conclusion, the data provide evidence that IMV particles are an end-stage 
product of OPV maturation that has lost the ability to become EV by acquiring the 
A26 protein, and that the A26L gene operates as a switch controlling the 
differentiation of developing virions into IMV. Formal proof of this requires analysis 
of a revertant virus constructed by re-insertion of the A26L gene into the original 
locus in vl6A26L. The hypotheses that EV production is limited by the supply of 
Golgi-derived membranes for envelopment, and that IMV and EV are both 
independent end-stages of maturation, are not mutually exclusive.
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4 Construction of Secondary Recombinant VACV using Reverse 
Guanine Phosphoribosyl Transferase (GPT) Selection
4.1 Introduction
Following the construction of the A26L deletion mutant vl6A26L1.1.1.1.1, it 
was necessary to construct a revertant recombinant VACV by re-inserting A26L 
under the control of its native promoter, and hence restore function. This was 
required to validate the phenotype observed in the deletion mutant. In parallel with 
this, a panel of recombinants were designed using a variety of promoters to 
modulate A26L expression. Characterisation of such recombinants has the 
potential to further inform our understanding of the relationship between IMV and 
EV.
An approach described by Isaacs et al., (1990) describes reverse GPT 
selection used to negatively select against a recombinant VACV containing the 
EcoGPT gene (349). This allows growth of secondary recombinant virus where 
EcoGPT has been deleted by homologous recombination and replaced by a gene 
of interest. This method circumvents many of the problems inherent in other 
selection systems, such as insertional inactivation of the thymidine kinase (TK) 
gene, and allows the construction of a recombinant VACV that does not contain 
heterologous selection marker genes.
Six recombination cassettes for the construction of six secondary 
recombinant viruses were designed (Figure 4.1). Four of these recombinants were 
designed to examine the effects of altered expression kinetics for A26L, using 
promoters that will initiate transcription at different phases of the virus replicative
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Figure 4.1 Schematic of Secondary VACV Recombination Cassettes for Modulating 
Expression of A26L
Each construct was synthesised by PCR and cloned into pCR®-XL-TOPO® vector, a commercially 
available vector (Invitrogen, Ltd) as described in section 4.2. A represents the region of the parental 
VI5A26L1.1.1.1.1 genome; B the revertant construct; C the early/late construct; D null construct; E 
late construct; F early construct; G F13L construct. Nucleotide sequences can be found in Appendix 
Figures A2-A7.
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process. The remaining two include revertant and null recombinants. All the 
constructs utilised VACV genomic regions immediately upstream and downstream 
of the A26L gene and its promoter, to facilitate homologous recombination in 
vl5A26L1.1.1.1.1. The recombination event will result in deletion of the entire 
coding sequence of the EcoGPT gene and its attendant synthetic early/late 
promoter. This would generate a panel of secondary recombinant viruses with the 
minimum of non-native sequence.
The revertant recombinant VACV was designed to facilitate re-insertion of 
A26L under the control of the native promoter (NP), regenerating the wild-type 
phenotype and controlling for possible artefacts in the phenotype of the other 
recombinant viruses (Figure 4.1 B). This should demonstrate that the phenotype 
observed in vl6A26L1.1.1.1.1 is due to the deletion of A26L. This recombinant will 
be genetically and phenotypically identical to the wild-type.
The second recombinant VACV was designed to re-insert A26L into its 
original locus but under the control of a synthetic early/late promoter (E/LP) 
described by Hammond et al. (1997) (Figure 4.1 C) (327). It is predicted that this 
will result in constitutive expression of A26L and direct morphogenesis towards 
IMV maturation immediately upon virion assembly in late stages of replication, thus 
increasing IMV and reducing EV formation. This virus is a potential candidate for a 
live recombinant vaccine against smallpox, and possibly as a vector for vaccines 
against heterologous viruses and diseases.
The third recombinant VACV was designed to delete EcoGPT but not 
replace it (Figure 4.1 D). This null recombinant was designed as a control, to
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ensure that any observed phenotypic effects in the primary recombinant are not 
due to a previously undescribed effect of EcoGPT expression, or a positional effect 
of insertion of the EcoGPT gene. This recombinant was also designed to act as an 
internal control for reverse GPT selection. Reverse GPT selection allows the 
replication of non-EcoGPT-expressing viruses, including wild-type VACV. As 
described earlier, the revertant and wild-type strains are genetically and 
phenotypically identical and therefore cannot be distinguished. To address this, the 
null recombinant can be used to screen for both A26L and EcoGPT, where their 
absence is indicative of a true secondary recombinant. In this case, it is possible to 
extend the assumption that if the null recombinant has been constructed as a result 
of homologous recombination then the revertant is likely to be a true secondary 
recombinant, and not wild-type VACV, that may have been carried through the 
MPA selection process. This recombinant would also be useful for future studies as 
an alternative to vl6A26L1.1.1.1.1, in particular those in animals, where foreign 
genes may complicate the interpretation of results.
The additional secondary recombinants were designed to examine the 
effects of altered expression kinetics for A26L, using promoters that will initiate 
transcription at different phases of the virus replicative process. The fourth and fifth 
recombinants will contain a synthetic early promoter (EP) or a synthetic late 
promoter (LP) respectively, using the early and late elements of the synthetic E/LP 
described by Hammond et al. (1997) controlling the expression of A26L (Figures
4.1 E and 4.1 F) (327). It is predicted that when A26L is expressed from an EP, 
maturation of particles will favour IMV production in the early stages of maturation
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as an abundance of A26 will be present upon virion assembly, however at late 
times expression will cease and due to lack of available A26 maturation of EV may 
thus become dominant. Late expression of A26L will have a similar phenotype to 
wild-type, however expression of A26L may occur at an earlier time than in wild- 
type causing a switch from EV to IMV production at an earlier time in the infectious 
cycle. The final recombinant was designed to express A26L under the control of 
the F13L promoter (F13LP) (Figure 4.1G). F13L is an EV-specific protein that is 
required for IEV formation (117) and in the context set here, may be regarded as 
directing virus differentiation towards EV in the initial stages of virus late gene 
expression. Precisely co-ordinated expression of A26L and F13L may indicate 
which, if either, is the dominant controller of virus differentiation as IMV or EV.
4.1.1 Aims of This Study
The aim of this study was to replace the EcoGPT gene in vl6A26L1.1.1.1.1 
with a recombination cassette containing A26L under the control of a variety of 
promoters, to create a panel of six recombinants with potentially differing 
phenotypes. It was anticipated that modulation of A26L expression, so that it is 
constitutively expressed, would increase the ratio of IMV:EV by reducing the 
absolute quantity of virions that are available for envelopment. Such a reduction in 
EV has the potential to be attenuating giving rise to an improved smallpox vaccine 
and/or vaccine vector candidate.
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4.2 Results
4.2.1 Design and Construction of VACV Secondary Recombination Cassettes
The recombination cassettes (Figure 4.1) were constructed using PCR to 
synthesise the coding sequence of A26L gene utilising VACV IHD-J DNA as 
template, adding the appropriate promoter and upstream and downstream flanks 
as tails at the 5’ end of the primers. The constructs were made in two stages: the 
first to amplify A26L and the downstream flanking region, adding the appropriate 
promoter upstream of the initiation codon; the second to add the upstream flank to 
the 5’ end of the newly inserted promoter sequence.
4.2.1.1 Null Recombination Cassette
A null recombination cassette was designed to delete EcoGPT from the 
primary recombinant virus VI6A26L1.1.1.1.1 and not replace it with A26L therefore 
deleting the entire locus. This required a very small recombination cassette 
containing only upstream and downstream flanking regions of A26L, therefore 
construction of this cassette differs from the others described previously.
The oligonucleotides FLA3 and FLA4 were designed to amplify the 
oligonucleotides FLA1 and FLA2, respectively, which were complimentary 
sequences of the 63 bp region upstream of A26L gene immediately followed by the 
63 bp region downstream of A26L gene (Table 2.1). Care was taken when 
designing this construct to ensure that the coding sequences of both adjacent 
genes A27L and A25L were maintained. The resulting product of 126 bp was 
confirmed on an agarose gel (Figure 4.2A) and the construct was cloned into
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Figure 4.2 Synthesis of Secondary Recombination Cassettes
A PCR using primers FLA3 and FLA4 to synthesise the null recombination cassette (126 bp). Lane 
1 -  100 bp ladder; 2 -  empty; 3 -  null cassette; 4 -  empty; 5 -  Mwt marker IV.
B PCR using primers A2 and E4 to synthesise revertant recombination cassette (1691 bp). Lane 1
-  100 bp ladder; 2 -  empty; 3 -  revertant cassette.
C PCR using primers C2 and E4 to synthesise early/late recombination cassette (1739 bp). Lane 1
-  Mwt marker IV; lane 2 -  empty; lane 3 -  early/late cassette.
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pCR®-XL-TOPO® (Invitrogen). DNA sequencing confirmed the sequence integrity 
of the null construct.
4.2.1.2 Revertant Recombination Cassette
The revertant virus was required to have A26L re-inserted into its original 
locus in vl5A26L1.1.1.1.1 under the control of the NP. The genomic sequence 
upstream of A26L (VACV WR sequence) was studied for traits of late VACV 
promoters and a region of 36 bp that was predicted to contain the promoter and 63 
nucleotides of upstream flanking sequence was selected (Figure A2). Using 
primers A and E4, and then A2 and E4 (Table 2.1), the recombination cassette of 
1691 bp was constructed by PCR (Figure 4.2B) and cloned into pCR®-XL-TOPO® 
(Invitrogen). DNA sequencing confirmed the sequence integrity except for the 
upstream flanking region was absent. It was decided however, that the promoter 
sequence of the A26L gene should be sufficient for homologous recombination and 
therefore transfection experiments should begin with this construct.
4.2.1.3 Early/Late Recombination Cassette
In addition to a revertant virus, a further recombinant virus was to be 
constructed in which A26L was re-inserted into its original locus in 
vl5A26L1.1.1.1.1 under the control of a synthetic E/LP (327). The cassette was 
constructed in two stages using primers C and E4 in the first stage and primers C2 
and E4 in the second stage (Table 2.1). The second stage construct proved to be 
more problematic to synthesise as the PCR to add the upstream flank was
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inefficient and produced only a small amount of product of the correct size (1739 
bp), even though several attempts were made to try to optimise the reaction 
(Figure 4.2C). Cloning of this second stage construct was unsuccessful and as a 
result, it was decided to use the gel purified PCR product in the transfection. To 
conserve DNA, it was decided to delay sequencing and to wait until the 
recombinant virus had been isolated so that viral DNA could be used to check the 
final sequence.
4.2.1.4 Early, Late and F13L Recombination Cassettes
Recombination cassettes were designed so that the EcoGPT gene would be 
replaced by A26L under the control of either a synthetic EP, a synthetic LP or the 
F13LP (Figures A5-A7). The F13LP sequence was predicted by studying the 
region upstream of the F13L gene (GenBank Accession number AA089331) in the 
VACV WR genome sequence for traits of poxvirus promoters identifying a region of 
27 bp. This region has a characteristic TAAATG initiation sequence that is common 
in poxvirus late promoters. The inserts were constructed by PCR using primers B, 
D and F for EP, LP and F13LP respectively, and the reverse primer E4 to 
synthesise the A26L gene from VACV IHD-J DNA, adding the appropriate 
promoter and a downstream flank (Table 2.1). The second stage added the 
upstream flanking region to the 5’-end of the promoter sequence using the 
corresponding primers B2, D2 and F2, and the reverse primer E4 (Table 2.1).
Construction of EP, LP and F13LP secondary recombinant viruses was 
delayed until the revertant, E/LP and null recombinant viruses had been isolated,
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because it was felt it was not practical to attempt to isolate more than three 
recombinant viruses in parallel.
4.2.2 Construction and Selection of Secondary Recombinant EcoGPT- 
negative VACV by Homologous Recombination
Reverse EcoGPT selection enables the selection of secondary 
recombinants that have had their EcoGPT gene replaced by another gene of 
interest. This method takes advantage of the ability of EcoGPT to convert purine 
analogues into products that prevent EcoGPT-expressing viruses from replicating. 
The purine analogue used in this study was 6-thioguanine (6-TG) which has been 
shown to prevent the growth of EcoGPT-expressing viruses at a concentration of 
0.1-1 mM in tissue culture medium (349). The cell line for this had to be carefully 
chosen as those cell lines that contain the mammalian hypoxanthine-guanine 
phosphoribosyltransferase (HPRT) enzyme will incorporate 6-TG into DNA, a toxic 
event for both EcoGPT and non-EcoGPT-expressing virus. In this study STO cells, 
an HPRT-negative mouse embryonic fibroblast cell line, was used for selection of 
secondary recombinants in the presence of 0.1 mM 6-TG (349). The resulting 
EcoGPT-negative virus present can be easily amplified with each round of 
selection, and by comparing growth in the presence and absence of drug, it is 
possible to monitor the reduction of residual EcoGPT-expressing virus with each 
round of 6-TG selection, until it is eliminated.
The null, revertant and early/late constructs described above were 
introduced into the parental VI5A26L1.1.1.1.1 genome using upstream and
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downstream flanking regions that were homologous to regions upstream and 
downstream of the EcoGPT locus (formerly A26L locus in VACV IHD-J), as 
previously used in Chapter 3. The resulting viruses were amplified under reverse 
EcoGPT selection conditions.
4.2.2.1 Isolation of Secondary Recombinant VACV
Progeny virus was harvested and cultured in STO cells under 6-TG 
selection for 5 passages. A small stock of each putative recombinant virus was 
produced by culture in STO cells in the presence of 6-TG at low MOI for 24 hours, 
and 1 ml was used to prepare viral DNA.
4.2.2.2 Screening of Secondary Recombinant VACV DNA by PCR
The null recombinant virus acts as a control for the 6-TG selection method, 
as absence of the A26L in this virus would strongly suggest that the other 
recombinant VACVs are true secondary recombinants, and the A26L signal 
observed in their DNA is not due to contaminating wild-type VACV. PCRs were 
carried out to confirm the genotype of the putative null recombinant (Figure 4.3). 
The EcoGPT gene was not detected, however there was a strong signal for A26L 
of ~1628 bp. This indicates that the virus isolated during the selection was A26L 
positive and this was therefore most likely to be wild-type virus that has been 
carried over in the VI5A26L1.1.1.1.1 stock used in the transfections. It is possible 
that a secondary recombinant was indeed produced as a result of homologous 
recombination during the transfection. However, if contaminating wild-type virus
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Figure 4.3 Screening of the Null Secondary Recombinant by PCR
A PCR for A26L (1628 bp) using primers A and E4. Lane 1 -  100 bp ladder; lane 2 -  wt VACV IHD-
J; lane 3 -  VI6A26L1.1.1.1.1; lane 4 -  null recombinant.
B PCR for EcoGPT (500 bp) using primers GPT1 and GPT2. Lane 1 -  100 bp ladder; lane 2 -  wt
VACV IHD-J; lane 3 — vl5A26L1.1.1.1.1; lane 4 -  null recombinant.
C PCR for A27L (300 bp) using primers A27LF and A27LR. Lane 1 -  100 bp ladder; lane 2 -  wt 
VACV IHD-J; lane 3 -  vl6A26L1.1.1.1.1; lane 4 -  null recombinant.
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was present, this would be likely to rapidly amplify during the reverse selection 
against EcoGPT expression, and this would explain the data in Figure 4.3A.
This data casts doubt upon the validity of the other secondary recombinants, 
and suggests the very real possibility that they may in fact be contaminating wild- 
type virus that has survived below the level of PCR detection in parental 
vl6A26L1.1.1.1.1 cultures. It would be difficult to determine whether the isolated 
viruses were true secondary recombinants, in particular a revertant, which was 
designed to be genetically identical to wild-type VACV IHD-J.
Although vl6A26L1.1.1.1.1 used in the transfections had undergone 5 
rounds of plaque purification by limiting dilution, PCRs to detect A26L were 
negative and A26 could not be detected by Western blotting, it must nevertheless 
be concluded that wild-type virus had survived as a vanishingly small population in 
the vl6A26L1.1.1.1.1 stock. To examine this possibility, viral DNA was extracted 
from the VI5A26L1.1.1.1.1 stock used in the transfections, and the PCRs repeated 
for A26L, A27L and EcoGPT (Figure 4.4). This confirmed the apparent absence of 
A26L in the virus stock, and so the quantity of contaminating wild-type VACV IHD-J 
must be below the level of sensitivity of the PCR.
At this point it was decided to carry out a further round of plaque purification 
of VI5A26L1.1.1.1.1 to try to eliminate the remaining wild-type VACV IHD-J and to 
repeat the transfection experiments for each construct using this virus.
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Figure 4.4 Screening of Extracted DNA from vl5A26L1.1.1.1.1 Stock by PCR
A PCR for A27L (300 bp) using primers A27LF and A27LR. Lane 1 -  100 bp ladder; 2 -  wt VACV 
IHD-J; 3 -  VI5A26L1.1.1.1.1.
B PCR for A26L (1628 bp) using primers A and E4. Lane 1 -  100 bp ladder; 2 -  wt VACV IHD-J; 3 
-VI5A26L1.1.1.1.1.
C PCR for EcoGPT (500 bp) using primers GPT1 and GPT2. Lane 1 -  100 bp ladder; 2 -  wt VACV 
IHD-J; 3 - VI6A26L1.1.1.1.1; 4 -p 1107 .
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4.2.3 Repeat Plaque Purification of VI5A26L1.1.1.1.1
Quantification of the parental clone vl6A26L1.1.1.1.1 used in the 
transfections in this chapter was repeated and a further round of plaque purification 
by limiting dilution performed, to try to remove final traces of wild-type VACV IHD-J. 
This was done as previously described in section 2.6.2, and resulted in the 
isolation of 5 clones. Viral DNA was extracted and PCRs to confirm the absence of 
the A26L gene and the presence of the EcoGPT gene were carried out (Figure 
4.5).
The absence of the A26 protein was also confirmed in each clone by 
Western blot using polyclonal rabbit antisera raised against A26 protein (courtesy 
of Dr D.O. Ulaeto) (Figure 4.6A). The Western blot in Figure 4.6B demonstrates 
that similar concentrations of viral proteins were loaded per sample by probing with 
mouse antisera from raised against the Lister strain of VACV (courtesy of Amanda 
Phelps).
4.2.3.1 MPA Inhibits Replication of wt VACV-IHD-J
To investigate the inhibition of replication provided by culturing viruses in 
reduced concentrations of MPA medium, x 105 pfu per ml of VI6A26L1.1.1.1.1 
or VACV IHD-J was titrated in RK13 cells in the presence of 1 x MPA medium, 0.1 x 
MPA medium or in the absence of drug. Replication of VI5A26L1.1.1.1.1 in cultures 
appeared to be similar in both the presence and absence of drug as expected, 
although with a slight inhibition when cultured in 1x MPA medium (Figure 4.7).
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Figure 4.5 Screening by PCR of Extracted Viral DNA from Repeat Plaque Purified Clones 
Derived from VI5A26L1.1.1.1.1
A PCR for A27L (-300 bp) using primers A27LF and A27LR. Lane 1 -  100 bp ladder; 2 -  clone 
VI6A26L1.1.1.1.1.1; 3 -  clone VI6A26L1.1.1.1.1.2; 4 -  clone VI6A26L1.1.1.1.1.3; 5 -  clone 
VI6A26L1.1.1.1.1.4; 6 -clone vl6A26L1.1.1.1.1.5; 7 -  wt VACV IHD-J; 8 -  vl6A26L1.1.1.1.1.
B PCR for A26L (-1628 bp) using primers A and E4. Lane 1 -  100 bp ladder; 2 -  clone 
VI5A26L1.1.1.1.1.1; 3 -  clone VI5A26L1.1.1.1.1.2; 4 -  clone VI5A26L1.1.1.1.1.3; 5 -  clone 
VI5A26L1.1.1.1.1.4; 6 -  clone VI5A26L1.1.1.1.1.5; 7 -  wt VACV IHD-J; 8 -  VI5A26L1.1.1.1.1.
C PCR for EcoGPT (~500 bp) using primers GPTF and GPTR. Lane 1 -  100 bp ladder; 2 -  clone 
VI5A26L1.1.1.1.1.1; 3 -  clone VI6A26L1.1.1.1.1.2; 4 -  clone vl6A26L1.1.1.1.1.3; 5 -  clone 
VI5A26L1.1.1.1.1.4; 6 -  clone vl6A26L1.1.1.1.1.5; 7 -  wt VACV IHD-J; 8 -  vl5A26L1.1.1.1.1.
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Figure 4.6 Detection of A26 by Immunoblotting in Repeat Plaque Purified Clones Derived 
from VI6A26L1.1.1.1.1
A A26 was detected by Western blotting analysis of clones using a-4c rabbit sera. Lane 1 -  marker; 
2 -  clone vl6A26L1.1.1.1.1.1; 3 -  clone VI6A26L1.1.1.1.1.2; 4 -  clone vl5A26L1.1.1.1.13; 5 -  clone 
VI5A26L1.1.1.1.1.4; 6 -  clone VI6A26L1.1.1.1.1.5; 7 -  wild-type VACV IHD-J; 8 -  marker.
B VACV proteins were detected by Western blotting analysis of clones using a-Lister mouse sera to 
demonstrate equal loading. Lane 1 -  marker; 2 -  clone vl5A26L1.1.1.1.1.1; 3 -  clone 
VI6A26L1.1.1.1.1.2; 4 -  clone VI5A26L1.1.1.1.1.3; 5 -  clone vl6A26L1.1.1.1.1.4; 6 -  clone 
VI5A26L1.1.1.1.1.5; 7 -w ild-type VACV IHD-J; 8 -  marker.
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Figure 4.7 Titration of VI5A26L1.1.1.1.1 in the Presence of MPA in RK13 cells
~105 pfu vl5A26L1.1.1.1.1 was serially diluted 1:3 across a 96-well tissue culture plate. 50pl was 
transferred to corresponding wells seeded with RK13 cells. Wells were topped up with 50pl DMEM 
(A); 50pl MPA medium to give final concentrations of 1x (B) and 0.1x (C) and incubated for 5 days 
at 37 °C, 5 % C 02 before fixing to final concentration (v/v) 1 % formalin and staining with 1 % 
crystal violet.
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Cell death was apparent in the presence of 1x MPA around the edges of the wells 
indicating the toxic effect of the drug at this concentration. Conversely, replication 
of VACV IHD-J appeared to be dramatically inhibited in both 1x and 0.1x MPA 
compared to growth in the absence of drug (Figure 4.8). At the higher 
concentrations of VACV IHD-J, there is evidence of viral replication and this was 
confirmed using a light microscope to inspect the monolayers more closely. There 
did appear to be more replication occurring in the presence of 0.1x MPA compared 
to 1x MPA. To quantify this, plates were scanned on a 96-well plate reader at an 
absorbance of 570 nm (Figure 4.9A). In VI5A26L1.1.1.1.1 there was approximately 
0.5 log reduction in virus replication in the presence of 1x MPA compared to in 0.1 x 
MPA and no drug. Interestingly, there is approximately 1 log reduction in replication 
of VACV IHD-J in the presence of 1x MPA and 0.5 log reduction in the presence of 
0.1x MPA, compared to in the absence of drug (Figure 4.9B). The experiments 
were repeated to confirm these findings and again replication of VACV IHD-J was 
inhibited in the presence of MPA as seen in the first experiments. This 
demonstrated that MPA was able to inhibit replication of wild-type VACV IHD-J at 
concentrations of approximately 102-103 pfu or less, and there was little difference 
between the inhibitory effect of 1x and 0.1x MPA.
4.2.3.2 Culture of New Clones Derived from vl5A26L1.1.1.1.1 in MPA and 6-TG
Differential titres of these clones in the presence and absence of 0.1 x MPA 
demonstrated that MPA resistant viruses represented the majority of the viruses in 
culture (Table 4.1 A). The slight reduction in titre in the presence of MPA may be
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Figure 4.8 Titration of VACV IHD-J in the Presence of MPA in RK13 cells
~105 pfu VACV IHD-J was serially diluted 1:3 across a 96-well tissue culture plate. 50 pi was 
transferred to corresponding wells seeded with RK13 cells. Wells were topped up with 50 pi DMEM 
(A); 50 pi MPA medium to give final concentrations of 1x (B) and 0.1x (C) and incubated for 5 days 
at 37 °C, 5 % C 0 2 before fixing to final concentration (v/v) 1 % formalin and staining with 1 % 
crystal violet.
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Figure 4.9 Absorbance (570 nm) of Differential Titrations of vl6A26L1.1.1.1.1 and VACV IHD-J
~105 pfu VI6A26L1.1.1.1.1 (A) and ~105 pfu VACV IHD-J (B) was serially diluted 1:3 across a 96- 
well tissue culture plate. 50 pi was transferred to corresponding wells seeded with RK13 cells. Wells 
were topped up with 50 pi DMEM (♦), or 50 pi MPA medium to give final concentrations of 0.1 x (■) 
and 1x ( A)  and incubated for 5 days at 37 °C, 5 % C 0 2 before fixing to final concentration (v/v) 1 % 
formalin and staining with 1 % crystal violet. Plates were scanned on a Titretek multiskan plus MKII 
plate reader and the absorbance at 570 nm recorded.
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A No selection
Clone No selection 
(TCIDso/ml)
MPA
(TCIDso/ml)
Differential
(%)
VI5A26L1.1.1.1.1.1 2.62x10B 1.47x10“ 56
VISA26L1.1.1.1.1.2 4.92x10“ 2.43x10“ 49
VI6A26L1.1.1.1.1.3 3.98x10“ 1.5x10b 38
VI6A26L1.1.1.1.1.4 3.97x10“ 4.46x10B 112
VI6A26L1.1.1.1.1.5 5.64x10“ 3.31 x10B 59
B 6-TG Selection Passage 1
Clone No selection 
(TCIDso/ml)
MPA
(TCIDso/ml)
Differential
(%)
VI5A26L1.1.1.1.1.1 2 . 1 x 1 0 b 1.48x10“ 7
VI5A26L1.1.1.1.1.2 1.66x10“ 2.73x10“ 16
VI5A26L1.1.1.1.1.3 1.79x10“ 3.1x10“ 17
VI5A26L1.1.1.1.1.4 1.33x10“ 1.84x10“ 14
VI5A26L1.1.1.1.1.5 1.18x10“ 1.02x10“ 9
C 6-TG Selection Passage 2
Clone No selection 
(TCIDso/ml)
MPA
(TCIDso/ml)
Differential 
__ (%)
VI6A26L1.1.1.1.1.1 2.51x10' 9.55x10“ 38
VI5A26L1.1.1.1.1.2 6.68x10“ 2.99x10“ 45
VI6A26L1.1.1.1.1.3 2.46x10' 6.25x10“ 25
VI6A26L1.1.1.1.1.4 8.19x10“ 2.1x10“ 26
VI6A26L1.1.1.1.1.5 6.08x10“ 2.29x10“ 38
D 6-TG Selection Passage 3
Clone No selection 
(TCIDso/ml)
MPA
(TCIDso/ml)
Differential
(%)
VI5A26L1.1.1.1.1.1 1.29x10“ 1.95x10“ 15
VI6A26L1.1.1.1.1.2 7.39x10“ 7.42x10“ 10
VI5A26L1.1.1.1.1.3 5.97x10“ 2.63x10“ 4
VI6A26L1.1.1.1.1.4 2.46x10“ 2.59x10“ 10
VI5A26L1.1.1.1.1.5 3.17x10“ 3.04x10“ 10
Table 4.1 Virus Titres of Repeat Plaque Purified Clones Derived from vl6A26L1.1.1.1.1
Virus was quantitated by Reed-Muench limiting dilution analysis in RK13 cells in the presence and 
absence of MPA selection. The differential is the titre in selection medium as a percentage of the 
titre in non-selective medium. A Virus titres of clones from plaque purification cultures. B Virus titres 
of clones from 1st passage in 0.1 mM 6-TG in STO cells. C Virus titres of clones from 2nd passage 
in 0.1 mM 6-TG in STO cells. D Virus titres of clones from 3rd passage in 0.1 mM 6-TG in STO cells.
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due to the toxic effects of MPA on the cells that may impact on the efficiency of 
replication of virus and perhaps the burden of expression of EcoGPT leading to a 
decrease in viral yield.
To confirm the absence of VACV IHD-J in these stocks, clones were 
cultured in STO cells in the presence of 0.1 mM 6-TG and differential titres 
obtained in the presence of 0.1 x MPA medium. If the clones could undergo 
sequential passage where virus was unable to grow in the presence of 6-TG they 
would be likely to be free from wild-type VACV IHD-J. STO cells were infected at 
low MOI and incubated for 48 or 72 hours as described in section 2.6.1.
In the first passage, no growth was observed in the presence of drug, 
compared to 100 % CPE observed in the absence of drug. The differential titres 
showed between only 7-17 % of virus was MPA-resistant following 1 round of 
negative selection in 6-TG: much lower than anticipated (Table 4.1 B). In the 
second and third passages of 6-TG selection, 100 % CPE was observed for each 
clone in the presence and absence of 6-TG. The differential titres demonstrated a 
reduction in MPA resistant virus in each clone (Table 4.1C and D). This suggested 
that 6-TG was effectively inhibiting the replication of EcoGPT-expressing 
recombinants represented by reduced quantities of virus when titrated in MPA 
medium, yet in the absence of MPA medium overall numbers of virus were not 
reduced. It is possible that the replicating virus maybe contaminating wild-type 
virus that increased when MPA selection was removed, or perhaps 6-TG selection 
was overcome by EcoGPT positive virus, although there was no evidence of this in 
the first passage.
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PCRs of extracted viral DNA from the third round of passage in 6-TG 
demonstrated that 2 out of the 5 clones contained the A26L gene and therefore 
were contaminated with wild-type virus, and all clones were found to have the 
EcoGPT gene (Figure 4.10). This suggests that clones VI6A26L1.1.1.1.1.3 and 
VI6A26L1.1.1.1.1.4 are mixed species, although the levels of wild-type virus in 
these clones may be considered low, as weak signals for the A26L gene could only 
be detected following 3 rounds of reverse selection. This does not explain why 
clones absent of wild-type virus were also able to replicate in these cultures. It is 
possible that selective pressure has caused a mutation in the EcoGPT gene in 
these clones which results in an inactive gene product, allowing replication in the 
presence of 6-TG. To confirm this, the EcoGPT region from each clone could be 
sequenced to look for mutations in the DNA sequence.
4.3 Discussion
The construction and isolation of a panel of secondary recombinant VACVs 
was attempted using reverse EcoGPT selection in this study as it has several 
advantages over other selection methods. Positive selection is an effective 
selective strategy to obtain recombinant viruses however, construction of these 
viruses that contain selection marker genes to enable their isolation from wild-type 
or parental viruses is not ideal, and these selection marker genes may affect the 
phenotype in the resulting recombinant virus. Generation of secondary 
recombinant viruses without selection marker genes using reverse EcoGPT 
selection would be advantageous for potential vaccine candidates, and would
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Figure 4.10 Screening by PCR of Repeat Plaque Purified Clones Derived from 
vl5A26L1.1.1.1.1 Following 3 Rounds of Reverse EcoGPT Selection in STO cells + 0.1 mM 6- 
TG
A PCR for EcoGPT (500 bp) using primers GPT1F and GPTR. Lane 1 -  100 bp ladder; 2 -  clone
VI6A26L1.1.1.1.1.1; 3 -  clone VI6A26L1.1.1.1.1.2; 4 -  clone vl5A26L1.1.1.1.1.3; 5 -  clone
VI6A26L1.1.1.1.1.4; 6 -  clone VI6A26L1.1.1.1.1.5; 7 -  wt VACV IHD-J; 8 -  vl6A26L1.1.1.1.1; 9 -  
100 bp ladder.
B PCR for A26L (1628 bp) using primers A and E4. Lane 1 -  100 bp ladder; 2 -  clone
VI6A26L1.1.1.1.1.1; 3 -  clone VI6A26L1.1.1.1.1.2; 4 -  clone VI5A26L1.1.1.1.1.3; 5 -  clone
VI6A26L1.1.1.1.1.4; 6 -  clone VI5A26L1.1.1.1.1.5; 7 -  wt VACV IHD-J; 8 -  100 bp ladder.
eliminate the possibility that these genes may have phenotypic effects. Other 
selection methods such as insertional inactivation of the TK gene allows isolation 
of TK-negative viruses in the presence of bromodeoxyuridine (BrdU), however, 
spontaneous TK-negative mutants can occur and inactivation of the TK gene 
results in attenuation in vivo (92;352;353).
Alternative methods that allow initiation of expression of genes using 
inducible promoters such as the TET- and lac- repressor/operator systems were 
considered for use in this study (173;354;355). These would result in the 
construction of a secondary recombinant virus where A26L is re-inserted into it 
original locus under the control of an inducible promoter. The phenotype of the 
proposed recombinants in this study could have been studied by inducing 
expression of A26L at various points in the replicative cycle to try to understand the 
relationship between IMV and EV maturation. These systems are notoriously leaky, 
and complete repression of a gene of interest is virtually impossible. Due to this, 
the use of inducible promoter systems was not considered further.
As demonstrated in this study, the reverse EcoGPT selection method also 
appears to have limitations. This method allows the growth of ail non-EcoGPT- 
expressing virus, including wild-type VACV. Following serial rounds of propagation 
of virus in 6-TG treated cultures, the isolated viruses, including the null mutant, 
were found to contain the A26L gene when the DNA was assessed by PCR. This 
strongly suggested that these viruses were not bona fide recombinants but were 
contaminating wild-type virus. It is likely that the undetectable residual wild-type 
virus present in the VI5A26L1.1.1.11 stock, used as the parent strain in this study,
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was able to propagate during the rounds of 6-TG selection, thus resulting in a 
population of VACV that contained the A26L gene. Even after a further round of 
plaque purification, the new clones derived from vl5A26L1.1.1.1.1 still contained 
traces of wild-type virus. This may be due to the particle/pfu ratio (reported as 
between 12.7 to 64.6 virions) (121), where a plaque undoubtedly will arise from 
more than one virus particle, and so conceivably a truly pure population of 
recombinant VACV is unobtainable. If this is the case, purification by either the 
plaque picking or by the limiting dilution method is unlikely to be more favourable 
than the other, as both rely on plaque formation. In addition, the methodology 
reported by Isaacs et at. (1990) has been adapted in this study to first enrich for 
putative secondary recombinant VACV thus reducing the quantities of parental 
virus prior to plaque purification. In Isaacs and colleagues study, plaque purification 
by plaque picking in STO cells in the presence of 6-TG commenced immediately 
following the transfection and infection event. It is unlikely that these changes 
would negatively affect the success of this method, as the enrichment step used in 
this study was intended as an enhancement to the reported method.
Interestingly in the study, repeated passage of EcoGPT-expressing VACV 
resulted in 6-TG resistant VACV. Some of these viruses were proven to be a 
mixture of VI5A26L1.1.1.1.1 and wild-type VACV as they contained both the 
EcoGPT and A26L genes, however some of these viruses contained the EcoGPT 
only. It is possible that the EcoGPT gene was mutated in these viruses due to 
selective pressure, thus enabling replication in 6-TG treated cultures. Spontaneous 
deletion of or random mutations in positive selection marker genes such as
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EcoGPT in VACV, to our knowledge, has not been reported prior to or during the 
course of this study. This may be due the fact that reverse EcoGPT selection is not 
widely utilised for the construction of recombinant VACV, and although mutations 
are likely to occur quite frequently, they may only be highlighted during reverse 
EcoGPT selection in instances such as these. Definitive proof of this would require 
DNA sequencing of the EcoGPT gene in each of these viruses to determine 
mutations of the coding sequence.
In conclusion, success of the reverse EcoGPT method for generation of 
secondary recombinant VACV has been shown to be dependent on the purity of 
the stocks of the parent strain as all non-EcoGPT-expressing viruses will 
propagate using this method. The possibility of mutation of the EcoGPT gene due 
to selective pressure should also be considered. It is likely that secondary 
recombinant viruses were generated throughout this study, however, due to the 
low frequency of a recombination event, recombinant viruses were unable to 
compete with the residual wild-type virus that propagated from VI6A26L1.1.1.1.1 
parent strain stocks in the presence of 6-TG.
153
5 Generation of Secondary Recombinant Viruses using a 
Positive Selection Method: neomycin resistance
5.1 Introduction
Deletion of the A26L gene in VACV has provided insight into the 
mechanisms by which IMV is produced during the infectious cycle. However, 
formal proof of this requires the construction of a revertant virus and a secondary 
A26L deletion mutant, replacing the EcoGPT gene with an alternative dominant 
selectable marker gene. In addition to this, a third recombinant VACV was 
designed to express the A26L gene constitutively where overexpression of A26 
may result in increased production of IMV, reducing the numbers of virions 
available for wrapping, thus reducing EV formation.
In this study, the G418R gene was introduced into VI6A26L1.1.1.1.1.1 
(section 4.2.3) to create a panel of secondary recombinant VACVs. G418R confers 
resistance to Geneticin® (G418, neomycin), an aminoglycoside antibiotic that 
inhibits eukaryotic protein synthesis by interfering with 80s ribosome function (356). 
VACV replication is essentially blocked and visible plaque formation is inhibited in 
cultures supplemented with 2 mg/ml Geneticin®, where the extent of inhibition can 
be increased by pre-treating cells with Geneticin® prior to infection (357). This is 
likely due to a reduction in the expression of a subset of late viral genes, however it 
is unclear whether the effect is at the translational or post-translational level (357). 
No equivalent enzymatic activity exists in eukaryotic systems therefore 
spontaneous G418-resistant mutants are highly unlikely to occur. Inhibition can 
only be overcome by introducing the G418R gene into the VACV genome, therefore
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this dominant selectable marker can be used to isolate recombinant virus and 
rapidly reduce the quantities of parental virus. This positive selection method 
introduces another foreign gene (G418R) for which the experimental control is its 
presence in all secondary recombinant VACVs in this study, and precludes 
problems associated with negative selection such as reverse GPT selection (349) 
and insertion into non-essential genes such as the TK gene (358).
All constructs were designed to utilise the EcoGPT gene as flanking regions 
to facilitate homologous recombination into the original A26L locus in 
vl5A26L1.1.1.1.1.1. Recombination events will result in a deletion of a 350 bp 
internal region of the EcoGPT gene, replacing it with the G418R gene expressed 
from a synthetic early/late promoter (327), linked to the A26L gene and its 
engineered attendant promoter sequence.
5.1.1 Aims of This Study
To design and construct a panel of secondary recombinant VACVs to a) re­
insert the A26L gene into its original locus thus creating a revertant; b) replace the 
EcoGPT gene with a different selection marker gene, G418Rand c) constitutively 
express the A26L gene from a synthetic early/late promoter. These recombinants 
will be used to confirm the earlier findings in this study, and may provide further 
insight into the formation and function of IMV, where modulation of A26 may result 
in an attenuated VACV strain that could be used to develop a safer alternative to 
current smallpox vaccines.
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5.2 Results
5.2.1 Design of Recombination Cassettes
A construct was designed to re-insert the A26L gene expressed from its 
native promoter (using WR sequence as described in Chapter 4) into the original 
locus in vl6A26L1.1.1.1.1.1, where the EcoGPT gene had been previously 
inserted, and thus create a revertapt recombination cassette (Figure 5.1A). The 
recombination cassette was designed so that recombination was facilitated by 
upstream flanking (UF) and downstream flanking (DF) regions homologous to the 
first and last 50 residues of the EcoGPT gene situated at the 5’- and the 3’- ends of 
the construct; this would insertionally inactivate EcoGPT. The construct also 
contained the G418R gene expressed from a synthetic early/late promoter (327) 
that confers resistance to Geneticin® allowing for positive selection (357). 
Expression of A26L should occur at late times during the infectious cycle to restore 
the wild-type phenotype.
To generate the secondary A26L deletion mutant, a construct was designed 
to re-insert a disrupted A26L gene (disrupted by introducing a frarrieshift mutation 
at position 4, and stop codons throughout the sequence at positions 226, 484, 832, 
1069 and 1324), where a promoter sequence upstream of the gene was absent 
(Figure 5.1 B). As in the revertant, this construct was designed to be inserted into 
the original A26L locus in vl5A26L1.1.1.1.1.1, facilitated by UF and DF regions 
homologous to the EcoGPT gene, and contained the G418R gene. A26L should not 
be expressed in this recombinant and the phenotype should reproduce that of the
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Figure 5.1 Schematic of Secondary VACV Recombination Cassettes for Modulating 
Expression of A26L
Each construct was synthesised by GeneArt AG (Germany). Upstream flanking (UF) and 
downstream flanking (DF) regions correspond to the first and last 50 nucleotides of the EcoGPT 
gene respectively, to facilitate homologous recombination with vl5A26L1.1.1.1.1.1 DNA (A). The 
G418r gene expressed from a synthetic early/late promoter (E/LP) confers resistance to Geneticin®, 
allowing positive selection of recombinant viruses (327;357). Constructs B and D were designed to 
express A26L from its native promoter (NP) for a revertant virus or from a synthetic E/LP (327) for a 
recombinant VACV that overexpresses A26, respectively. Construct C was designed with no 
promoter sequence for A26L and a disrupted A26L sequence with engineered stop codons and a
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frameshift mutation for a secondary A26L deletion mutant. DNA sequences can be found in Figures 
A8-10. Positions of primers used for PCR screening purposes are indicated by arrows. 
a Smal sites were engineered at each end of the construct to facilitate excision of the construct from 
the plasmid vector if necessary.
b Not\ sites were engineered to facilitate inactivation of G418R if necessary.
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primary deletion mutant, vl6A26L1.1.1.1.1.1. This mutant would act as an internal 
control to observe the effect, if any, of the presence of selection marker genes.
The final construct was designed to re-insert A26L into the original locus, 
constitutively expressed from a synthetic early/late promoter (327) to overexpress 
A26L (Figure 5.1 C). As in the revertant and secondary deletion mutant, 
homologous recombination was facilitated by UF and DF regions homologous to 
the EcoGPT gene, and the construct contained the G418R gene. It was anticipated 
that expression of A26L throughout the replicative cycle would result in an 
abundance of A26 protein and thus increase the proportion of virions maturing as 
IMV. This would likely result in a concomitant decrease in EV production, and may 
provide a method to achieve an attenuated VACV with reduced dissemination due 
to decreased EV production, yet maintained immunogenicity as the two distinct 
forms of virions are still produced.
These constructs were designed with Sma\ restriction sites at the 5’- and 3’- 
ends to facilitate excision of the construct from the plasmid vector, and Not\ 
restriction sites upstream of the synthetic early/late promoter of the G418R gene 
and within the G418R gene to allow inactivation of this gene if required.
5.2.2 Construction of Recombination Cassettes
Constructs were synthesised by GeneArt AG (Germany) and supplied as 
cloned sequences in plasmid vectors conferring ampicillin resistance (AmpR). 
Obtaining DNA sequences in this way should guarantee sequence integrity, and
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due to the similarity of these sequences, the constructs were ‘built’ in parallel with 
relative efficiency and reduced cost.
Plasmids were transformed into TOP10 chemically competent cells 
(Invitrogen, Ltd) as described in section 2.3.8, and transformants selected for 
ampicillin resistance encoded by the AmpR gene. The presence of plasmid was 
confirmed following extraction from 1 ml bacterial cells (section 2.3.9).
5.2.3 Construction and Selection of Secondary Recombinant Viruses
Purified preparations of each plasmid were transfected into RK13 cells as 
described in section 2.4.5, and subsequently infected at MOI 0.1 with 
vl5A26L1.1.1.1.1.1. Putative recombinant virus was enriched and selected for in 
the presence of Geneticin® (2 mg/ml) (Invitrogen, Ltd), as described in section 
3.2.5. for a total of 6 passages. To increase the effect of inhibition, RK13 cells were 
pre-incubated in Geneticin® (2 mg/ml) for 2 hours prior to infection to allow the drug 
to penetrate the cells and inhibit protein synthesis (357). A crude stock of each 
putative recombinant virus was prepared by infecting RK13 cells in a T25 tissue 
culture flask cultured in Geneticin® (2 mg/ml) for 24 hours.
The inhibitory effect of Geneticin® on G418-negative virus was confirmed 
using the parental strain vl6A26L1.1.1.1.1.1. RK13 cells were infected at a range of 
MOIs in the presence and absence of Geneticin®. Replication of virus was reduced 
in the presence of Geneticin® at low MOI, and following a further 2 passages virus 
replication was undetected demonstrating the quantity of virus was substantially 
reduced following serial passage in the presence of 2 mg/ml Geneticin®.
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5.2.4 Plaque Purification of a Revertant VACV
Putative revertant virus from passage 6 was plaque purified by limiting 
dilution analysis (section 2.6.2) in RK13 cells to obtain a pure clonal population of 
virus. Three rounds of purification by limiting dilution were carried out, followed by 
a fourth round using a modified plaque titration method by limiting dilution was 
performed as described in section 2.6.2 (Figure 5.2). This resulted in 3 clones, of 
which only vl6A26L.rev2.2.3.2 was confirmed as a bona fide revertant virus where 
the EcoGPT gene had been replaced by the A26L and G418R genes (Figure 5.3). 
A purified stock was prepared of vl5A26L.rev2.2.3.2 cultured in RK13 cells in the 
presence of Geneticin® as described in section 2.5.2 and virus was quantitated as 
3.69 x 109 TCID5o/ml by Reed-Muench limiting dilution analysis (section 2.5.3).
5.2.5 Plaque Purification of the Secondary A26L Mutant
Putative recombinant virus from passage 6 was plaque purified as for the 
revertant virus (section 5.2.4), using 4 sequential rounds. To improve the 
probability of isolating recombinant virus, individual plaques were picked from virus 
cultures under an agarose overlay for the first 3 rounds (section 2.6.2), followed by 
a final round using the limiting dilution method (Figure 5.4). This resulted in 5 
clones and PCR analysis demonstrated that vl6A26L.neo3.3.3.3 was a bona fide 
recombinant virus where the EcoGPT gene had been replaced by a disrupted 
A26L gene and the G418R gene (Figure 5.5). A purified stock was prepared of 
clone 3 cultured in RK13 cells in the presence of Geneticin® as described in
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construct
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Figure 5.2 Flow Diagram Representing Process of Isolation of Revertant VACV
The revertant virus, denoted here a vl5A26L.rev2.2.3.2, was derived from the parental strain 
vl5A26L1.1.1.1.1.1 following transfection of cells with the revertant construct (section 5.2.2 and 
5.2.3). Putative recombinant virus was isolated following 6 passages in 2 mg/ml Geneticin® and 4 
rounds of plaque purification.
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Figure 5.3 Screening of Revertant Clones vl6A26L.rev2.2.3.1, vl6A26L.rev2.2.3.2 and 
vl6A26L.rev2.2.3.3 by PCR
PCRs were performed for the A26L gene (1628 bp) using primers A and E4 (A), for a region of the 
G418r gene (~250 bp) using primers neol and neo2 (B) and the EcoGPT gene (~450 bp) using 
GPTF and GPTR (C) on viral DNA extracted of putative revertant clones from plaque purification 4.
A Lane 1 -  100 bp marker; lane 2 -  vl5A26L.rev2.2.3.1; lane 3 -  vl5A26L.rev2.2.3.2; lane 4 -  
vl5A26L.rev2.2.3.3; lane 5 - V A C V  IHD-J DNA; lane 6 -v l6A 26L1 .1.1.1.1.1 DNA.
B Lane 1 -  100 bp marker; lane 2 -  vl5A26L.rev2.2.3.1; lane 3 -  vl5A26L.rev2.2.3.2; lane 4 -  
vl5A26L.rev2.2.3.3; lane 5 -  VACV IHD-J DNA; lane 6 -  revertant construct (GeneArt plasmid).
C Lane 1 -  100 bp marker; lane 2 -  vl5A26L.rev2.2.3.1; lane 3 -  vl5A26L.rev2.2.3.2; lane 4 -  
vl5A26L.rev2.2.3.3; lane 5 - V A C V  IHD-J DNA; lane 6 -v l6A 26L1 .1.1.1.1.1 DNA.
D Schematic of the revertant construct. Positions of primers are indicated by arrows.
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Figure 5.4 Flow Diagram Representing Process of Isolation of Secondary A26L Deletion 
VACV
The secondary A26L deletion virus, denoted here a vl5A26L.neo3.3.3.3, was derived from the 
parental strain vl6A26L1.1.1.1.1.1 following transfection of cells with the secondary A26L deletion 
construct (section 5.2.2 and 5.2.3). Putative recombinant virus was isolated following 6 passages in 
2 mg/ml Geneticin® and 4 rounds of plaque purification.
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Figure 5.5 Screening of Putative vl5A26L.neo Clones by PCR
PCRs were performed for the A26L gene (1628 bp) using primers A and E4 (A), the EcoGPT gene 
(~450 bp) using GPTF and GPTR (B) and for a region of the G418R gene (~300 bp) using primers
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neoF and neoR (C) on viral DNA extracted from putative secondary A26L deletion virus from plaque 
purification 4.
A Lane 1 -  100 bp marker; lane 2 -  vl5A26L.neo3.3.3.1; lane 3 -  vl5A26L.neo3.3.3.2; lane 4 -  
vl6A26L.neo3.3.3.3; lane 5 -  vl5A26L.neo3.3.3.4; lane 6 -  vl5A26L.neo3.3.3.5; lane 7 -  VACV 
IHD-J DNA; lane 8 -  vl5A26L1.1.1.1.1.1 DNA; lane 9 -  100 bp marker.
B Lane 1 -  100 bp marker; lane 2 -  vl5A26L.neo3.3.3.1; lane 3 -  vi5A26L.neo3.3.3.2; lane 4 -  
vl5A26L.neo3.3.3.3; lane 5 -  vl6A26L.neo3.3.3.4; lane 6 -  vl5A26L.neo3.3.3.5; lane 7 -  VACV 
IHD-J DNA; lane 8 -  vl6A26L1.1.1.1.1.1 DNA; lane 9 -  100 bp marker.
C Lane 1 -  100 bp marker; lane 2 -  vl5A26L.neo3.3.3.1; lane 3 -  vl5A26L.neo3.3.3.2; lane 4 -  
vl5A26L.neo3.3.3.3; lane 5 -  vl5A26L.neo3.3.3.4; lane 6 -  vl5A26L.neo3.3.3.5; lane 7 -  secondary 
A26L deletion construct.
D Schematic of secondary deletion construct. Positions of primers are indicated by arrows.
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section 2.5.2 and virus was quantitated as 1.09 x 109 TCID5o/ml by Reed-Muench 
limiting dilution analysis (section 2.5.3).
5.2.6 Plaque Purification of vl5A26L.EL
Putative recombinant virus from passage 6 was plaque purified as for the 
revertant virus (section 5.2.4), using 3 sequential rounds by limiting dilution. The 
resulting clones were examined for their ability to replicate in the presence of 
Geneticin® with each round of plaque purification suggesting that the proportion of 
G418r+ virus was diminishing, questioning the ability of virus overexpressing A26L 
to form plaques. It was plausible that the increased production of A26 would not 
only lead to increased IMV, but also a dramatic reduction in EEV that would render 
the virus unable to form plaques. If this were the case, using a method to clone a 
virus that is reliant on plaque formation is virtually useless as the recombinant virus 
is unable to produce plaques and thus cannot be plaque purified. Plaquing 
observed in the earlier rounds of amplification in Geneticin® may be a result of a 
mixed population containing both parental (plaque forming) and secondary 
recombinant (non-plaque forming) viruses.
5.2.6.1 Growth of Putative vl5A26L.EL in Different Cell Lines to Increase 
Virus Replication
Two approaches were used to attempt to increase the proportion of G418R+ 
virus and reduce parental virus. The first approach was to harvest virus from the 
culture supernates of infected RK13 cells in the presence of Geneticin®, to 
maximise the proportion of EEV in the sample (181). EEV is reported to have a
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lower particle/pfu ratio than IMV (121), therefore this approach reduces the 
probability of using a mixed population of viruses to infect subsequent cultures. 
This should reduce carry-over of parental virus. Alternatively, putative recombinant 
virus was cultured in BSC40 cells, as the increased rate of replication in BSC40 
cells relative to RK13 cells may counteract possible deleterious effects of early 
production of A26. This should enrich cultures for the secondary recombinant and 
reduce parental virus. In both cell lines, plaque formation diminished over 3 
sequential passages, suggesting that this virus was unable to produce EEV, or that 
the virus was unable to replicate in the presence of Geneticin®.
To determine the presence of virus in each of the cultures, DNA was 
extracted and PCRs for the A27L gene were carried out (Figure 5.6). The A27L 
gene was detected in passage 1 and 2 in RK13 cultures, but not in passage 3; and 
in passage 1, 2 and 3 in BSC40 cultures, but not at the highest dilutions in passage 
3, confirming the presence of virus in cultures as demonstrated when grown in 
tissue culture. Overall, this indicated that the isolated virus was unable to replicate 
in the presence of Geneticin®, resulting in a reduction in progeny virus as opposed 
to the enrichment in culture expected from a G418R+ recombinant.
5.2.7 Plaque Purification of vl5A26L.EL from a Repeat Transfection
The transfection was repeated as described in section 2.4.5, and progeny 
recombinant virus amplified in Geneticin®-treated cultures for a total of 6 passages. 
On consideration of previous attempts to plaque purify recombinant viruses by 
limiting dilution, a combination of the agarose overlay method to pick individual
168
Figure 5.6 Screening of Putative vl5A26L.EL Cultured in RK13 Cells and BSC40 Cells by PCR
PCRs were performed for A27L (-300 bp) using A27LF and A27LR on DNA extracted from virus 
cultured in RK13 cells or BSC40 cells for 3 passages. Wt VACV IHD-J and VI6A26L1.1.1.1.1.1 DNA 
were used as positive controls. Lane 1 -  100 bp marker; lane 2 -  virus from RK13 passage 1; lane 
3 -  virus from RK13 passage 2; lane 4 -  virus from RK13 passage 3; lane 5 -  empty; lane 6 -  virus 
from BSC40 passage 1; lane 7 -  virus from BSC40 passage 2; lane 8 -  virus from BSC40 passage 
3; lane 9 - w t  VACV IHD-J DNA; lane 1 0 - vl6A26L1.1.1.1.1.1 DNA.
plaques, followed by 3 rounds of purification by limiting dilution was carried out 
(Figure 5.7) (section 2.6.2). PCR analysis of the 2 resulting viruses demonstrated 
that only clone vl6A26L.EL2.2.1.2 was a bona fide recombinant where the EcoGPT 
gene had been replaced by the A26L and G418R genes (Figure 5.8).
A purified stock was prepared of vl5A26L.EL2.2.1.2 cultured in RK13 cells 
in the presence of Geneticin® as described in section 2.5.2 and virus was 
quantitated as 1.67 x 109 TCID50/ml by Reed-Muench limiting dilution analysis 
(section 2.5.3).
5.2.8 Confirming the Isolation of Recombinant VACVs
Using DNA extracted from RK13 cells infected with vl5A26L.rev2.2.3.2, 
VI5A26L.EL2.2.1.2 and vlSA26L.neo3.3.3.3, PCRs were performed to amplify the 
upstream flanking regions of the A26L gene. Resulting PCR products were isolated 
from gels and the sequence integrity confirmed by Lark Technologies. Sequence 
data confirmed the presence of the native promoter in vl5A26L.rev2.2.3.2 and the 
synthetic early/late promoter in VI6A26L.EL2.2.1.2, and the absence of a promoter 
in vl6A26L.neo3.3.3.3 upstream of the engineered A26L gene. The engineered 
frameshift mutation at position 4 was also confirmed in vl5A26L.neo3.3.3.3.
Following propagation and purification of vl5A26L.rev2.2.3.2, 
VI6A26L.EL2.2.1.2 and vl6A26L.neo3.3.3.3, the presence of A26 protein in each 
virus was assessed by Western blot (Figure 5.9). The presence of a band of the 
same molecular weight of A26 (-60 kDa) was observed in wild-type VACV IHD-J,
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Figure 5.7 Flow Diagram Representing Process of Isolation of VI5A26L.EL
The recombinant VACV to overexpress A26 from a synthetic early/late promoter, denoted here a 
VI5A26L.EL2.2.1.2, was derived from the parental strain vl5A26L1.1.1.1.1.1 following transfection of 
cells with the early/late construct (section 5.2.2 and 5.2.3). Putative recombinant virus was isolated 
following 6 passages in 2 mg/ml Geneticin® and 4 rounds of plaque purification.
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Figure 5.8 Screening of Putative vl5A26L.EL Clones from Plaque Purification 4 by PCR
PCRs were performed on extracted DNA for the, for a region of the G418R gene (~250 bp) using 
primers neol and neo2 (A), for the A26L gene (1628 bp) using primers A and E4 (B) and for the 
EcoGPT gene (~450 bp) using primers GPTF and GPTR (C).
A Lane 1 -  100 bp marker; lane 2 -  clone vl5A26L.EL2.2.1.1; lane 3 -  clone vl5A26L.EL2.2.1.2; 
lane 4 -  wt VACV IHD-J DNA; lane 5 -  GeneArt early/late construct.
B Lane 1 -  100 bp marker; lane 2 -  clone vl5A26L.EL2.2.1.1; lane 3 -  clone vl5A26L.EL2.2.1.2; 
lane 4 -  wt VACV IHD-J DNA.
C Lane 1 -  100 bp marker; lane 2 -  clone vl5A26L.EL2.2.1.1; lane 3 -  clone vl5A26L.EL2.2.1.2; 
lane 4 -  wt VACV IHD-J DNA.
D Schematic of early/late construct. Primers positions are indicated by arrows.
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vl5A26L.rev2.2.3.2 and VI5A26L.EL2.2.1.2, whereas this band was absent in both 
vlSA26L.neo3.3.3.3 and VI6A26L1.1.1.1.1.1. A secondary non-specific band of 
approximately 35 kDa was observed in all viruses, and the similar band intensities 
were indicative of equivalent amounts of protein loaded onto the gel. Interestingly, 
the band intensity of A26 in VI5A26L.EL2.2.1.2 appeared to be more intense than 
with wild-type and vl5A26L.rev2.2.3.2 suggesting that this virus contains more A26 
protein and was indicative of increased synthesis of A26.
5.3 Discussion
In this study, a panel of secondary recombinant VACVs were successfully 
engineered to a) restore the A26L gene expressed from its own promoter thus 
restoring the wild-type phenotype; b) replace the EcoGPT selection marker gene 
with the G418r gene and a disrupted copy of the A26L gene to produce a 
secondary A26L deletion mutant; and c) restore the A26L gene expressed from a 
synthetic early/late promoter to result in overexpression of A26.
Exploiting the ability of these viruses to replicate in the presence of 
Geneticin® (afforded by the engineered G418R gene) allowed selection and 
amplification of secondary recombinant virus at the expense of parental primary 
recombinant virus. Previous reports suggest 2 mg/ml of Geneticin® results in up 
to84 % inhibition of growth of wild-type virus at MOI 5 without the pre-treatment of 
cells (357), therefore to ensure maximum inhibition, selection was carried out using 
MOI < 1, and cells were pre-treated with Geneticin® for 2 hours prior to infection. 
For each recombinant virus, at least 6 rounds of amplification under selective
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Figure 5.9 Immunoblotting for A26 Protein
Approximately 107 pfu of purified virus was run on a tricine gel under reducing conditions to 
separate viral proteins. Proteins were transferred onto a nitrocellulose membrane and probed with 
polyclonal antisera to A26 raised in New Zealand White rabbits. Lane 1 -  wt VACV IHD-J; lane 2 -  
vl5A26L.rev2.2.3.2; lane 3 -  vl6A26L.EL2.2.1.2; lane 4 -  vl5A26L.neo3.3.3.3; lane 5 -  
VI5A26L1.1.1.1.1.1.
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conditions and 4 rounds of plaque purification were required to remove traces of 
parental virus. To achieve pure, clonal populations of each virus, a combination of 
both plaque-picking using agarose overlay to obtain virus originating from a single 
plaque, and a high-throughput method by limiting dilution was successful. 
Purification was more thorough than standard practice (to plaque purify 3 times), 
however, it was a necessity as some clones were mixed populations of 
recombinant and parental virus, as detected by PCR. Carry over of parental virus 
may highlight a reduced efficacy of G418R as a dominant selectable marker, 
relative to what can be achieved (357). Studies by Franke et at. (1985) 
demonstrated maximum inhibition of parental virus when cells were pre-treated for 
48 hours in Geneticin®, however this was not feasible in this study as prolonged 
treatment of cells that would be required (-4-5 days) resulted in cell death.
Isolated clones of vl6A26L.rev, vl6A26L.neo and vl5A26L.EL were negative 
when screened for the EcoGPT gene of the parental primary recombinant virus by 
PCR, indicating deletion of the gene and removal of parental virus from the culture. 
In addition, these viruses were positive for the A26L and G418R genes by PCR, 
and the sequence integrity of the promoter regions upstream of the engineered 
A26L gene in each virus was confirmed. Immunoblotting established the production 
of A26 protein in vl6A26L.rev, vl6A26L.neo and VI6A26L.EL, and its absence in the 
A26L deletion mutants. For all future studies, the terms vl5A26L.rev refers to clone 
vl6A26L.rev2.2.3.2, vl6A26L.neo refers to clone vl5A26L.neo3.3.3.3 and 
VI6A26L.EL refers to clone vl6A26L.EL2.2.1.2.
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Although the purity of each clone was verified at the DNA and protein level, 
previous experience suggests that contaminating parental virus may be present at 
undetectable levels. For this reason, propagation of recombinant VACV for high 
titre stocks was always in the presence of 2 mg/ml Geneticin® to prevent 
amplification of parental virus. For future experiments, it was assumed that the 
presence of undetectably low quantities of parental virus would not affect the 
results of the assays used in subsequent studies.
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6 Characterisation of Secondary Recombinant VACVs
6.1 Introduction
In addition to the roles of A26 reported by other researchers (134;188;342;351), 
previous experiments described in Chapter 3 demonstrated a role for A26 in IMV 
morphogenesis, as first hypothesised by Ulaeto and co-workers (116). Using the 
panel of recombinants described in Chapters 3 and 5, including two different A26L 
deletion mutants and a matched revertant control, the function of A26 was 
investigated further by examining the kinetics of IMV and EV production throughout 
the infectious cycle using metabolically labelled virus separated through CsCI 
density gradients. The production of IMV was expected to be reduced throughout 
the infection when A26L was deleted, with EV production being unaffected. 
Treatment of cultures with BFA was expected to result in increased EEV 
production after BFA removal when A26L was deleted, as observed in Chapter 3. 
This would support the hypothesis that A26 acts as a differentiation switch, causing 
maturation of virions to switch from EV to IMV. If this were the case, acquisition of 
A26 on the surface of the virion would serve to negatively regulate EV production 
as particles could no longer mature as EV. Recent reports provide evidence that 
the acquisition of A26 by virions is mediated by a direct association of A26 with 
A27 (134;351) and this might act to prevent the interaction of A27 with Golgi 
membranes thus preventing EV formation (346). In contrast, when the A26L gene 
was overexpressed, IMV was expected to be synthesised earlier than normal in the 
infectious cycle, resulting in increased IMV maturation relative to EV.
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6.1.1 Aims of This Study
The revertant vl5A26L.rev and vl5A26L.neo produced in Chapter 5 were 
used to confirm the role of A26 in maturation of IMV, as demonstrated with 
vlSA26L in Chapter 3. In addition, these viruses were used to eliminate the 
possibility that the selection marker gene, EcoGPT, had a negative effect on viral 
replication. These viruses, together with wild-type IHD-J and COP strains, were 
characterised for their ability to produce IMV and EV in vitro. A third recombinant, 
designed to constitutively express A26L throughout the replicative cycle, was 
included in this study where the production of IMV was predicted to be increased, 
reducing the number of virions available for wrapping and thus reducing EV 
formation. These recombinants may provide further insight into the formation and 
function of IMV, and modulation of A26 may result in an attenuated phenotype, that 
may have potential as a safer alternative to current smallpox vaccines.
6.2 Results
6.2.1 Comparative Growth Kinetics of Recombinant VACVs
To compare the ability of IHD-J, vl5A26L, vl5A26L.rev, vl5A26L.neo and 
vl5A26L.EL to replicate in tissue culture, one-step growth curves were performed 
in BSC40 cells. This would demonstrate any differences in the growth rates of each 
of the viruses, and confirm the reduction in titre when A26L is deleted, as observed 
with vl6A26L in Chapter 3. VACV COP was also included to determine whether 
there was a difference in growth kinetics to the IHD-J strain, as COP has several 
lesions in its genome, including a truncation of the A26L gene. The experiment was
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performed in triplicate in 24-well tissue culture plates, infecting at MOI 10 to ensure 
synchronous infections. Cultures were harvested at 6, 12, 16, 24, 30 and 48 hours 
p.i. and virus quantitated by Reed-Muench limiting dilution analysis (Figure 6.1). 
The data was log™ transformed and fitted to a one-phase exponential association 
model to allow statistical analyses (Figure 6.2). Using this model (Y=Ymax(1-exp(- 
KX))), F-tests with Bonferroni’s post-tests were performed to compare the growth 
rates (K) of each strain of virus. There was no significant difference between the 
growth rates of all the viruses tested (p=0.3126). Using a two-way ANOVA analysis 
with Bonferroni’s post-tests there was a significant reduction in virus yield in 
VI5A26L cultures compared to IHD-J (p=0.002), and in vl6A26L.neo cultures 
compared to vl6A26L.rev (p=0.041).
The results of this experiment confirm the findings of Chapter 3, where 
deletion of the A26L gene in VI5A26L and vl5A26L.neo resulted in a decrease in 
total virus yield. This suggests that deletion of A26L may affect the ability of the 
virus to produce IMV, or possibly the stability or infectivity of IMV, and this was 
investigated further in this chapter. Importantly, these results indicate it is unlikely 
that the EcoGPT and G418R genes have a negative effect on viral yields, as similar 
phenotypes were observed in both vl5A26L and vl5A26L.neo. The wild-type 
phenotype was restored in the revertant and VI6A26L.EL, where the G418R gene 
was also present, confirming that the presence of this gene did not result in 
reduced viral yields.
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Figure 6.1 One-step Growth Curves for Recombinant VACVs
Freshly confluent monolayers of BSC40 cells in 24-well tissue culture plates were infected at MOI 
10 with IHD-J (■) or vl5A26L (A ) A; vl5A26L.rev (■) or vl5A26L.neo (A ) B; vl5A26L.rev (■) or 
vl5A26L.EL (•) C; IHD-J (■) or COP (•) D, in triplicate wells. Cultures were maintained at 37 °C in a 
5 % C 02 humidified atmosphere until the time of harvest. At the appropriate time p.i. replication 
was halted by freezing the cultures at -80 °C. Virus was liberated by three rounds of freeze-thaw 
followed by dounce homogenisation, prior to titration by Reed-Muench limiting dilution analysis in 
RK13 cells. Data is presented as mean TCID50/ml and SEM of triplicate cultures.
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Figure 6.2 Transformation of Data from One-step Growth Curves for Recombinant VACVs
Freshly confluent monolayers of BSC40 cells in 24-well tissue culture plates were infected at MOI 
10 IHD-J (■) or VI6A26L (A ) A; vl5A26L.rev (■) or vl5A26L.neo (A ) B; vl6A26L.rev (■) or 
vl6A26L.EL (•) C; IHD-J (■) or COP (•) D in triplicate wells. Cultures were maintained at 37 °C in a 
5 % C 0 2 humidified atmosphere until the time of harvest. At the appropriate time p.i. replication 
was halted by freezing the cultures at -80 °C. Virus was liberated by three rounds of freeze-thaw 
followed by dounce homogenisation, prior to titration by Reed-Muench limiting dilution analysis in 
RK13 cells. To allow statistical analyses, data was log10 transformed and fitted to a one phase 
exponential association model (** p=0.002; *p=0.041). Error bars represent SEM of triplicate 
cultures.
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6.2.2 Effect of Deletion of A26L on Maturation of IMV and EV
6.2.2.1 Comet Formation
The production of EEV by each of the recombinant VACV strains and the 
IHD-J and COP strains was determined by comet formation in RK13 cells (Figure 
6.3). Both A26L deletion mutants (Figure 6.3B and 6.3D) produced comets of a 
similar size to the wild-type IHD-J parent and vl6A26L.rev strains (Figure 6.3A and 
6.3C). Although virus was diluted to give approximately 1-105 TCID50 per well, it 
would appear that considerably less virus was present when vl5A26L was used 
(Figure 6.3B). vl5A26L.EL was also able to produce comets suggesting the 
production of EEV (Figure 6.3E), however as in vl5A26L, less virus appeared to be 
present in these cultures. This is possibly due to an experimental error where the 
stock was inadequately mixed before sampling. COP did not produce comets, 
suggesting the absence of EEV.
6.2.2.2 Kinetics of IMV and EV Production in BSC40 cells
To investigate the role of A26 in maturation of IMV, the production of IMV 
and EV in IHD-J, vl5A26L, vl5A26L.neo, vl5A26L.rev and COP was examined in 
vitro. This data was intended to build upon that discussed in Chapter 3, to 
determine the effect of deleting A26L on virus maturation and confirm that deletion 
of A26L results in a reduction in IMV.
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Figure 6.3 Comet Formation in Recombinant VACV Strains
IHD-J (A), VI5A26L (B), vl5A26L.rev (C), vl5A26L.neo (D), vl6A26L.EL (E) and COP (F) were 
diluted to approximately 1-105 TCID50 per ml and 1 ml used to infect wells of 6-well tissue culture 
plates seeded with RK13 cells as indicated. Cultures were maintained at 37 °C in a 5 % C 0 2 
humidified atmosphere and incubated on a slope to facilitate comet formation in the same direction, 
for 30 hours. Cultures were fixed and stained with 1 % (v/v) formaldehyde and 1 % (w/v) crystal 
violet.
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BSC40 cells were infected at MOI 10 and incubated for 6, 9, 12, 15 and 24 hours in 
culture medium supplemented with 10 pCi 3H thymidine. Total progeny virions 
were separated by ultracentrifugation through CsCI gradients which were then 
fractionated and subjected to liquid scintillation counting. Interestingly at all of the 
time points examined, IMV maturation appeared to dominate, even at earlier times 
p.i. (Figure 6.4) This result differs from previous reports where EV maturation 
occurs first in the replicative cycle in conjunction with detectable F13, followed by 
IMV maturation later with detectable A26 synthesis at 15 hours p.i., to become the 
majority of progeny by 24 hours p.i. (116).
In both A26L deletion mutants, there was a reduction in both IMV and EV at 
9 and 12 hours p.i., and a reduction in the ratio of IMV:EV at 12 hours p.i. for both 
viruses when compared to wild-type IHD-J (Figure 6.4A and B) or vl5A26L.rev 
(Figure 6.5A and B). In the later stages of the infectious cycle when IMV maturation 
was expected to dominate, there was a slight reduction in the ratio of IMV:EV at 15 
hours p.i., compared to the IHD-J parent (Figure 6.5C) and vl5A26L.rev (Figure 
6.4C). At 24 hours p.i., the ratio of IMV:EV was comparable in VI5A26L and IHD-J 
cultures (Figure 6.4D), however there is a reduction in IMV in vl5A26L.neo 
compared to vl5A26L.rev, reducing the ratio of IMV:EV (6.5D). The results are 
starkly different from those in Chapter 3 where a dramatic reduction in IMV was 
observed at 24 hours p.i. It is possible that there is a difference in the kinetics of 
virion production when using different cell lines as RK13 cells were used in 
Chapter 3, therefore the phenotype observed in A26L deletion mutants may be 
different when cultured in different cell lines.
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Figure 6.4 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and vl5A26L 
Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (■) 
and VI5A26L (▲) virus cultured in BSC40 cells. Progeny virus was harvested at 9 (A), 12 (B), 15
(C) and 24 (D) hours p.i. and subjected to ultracentrifugation through CsCI gradients. Peaks 1 and 2 
represent EV and IMV, respectively. Relative quantities of virus were calculated using the sum of 
counts (CPM) for peaks corresponding to EV (peak 1) and IMV (peak 2) from each trace. Ratios = 
sum of IMV counts/sum of EV counts.
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Figure 6.5 Analysis of IMV and EV by Radioactive Labelling of Virions in vl5A26L.rev and 
vl5A26L.neo Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from 
vl5A26L.rev (■) and vl5A26L.neo (A ) virus cultured in BSC40 cells. Progeny virus was harvested at 
9 (A), 12 (B), 15 (C) and 24 (D) hours p.i. and subjected to ultracentrifugation through CsCI 
gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of 
EV counts.
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In addition to the recombinants generated in this study, the kinetics of IMV 
and EV production were examined in COP. COP has a truncation of the A26L gene 
and is thus relevant to this study, although there are several lesions in the COP 
genome that may alter its maturation phenotype compared to other VACV strains. 
On comparison of COP to IHD-J, there were greater quantities of progeny virus at 
6 and 9 hours p.i in COP cultures (Figures 6.6A and B), and the ratio of IMV:EV in 
COP was increased at 6 hours p.i. compared to IHD-J. At the later time points, 
production of IMV and EV in COP were similar to that in IHD-J until 24 hours p.i., 
where EV was reduced and IMV increased in COP thus resulting in an increased 
ratio IMV:EV (Figures 6.6C and D).
These results suggest that deletion of A26L expression results in an altered 
phenotype whereby the relative quantities of IMV and EV are changed. This study 
also demonstrates that re-insertion of A26L into vl5A26L results in restoration of 
the wild-type IHD-J phenotype.
6.2.2.3 Kinetics of IMV and EV Production in RK13 cells (I)
As the phenotype observed in both A26L deletion mutants and COP in 
BSC40 cells differs from that in RK13 cells reported in Chapter 3, the kinetics study 
was repeated in the RK13 cell line to investigate whether the phenotype observed 
in Chapter 3 could be repeated. Cells were infected at MOI 10 with IHD-J, 
vl5A26L.rev, vl5A26L, vl5A26L.neo and COP and cultures supplemented with 3H 
thymidine. Cultures were harvested at 6, 9, 12, 15, 18, 24 and 30 hours p.i. and
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Figure 6.6 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and COP 
Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (b) 
and COP (o) virus cultured in BSC40 cells. Progeny virus was harvested at 6 (A), 9 (B), 12 (C), 15 
(D) and 24 (B) hours p.i. and subjected to ultracentrifugation through CsCI gradients. Peaks 1 and 2 
represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of EV counts.
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progeny virions subjected to ultracentrifugation though CsCI gradients to separate 
IMV and EV, as for previous experiments.
Cultures of vlSA26L produced less progeny particularly in the earlier stages 
of the infectious cycle (Figure 6.7A-C). As the infection progressed the quantities of 
IMV increased in VI5A26L cultures, although they were reduced compared to IHD-J 
(Figure 6.7D-F). EV production was also reduced compared to IHD-J resulting in 
an increased ratio of IMV:EV between 12 and 24 hours p.i. At 30 hours p.i., EV 
production was slightly increased compared to that of IHD-J, however, IMV was 
reduced and consequently the ratio of IMV:EV was reduced (Figure 6.7G).
A similar trend was observed in vl5A26L.neo, where less virus was 
produced at the earlier time points (Figure 6.8A-C). As the infection progressed, 
the quantities of IMV increased in vl5A26L.neo cultures, although IMV production 
was generally reduced compared to vl6A26L.rev (Figures 6.8D and E). At the later 
stages, EV production appeared to peak by 24 hours p.i., and production of IMV 
was reduced in vl5A26L.neo, resulting in a decreased ratio of IMV:EV (Figures 
6.8F and G).
Characterisation of COP in RK13 cells demonstrated an increase in both 
IMV and EV in the early stages of infection (Figure 6.9A and B), causing an 
increase in the ratio of IMV:EV when compared to IHD-J. As the infection 
progressed, the quantities of EV were reduced and IMV production was equivalent 
to IHD-J until 18 hours p.i. (Figure 6.9C-E). Production of virus in COP cultures 
appeared to cease at 24 and 30 hours p.i. resulting in reduced quantities of virus 
compared to IHD-J at the later time points (Figure 6.9F and G). However, due to a
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Figure 6.7 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and VI5A26L 
Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (■) 
and vl6A26L (A ) virus cultured in RK13 cells. Progeny virus was harvested at 6 (A), 9 (B), 12 (C), 
15 (D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation through CsCI 
gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of 
EV counts.
* Counts were too low in vl6A26L at 6 hours p.i. to calculate a ratio.
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(h)
vl5A26L.rev vl5A26L.neo
6 2.82 4.53
9 2.45 3.07
12 2.57 2.19
15 1.46 2.73
18 1.54 2.13
24 2.56 2.34
30 3.58 2.07
Figure 6.8 Analysis of IMV and EV by Radioactive Labelling of Virions in vl5A26L.rev and 
vl5A26L.neo Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from 
vl6A26L.rev (■) and vl5A26L.neo (A ) virus cultured in RK13 cells. Progeny virus was harvested at 
6 (A), 9 (B), 12 (C), 15 (D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation 
through CsCI gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV 
counts/sum of EV counts.
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Ratio IMV:EV
Time p.i. 
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Figure 6.9 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and COP 
Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (■) 
and COP (o) virus cultured in RK13 cells. Progeny virus was harvested at 6 (A), 9 (B), 12 (C), 15 
(D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation through CsCI gradients. 
Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of EV counts.
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decrease in EV formation throughout, the ratio of IMV:EV in COP cultures was 
increased, compared to IHD-J.
The kinetics of IMV and EV maturation in RK13 cells was similar to that in 
BSC40 cells, where deletion of A26L appeared to perturb the ratio of IMV:EV, even 
at late times p.i. The vl5A26L.rev behaved in a broadly similar manner to IHD-J, 
confirming restoration of the wild-type phenotype by re-introducing the A26L gene 
expressed from its natural promoter into vl6A26L. However, the effect of deletion of 
A26L was not as profound as the altered phenotype reported in Chapter 3. These 
results do not convincingly support the hypothesis that A26 modulates the relative 
quantities of IMV and EV, and do indicate that A26 does not appear to operate as a 
simple on/off switch of IMV maturation.
6.2.2.4 Kinetics of IMV and EV Production in RK13 cells (II)
The maturation of IMV and EV has been demonstrated to be similar in both 
BSC40 and RK13 cells, however the experiment was repeated in RK13 cells as 
confirmation. Cells were infected at MOI 10 with IHD-J, vl5A26L.rev, vl5A26L, 
vlSA26L.neo and COP, and the cultures were supplemented with 3H thymidine. 
Cultures were harvested at 6, 9, 12, 15, 18, 24 and 30 hours p.i. Progeny virions 
were separated by ultracentrifugation through CsCI gradients and the resulting 
fractions subjected to liquid scintillation counting.
Deletion of the A26L gene in VI5A26L resulted in a reduction in the 
quantities of progeny produced at earlier times p.i. (Figures 6.10A-C) compared to 
IHD-J, as observed in previous kinetics experiments in BSC40 and RK13 cells.
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Figure 6.10 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and vl5A26L 
Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (■) 
and vl5A26L (A ) virus cultured in RK13 cells. Progeny virus was harvested at 6 (A), 9 (B), 12 (C), 
15 (D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation through CsCI 
gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of 
EV counts.
* Counts too low to determine peaks and therefore to calculate ratio at 6 hours p.i. 
t  No data for IHD-J at 15 hours p.i. due to a cracked centrifuge tube.
Interestingly, IMV was the dominant particle produced in VI6A26L cultures, 
whereas EV production dominated in IHD-J cultures, as demonstrated by the 
increased ratio of IMV.EV compared to IHD-J at 12 hours p.i. As the infection 
progressed, quantities of IMV exceeded EV in both wild-type IHD-J and vl5A26L 
cultures, however the quantities of virus produced at 18 hours p.i. were reduced in 
vl5A26L (Figures 6.1 OD and E). At 24 hours p.i., the counts for both IMV and EV 
were greater in VI6A26L cultures than in IHD-J. This was likely due to experimental 
variation as this does not follow the trend observed in this experiment and previous 
experiments (Figure 6.1 OF). At 30 hours p.i. EV was reduced in vl6A26L, resulting 
in a slightly increased ratio of IMV:EV compared to IHD-J, which has not been 
observed in previous experiments (Figure 6.10G).
In vl6A26L.neo, a reduction in IMV and EV was observed compared to 
vl5A26L.rev at 9 hours p.i. (Figure 6.11B). Up to 24 hours p.i., EV production was 
dominant in both viruses reducing the ratio of IMV:EV to less than 1 (Figures 6.11C 
-F). The production of IMV and EV were comparable for the two viruses except at 
15 hours p.i. where the ratio of IMV:EV in vl5A26L.neo was increased compared to 
vl5A26L.rev. At 30 hours p.i., equivalent quantities of EV were produced and IMV 
was slightly reduced in vl5A26L.neo compared to vl5A26L.rev resulting in a 
reduction in the ratio of IMV:EV in vl6A26L.neo at late times p.i. (Figure 6.11G).
Examining the kinetics of IMV and EV in COP demonstrated that IMV was 
produced in greater quantity than EV throughout the infectious cycle resulting in an 
increased ratio of IMV:EV when compared to IHD-J (Figure 6.12). As the infection 
progressed, the quantities of IMV and EV were reduced compared to IHD-J
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Figure 6.11 Analysis of IMV and EV by Radioactive Labelling of Virions in vl5A26L.rev and 
vl5A26L.neo Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from 
vl5A26L.rev (■) and vl5A26L.neo (A)  virus cultured in RK13 cells. Progeny virus was harvested at 
6 (A), 9 (B), 12 (C), 15 (D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation 
through CsCI gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV 
counts/sum of EV counts.
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Figure 6.12 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and COP 
Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (■) 
and COP (•) virus cultured in RK13 cells. Progeny virus was harvested at 6 (A), 9 (B), 12 (C), 15
(D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation through CsCI gradients. 
Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of EV counts.
* Counts too low to determine peaks and therefore to calculate ratio at 6 hours p.i. 
t  No data for IHD-J at 15 hours p.i. due to a cracked centrifuge tube.
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(Figures 6.12E and F) and by 30 hours p.i. there was a dramatic reduction in EV 
which resulted in an increased ratio of IMV:EV compared to IHD-J (Figure 6.12G). 
These findings are similar to those in BSC40 and RK13 cells where the majority of 
progeny produced by COP was IMV.
Comparison of vl5A26L and vl5A26L.neo demonstrates some differences in 
their phenotypes although there was a general reduction in virus production in the 
early stages of replication. One of the major differences observed was the 
production of IMV in favour of EV in VI5A26L cultures, whereas EV production was 
favoured in vl6A26L.neo cultures during the early stages of the infectious cycle.
The reasons for this are unclear, as previous experiments in this chapter 
have demonstrated similar phenotypes for these viruses. It is possible that the cells 
used for this experiment have introduced some variability resulting in differing 
maturation kinetics between viruses and also across time points. In addition, where 
it has been consistently observed that the majority of progeny mature as IMV in 
this chapter, EV predominated in some cultures. It should also be noted that the 
CPM for this experiment were reduced compared to the previous two studies 
suggesting that the metabolic state of the cell cultures may not have been 
equivalent.
6.2.2.5 Examination of the Kinetics of IMV and EV Production in RK13 
cells of Varying Passage History
The differing maturation kinetics observed for the A26L deletion mutants 
was unclear, therefore to investigate whether this may be due to the passage
205
history of the cells, the production of IMV and EV was examined in RK13 cells at 
high and low passage, where high passage represented experiments reported in 
Chapter 3 and low passage in this chapter. From previously published data, the 
IHD-J strain should produce ~3-fold greater quantities of IMV than EV by 24 hours 
p.i. when grown in RK13 cells (181;359).
RK13 cells of low and high passage were infected at MOI 10, and 3H 
thymidine supplemented cultures incubated for 24 and 30 hours p.i. The 
experiment was performed three times, resulting in the comparison of cultures at 
passage 5, 11 and 18 (low) with passages 65, 71 and 78 (high). Progeny virions 
were separated by ultracentrifugation through CsCI gradients, and the gradients 
fractionated and subjected to liquid scintillation counting (Figure 6.13). The 
quantities of IMV and EV were calculated by summing the counts of each peak on 
the resulting trace (Figure 6.14). At 24 hours p.i., cells at low passage produced 
more EV than IMV, with the exception of P11 which produced approximately 
equivalent quantities (Figure 6.14A), and only at P5 was the difference between 
IMV and EV marked. After 30 hours p.i., EV production still dominated, again 
except for P11 where the quantities of IMV exceeded EV (Figure 6.14B). Cells at 
high passage produced greater quantities of EV at both 24 and 30 hours p.i. , 
although again the difference was only marked at one passage, P65 (Figure 6.14C 
and D).
The data indicated that different cultures of RK13 cells could give 
dramatically different IMV:EV ratios, and that this may have little to do with the
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Figure 6.13 Examination of Progeny in RK13 cells of Varying Passage Number
IHD-J was cultured in RK13 cells of various passage numbers (P): A -  P5; B -  P65; C -  P11; D -  
P71; E -  P18 and F -  P78, and harvested at 24 (■) and 30 (■) hours p.i. Progeny virions were 
subjected to ultracentrifugation through CsCI gradients. Peaks 1 and 2 represent EV and IMV, 
respectively.
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Figure 6.14 Examination of Progeny in RK13 cells of Varying Passage Number
IHD-J was cultured in RK13 cells of various passage numbers (P) at MOI 10 and harvested at 24 (A 
and C) and 30 (B and D) hours p.i. Progeny virions were subjected to ultracentrifugation through 
CsCI gradients (see Figure 6.13). Data is presented as the sum of counts (CPM) for the EV peak 
(■) and IMV peak (■) from each trace.
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passage history of the cells. This may conceivably be due to alterations in cellular 
metabolism that leads to a decrease in the rate of the infectious cycle. It is 
apparent that even when at low passage there is variation in the production of EV 
and IMV in these cells, and in all of the experiments the total progeny indicated by 
the total CPM of both EV and IMV also varied considerably. This suggests that 
there is inter-experimental variation that may not only affect the production of IMV 
and EV, but also the yield of radiolabelled virus that may not be attributed to the 
passage history of the cells.
Taking this into consideration, RK13 cells at low passage were used in 
future kinetics experiments. Prior to the next kinetics study, these cells were 
examined for their ability to produce IMV and EV (Figure 6.15). At 24 hours p.i. a 
majority of progeny produced was EV, however IMV was in slight majority in 
cultures harvested at 30 hours p.i.
6.2.3 Effect of Overexpression of A26L on Maturation of IMV and EV
To test the hypothesis that overexpression of A26L leads to increased IMV 
and decreased EV production, the ability of vl5A26L.EL to produce each particle 
was assessed. RK13 cells were synchronously infected at MOI 10 with IHD-J and 
vl6A26L.EL. Cultures were supplemented with 10 pCi 3H thymidine and virus 
harvested after 24 hours incubation. Total progeny virions were subjected to 
ultracentrifugation through CsCI gradients and fractions subjected to liquid 
scintillation counting (Figure 6.16A).
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Figure 6.15 Examination of Progeny in RK13 cells at Passage 2
IHD-J was cultured in RK13 cells at MOI. A Progeny virions were harvested at 24 (■) and 30 (■) 
hours p.i. and subjected to ultracentrifugation through CsCI gradients. Peaks 1 and 2 represent EV 
and IMV, respectively. B Data is presented as the sum of counts (CPM) for the EV peak (■) and 
IMV peak (■) for 24 and 30 hours p.i.
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Figure 6.16 Analysis of IMV and EV by Radioactive Labelling of Virions in IHD-J and 
vl5A26L.EL Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from IHD-J (■) 
and vl5A26L.EL (A ) virus cultured in RK13 cells (A-B) or in BSC40 cells (C-D). Progeny virus was 
harvested at 24 hours p.i. and subjected to ultracentrifugation through CsCI gradients. Peaks 1 and 
2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of EV counts.
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The results demonstrate an increase in IMV and a decrease in EV in 
VI5A26L.EL cultures compared to IHD-J, thus increasing the ratio of IMV:EV in 
vl6A26L.EL. IMV did not constitute the majority of progeny virions in IHD-J cultures 
and the counts were somewhat low. This demonstrated the variability in these 
assays, however, vlSA26L.EL was able to produce more IMV suggesting that IMV 
production was occurring earlier in the infectious cycle. It is possible that the limited 
production of IMV in the wild-type culture maybe due to limiting 3H thymidine. To 
try to mitigate this, the experiment was repeated and 20 pCi 3H thymidine was 
added to the culture medium to increase the availability of 3H thymidine. The 
production of IMV by IHD-J again was not as great as expected, suggesting that 
the levels of 3H thymidine available were not limiting in these cultures (Figure 
6.16B). These cultures also demonstrated an increase in IMV and a slight 
decrease in EV in vl5A26L.EL, thus increasing the ratio of IMV:EV relative to IHD- 
J. Subsequently, the kinetics of IMV and EV production were investigated in 
BSC40 cells as an alternative model. The experiment was performed twice, both 
times demonstrating increased IMV production and decreased EV production for 
vl6A26L.EL compared to IHD-J (Figure 6.16C and D), increasing the ratio of 
IMV:EV in vl5A26L.EL. In addition, production of IMV exceeded that of EV after 24 
hours in IHD-J cultures, demonstrating the expected phenotype at 24 hours p.i.
These results demonstrated that increased levels of IMV are produced in 
vl5A26L.EL cultures, suggesting that overexpression of A26L results in maturation 
of IMV at earlier times in the infectious cycle leading to a concomitant reduction in
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EV maturation. To investigate this further, the kinetics of IMV and EV maturation 
were assessed throughout the infectious cycle in BSC40 cells.
6.2.3.1 Kinetics in BSC40 cells
To further assess the phenotype of vlSA26L.EL observed in BSC40 cells 
and RK13 cells 24 hours p.i., the kinetics of IMV and EV maturation were 
investigated and compared to vl6A26L.rev, its matched control (Figure 6.17). 
Although limited progeny virus was produced at 6 and 9 hours p.i., increased 
amounts of IMV were produced relative to EV in vl5A26L.EL cultures thus 
increasing the ratio of IMV:EV compared to vl5A26L.rev (Figures 6.17A and B). As 
the infection progressed, the quantity of virus produced in VI5A26L.EL was reduced 
compared to vl5A26L.rev at 12 and 15 hours p.i. and the relative quantities of IMV 
were reduced leading to a reduced ratio of IMV:EV compared to vl6A26L.rev 
(Figures 6.17C and D). By 24 hours p.i. levels of IMV were increased relative to EV 
resulting in a markedly increased ratio of IMV:EV in VI5A26L.EL, compared to 
vl5A26L.rev culture (Figure 6.17E). This suggests that overexpression of A26 by 
VI6A26L.EL results in a relative increase in IMV and thus increases the ratio of 
IMV:EV, but only at very late times p.i. This may be due to the kinetics of 
expression from the synthetic early/late promoter, which was constructed to 
optimise absolute levels of expression but not the fine kinetics of expression within 
the early or late stages of the replicative cycle.
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Figure 6.17 Analysis of IMV and EV by Radioactive Labelling of Virions in vl5A26L.rev and 
VI5A26L.EL Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from 
vl5A26L.rev (□) and vl5A26L.EL (•) virus cultured in BSC40 cells. Progeny virus was harvested at 6 
(A), 9 (B), 12 (C), 15 (D) and 24 (B) hours p.i. and subjected to ultracentrifugation through CsCI 
gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV counts/sum of 
EV counts.
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6.2.3.2 Kinetics in RK13 cells (I)
Due to the difference in phenotype of vl6A26L observed in BSC40 cells 
(section 6.2.2.2) to that in previous experiments in RK13 cells in Chapter 3, the 
kinetics of IMV and EV production was examined for vlSA26L.EL also in RK13 
cells. Modulation of the A26L gene by VI5A26L.EL resulted in almost identical 
kinetics to vl5A26L.rev at 6 hours p.i. (Figure 6.18A), however production of IMV at 
9 and 12 hours p.i. was reduced while the quantities of EV were unchanged 
compared to vl5A26L.rev, resulting in a reduction in the ratio of IMV:EV in 
VI5A26L.EL (Figures 6.18B and C). As the infection progressed, IMV production 
increased and EV production was reduced in vlSA26L.EL compared to 
vl6A26L.rev, which was especially apparent at 15, 18 and 24 hours p.i., thus 
increasing the ratio of IMV:EV (Figures 6.18D-G). This suggests that 
overexpression of A26L creates an abundance of A26 which leads to increased 
maturation of progeny as IMV and thus reducing EV maturation. This confirms the 
findings in BSC40 cells reported earlier in this chapter.
6.2.3.3 Kinetics in RK13 cells (II)
The study of the kinetics of IMV and EV production was repeated in RK13 
cells, where overexpression of A26L in VI5A26L.EL resulted in reduced quantities 
of IMV and EV throughout the infectious cycle (Figure 6.19). A reduction in the ratio 
of IMV.EV was observed at 9 hours p.i. compared to vl5A26L.rev (Figure 6.19B). 
At 12 hours p.i., IMV production was equivalent to EV production in both viruses 
(Figure 6.19C), however, reduced quantities of both forms of virus were produced
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Ratio IMV:EV
Time p.i. 
(h)
vl5A26L.rev VI5A26L.EL
6 2.82 2.50
9 2.45 137
12 2.57 1.20
15 1.46 2.43
18 1.54 2.61
24 2.56 3.77
30 3.58 3.80
Figure 6.18 Analysis of IMV and EV by Radioactive Labelling of Virions in vl5A26L.rev and 
vl5A26L.EL Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from 
vl5A26L.rev (■) and vl5A26L.EL (•) virus cultured in RK13 cells. Progeny virus was harvested at 6 
(A), 9 (B), 12 (C), 15 (D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation 
through CsCI gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV 
counts/sum of EV counts.
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Ratio IMV:EV
Time p.i. 
(h)
vl5A26L.rev VI6A26L.EL
6 * *
9 1.66 1.46
12 1.08 1.00
15 0.57 0.69
18 0.95 1.13
24 0.96 0.89
30 1.36 1.45
Figure 6.19 Analysis of IMV and EV by Radioactive Labelling of Virions in vl5A26L.rev and 
VI5A26L.EL Cultures
Liquid scintillation counting of CsCI fractions of 3H thymidine labelled progeny virions from 
vl5A26L.rev (■) and vl6A26L.EL (•) virus cultured in RK13 cells. Progeny virus was harvested at 6 
(A), 9 (B), 12 (C), 15 (D), 18 (E), 24 (F) and 30 (G) hours p.i. and subjected to ultracentrifugation 
through CsCI gradients. Peaks 1 and 2 represent EV and IMV, respectively. Ratios = sum of IMV 
counts/sum of EV counts.
* Counts too low to determine peaks and therefore calculate ratio at 6 hours p.i.
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by vlSA26L.EL. As the infection progressed, IMV production increased relative to 
EV, increasing the ratio of IMV:EV at 18 hours p.i. in vl5A26L.EL relative to 
vl6A26L.rev (Figures 6.19E). At 30 hours p.i., IMV and EV were reduced in 
vl5A26L.EL compared to vl5A26L.rev, however, as IMV was the majority of 
progeny in vl5A26L.EL, the ratio of IMV:EV increased slightly compared to 
vl5A26L.rev (Figure 6.19G). This highlights the variability in the outcomes of these 
experiments.
6.2.4 Quantification of IMV Produced in VACV Cultures When A26L was 
Modified
Considering the complexity of the data obtained from CsCI gradients, the 
data from experiments described in sections 6.2.2 and 6.2.3 was used to 
determine whether deletion of A26L decreased the proportion of IMV, and if 
overexpression of A26L increased the proportion of IMV in cultures. The quantity of 
IMV as a percentage of total progeny virus produced in BSC40 cells at 24 hours 
p.i. and in RK13 cells at 30 hours p.i. was calculated for IHD-J, VI6A26L, 
vl5A26L.rev, vl6A26L.neo, COP and vl6A26L.EL cultures (Figure 6.20). There 
were no significant differences in the proportion of IMV produced in each culture in 
pairwise comparisons of all viruses using a repeated measures one-way ANOVA 
(overall p=0.48).
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Figure 6.20 Proportion of IMV Produced in Cultures When A26L was Deleted or 
Overexpressed
IHD-J (■), vl5A26L (■),vl5A26L.rev (■),vl5A26L.neo (■), COP (■) and vl6A26L.EL (■) were cultured 
in BSC40 cells for 24 hours (A) or RK13 cells for 30 hours (B and C). Data is accumulated from 
CsCI gradients presented previously in this chapter where the proportion of IMV (%) = sum of 
counts (CPM) for the IMV peak /total counts (sum of counts (CPM) for IMV and EV peaks) from 
each trace x 100.
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6.2.5 Transmission Electron Microscopy (TEM)
To investigate whether modulation of A26 resulted in a gross defect in virion 
assembly or morphology that may explain the perturbation of virion maturation in 
recombinant cultures, viruses were cultured in RK13 cells at MOI 10 for 24 hours 
and then processed for TEM as described in section 2.5.8. In each of the samples 
examined, fully mature non-enveloped intracellular virions were observed that were 
brick-shaped, and contained a dumb-bell shaped core (Figure 6.21). Virions were 
also observed at the cell surface demonstrating egress of virions from the cells. 
Other structures characteristic of VACV morphogenesis such as crescents and 
spherical immature virions were also observed, suggesting normal morphogenesis 
in the recombinants generated in this study.
6.2.6 Expression Kinetics in VACV Cultures
To examine the kinetics of expression of A26L in the recombinant viruses, 
TaqMan® assays for the A26L, A27L and F13L genes were designed and 
optimised by Applied Biosystems (UK) (Table 6.1). Based on the WR genome 
sequence, the entire coding sequences of both the A27L and F13L genes were 
used for the assay design. A region of 345 bp (nucleotides 487 to 832) of the A26L 
gene was targeted on the basis that the target sequence was absent from COP, 
thus COP was used in these experiments as a negative control for A26L. The 
eukaryotic 18s rRNA gene was used as an endogenous control in all expression 
assays to normalise the quantity of template mRNA in each well (32;360). To 
validate the amplification efficiencies of the TaqMan® assays compared to the
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Figure 6.21 Transmission Electron Micrographs of Recombinant VACVs in RK13 cells
RK13 cells were infected at MOI 10 with IHD-J (A), or vl5A26L (B), vl6A26L.rev (C), vl6A26L.neo 
(D) or vl5A26L.EL (E) and incubated for 24 hours at 37 °C in a humidified 5 % (v/v) C 02 
atmosphere. Cells were fixed in 500 pi Karnovski fixative for a minimum of 18 hours at 4 °C and 
processed for TEM as described in section 2.5.8. Arrows indicate the virion membrane. Asterisks 
indicate dumb-bell shapdd cores. The arrow-head in B indicates a putative additional membrane 
resulting in a partially enveloped virion.
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Gene Forward primer 5’- to 3’- Reverse primer 5’- to 3’- Probe 5’- to 3’-
A26L AC G GAT C AC AG GTAT AT 
CACGACAT
GTACATAAATGCGTATA
GTAGTCTACCTATCTCT
TCGTAATGCC
GGTTTTC
A27L ACGCAACGAT GAAGTT C 
TATTTAGGT
C C AG AG AT AT CAT AG C 
CGCTCTTAG
CAGCGTGATT
TTCC
F13L CCTTTAATAGCGCAAAA
AATTCATGGTT
GCAGTGCTAACTGGCA
AACAA
CAAGCCGCAG 
AG CAT
Table 6.1 Primer and Probe Sequences in TaqMan® Assays
Oligonucleotides sequences were designed by Applied Biosystems (UK) to detect the A26L, A27L 
and F13L genes using the Applied Biosystems 7000 Real-Time PCR System.
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endogenous control, amplification of each target sequence was quantified over a 
range of dilutions of template mRNA as described in section 2.7 (Figure 6.22). For 
each gene, the delta cycle threshold (ACt) values were similar over a range of 10- 
fold dilutions of template mRNA, where the absolute value for the gradient of each 
data set was ~0.1, indicating similar amplification efficiencies for the target genes 
and the endogenous control. This value was slightly higher for the F13L assay and 
on consultation with Applied Biosystems (UK), it was considered that this should 
not affect future experiments.
6.2.6.1 Expression of A26L in vl5A26L.EL Cultures
Constitutive expression of A26L was predicted to increase IMV maturation 
earlier in the infectious cycle and therefore increase the proportion of IMV 
produced compared to IHD-J and vl5A26L.rev. This was not observed and 
therefore quantitative RT-PCR was used to examine whether the A26L gene was 
expressed earlier than in vl5A26L.rev cultures.
Previous studies suggest that the synthetic early/late promoter used in this 
study results in at least 2-fold increase in expression compared to the natural 7.5K 
promoter up to 9 hours p.i. (327). This would suggest that during the early phase of 
the infectious cycle, A26L transcripts should be more abundant in vl6A26L.EL than 
in vl5A26L.rev, as indicated by an increased fold change in expression.
RK13 cells were infected at MOI 10 with vl6A26L.EL or vl6A26L.rev and 
cultured for 1, 2, 3, 6, 12, 15, 18, 24 and 30 hours. Cultures were harvested at 0 
hours also to determine a baseline for gene expression. RNA was extracted from
227
121
10 -
Ar
8 -
B
*■»
S3 6 -
4 -
2 - 
0 - 1
-3 -2 -1 
Log10 Cone RNA (ng)
y = -0.0265X + 10.275
* y ■ -0.2067X + 8.5667 
y = -0.0703X + 8.227
Figure 6.22 Amplification Efficiencies of TaqMan Assays
Serial dilutions (10-fold) of extracted mRNA from IHD-J infected cultures at 6 hours p.i. were made 
and expression of the A26L (♦), F13L (A ) and A27L (■) genes determined as relative quantities 
compared to 18s rRNA (ACt). Trendlines were added using the Microsoft Excel® function. Data is 
representative of triplicate wells.
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each culture and transcription of the A26L, A27L and F13L genes was quantified 
by real-time RT-PCR using the 18s rRNA gene as an endogenous control (section 
2.7), as a measure of gene expression (Figure 6.23). Detectable transcription of 
the A26L gene began at 1 hour p.i., where the quantity steadily increased until 12 
hours p.i. and this level of. transcription was maintained throughout the infectious 
cycle (Figure 6.23A). Similar fold changes demonstrated expression of the A26L 
gene did not occur earlier, or in greater quantities in VI5A26L.EL than vl5A26L.rev 
in the cultures tested. Similar patterns of expression were also observed for the 
A27L and F13L genes (Figures 6.23B and C). Using a two-way ANOVA with 
Bonferroni’s post-tests, there were no significant differences in the expression of 
the genes tested in these viruses (A26L p=0.90; A27L p=0.23; F13L p=0.67).
6.2.6.2 Expression Kinetics of the A26L, A27L and F13L Genes in 
Recombinant VACV Cultures Throughout Infection in RK13 cells
This study was performed to compare gene expression during the late 
phase of the infectious cycle in viruses where A26L is deleted or disrupted. It was 
anticipated that A26L would not be detected in VI6A26L, vl5A26L.neo and COP, 
and the levels of expression of the A27L and F13L genes would be unaffected. 
RK13 cells were infected at MOI 10 with IHD-J, vl5A26L.rev, vl5A26L, 
vl5A26L.neo or COP and cultured for 12, 15, 18, 24 and 30 hours. Cultures were 
harvested at 0 hours also to determine a baseline for gene expression, and gene 
transcription was quantified by real-time RT-PCR, as a measure of gene 
expression (Figure 6.24). Expression of the A26L gene was slightly reduced in
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Figure 6.23 Expression Kinetics in vl6A26L.EL Cultures Throughout the Infectious Cycle
RK13 cells were infected at MOI 10 with vl5A26L.rev (■) or vl6A26L.EL (•) and cultures harvested 
at 0, 1, 2, 3, 6, 12, 15, 18, 24 and 30 hours p.i. RNA was isolated from each culture and expression 
of the A26L (A), A27L (B) and F13L (C) genes determined using the AACt method (335). Data is 
presented as means and SEM of triplicate cultures.
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Figure 6.24 Expression Kinetics Throughout the Infectious Cycle in Recombinant VACV 
Cultures
RK13 cells were infected at MOI 10 with the IHD-J (■),vl5A26L.rev (■),vl6A26L ( A),vl5A26L.neo 
(A ) or COP (•) and cultures harvested at 0, 12, 15, 18, 24 and 30 hours p.i. RNA was isolated from 
each culture and expression of the A26L (A and B), A27L (C and D) and F13L (E and F) genes 
determined using the AACt method (335). Data is presented as means and SEM of triplicate 
cultures. A26 transcription was not detected in COP cultures and is therefore absent in A and B.
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compared to vl5A26L.rev although this was not statistically significant (p=0.10), 
and expression was not detected in COP cultures. Unexpectedly, levels of 
expression were significantly increased in VISA26L cultures compared to both IHD- 
J and vl5A26L.rev (p=0.02) (Figure 6.24A). Expression of the A27L and F13L 
genes increased over time also, peaking at 24 hours p.i., however, the levels of 
expression appeared to vary between viruses (Figure 6.24C-G). Expression of both 
the A27L and F13L genes were significantly reduced in vl6A26L.neo compared to 
vl5A26L.rev (p=0.0075 and p=0.032), and increased in vl5A26L compared to 
VACV IHD-J (p=0.004 and p=0.043).
On deeper examination of the raw data, this apparent increase in 
expression of A26L in vl6A26L cultures appears to be an artefact of decreased 
detection of A26L transcription at t=0, which leads to an increased fold change at 
all subsequent time points in comparison. The decrease in expression in 
vl5A26L.neo also appears to be an artefact of increased detection at t=0, which 
leads to a decrease fold change in comparison. Therefore in an attempt to 
“normalise” the data, AACt values were adjusted using IHD-J t=0 and vl5A26L.rev 
t=0 as baselines for vl5A26L and for vl5A26L.neo, respectively, and the fold 
change re-calculated (Figure 6.25). This demonstrated similar expression kinetics 
for all genes tested, suggesting that A26L was detected in VI5A26L and 
vl5A26L.neo cultures yet levels of expression were no longer statistically different 
to that of IHD-J and vl5A26L.rev (p>0.05). This also confirmed that expression of 
A27L had not been disrupted by mutation of the neighbouring locus.
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Figure 6.25 Expression Kinetics Throughout the Infectious Cycle in Recombinant VACV 
Cultures
RK13 cells were infected at MOI 10 with the IHD-J (■),vl5A26L.rev (b),vI6A26L ( A),vl5A26L.neo 
(A ) or COP (•) and cultures harvested at 0, 12, 15, 18, 24 and 30 hours p.i. RNA was isolated from 
each culture and expression of the A26L (A and B), A27L (C and D) and F13L (E and F) genes 
determined using the AACt method (335). Data is presented as means and SEM of triplicate 
cultures. A26 transcription was not detected in COP cultures and is therefore absent in A and B. 
Note: the AACt value for vl5A26L and vl5A26L.neo have been calculated using IHD-J or 
vl5A26L.rev baseline at t=0, respectively, for all genes.
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6.3 Discussion
This study was intended to build on previously reported data in Chapter 3, 
and to address more recent reports to elucidate the role of A26 in virion 
morphogenesis (1-4;6;27). One-step growth curves demonstrated a reduction in 
virus yields in both VI5A26L and vl5A26L.neo, and yet their growth rates remain 
unchanged, when compared to IHD-J and vl5A26L.rev, respectively. This supports 
the data presented in Chapter 3 for VI6A26L in RK13 cells, suggesting that a 
reduction in yields was due to deletion of the A26L gene as opposed to the 
presence of a selection marker gene. The yields in VI5A26L.EL and vl5A26L.rev 
were equivalent to IHD-J, demonstrating restoration of the wild-type phenotype in 
vl6A26L.rev, and confirming the null effect of expression of A26L from a synthetic 
early/late promoter and the presence of selection marker genes. The data also 
demonstrates similar growth rates for all viruses used in this study, where a 
difference would have been problematic for the planned kinetic studies. 
Interestingly, COP was able to replicate as well as the IHD-J strain and reached 
similar yields. Although COP possesses a truncated A26L gene, it has never been 
shown whether a truncated protein is assembled into the virion (Dr D. Pickup, 
personal communication). If the truncate is not incorporated into the virion, this 
strain may be expected to behave as an A26L deletion mutant and therefore have 
reduced viral yields. As growth of COP was unaffected, it would appear that the 
truncated A26L gene in COP is not equivalent to an A26L deletion.
Separation of IMV and EV through CsCI gradients was used to examine the 
kinetics of IMV and EV production in recombinant cultures, and to monitor the
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changes in ratio of IMV:EV throughout the infectious cycle. Using 3H thymidine to 
metabolically label viral DNA allows quantitation of virions regardless of the 
particle/pfu ratio, which may differ between IMV and EV (11), and mitigates the 
effect, if any, on particle aggregation elicited by altering the surface of the virion by 
deletion of A26. This data was intended to provide further insight into the function 
of A26, where deletion resulted in a dramatic reduction in IMV as reported in 
Chapter 3.
Examination of vl6A26L and vl5A26L.neo cultures demonstrated a general 
reduction in IMV, resulting in a decreased ratio of IMV:EV throughout the infectious 
cycle when compared to the IHD-J and vl5A26L.rev strains. However, the extent of 
this reduction varied between the replicates and was not statistically significant; 
and the reduction was minimal compared to a dramatic reduction in IMV reported 
in Chapter 3. The reason for this discrepancy is unknown, however the cell type 
used, metabolic state or the passage history of the cells may contribute to the 
variability in IMV and EV production observed throughout this study.
If A26 is a differentiation switch and is required for maturation as IMV, then 
vlSA26L and vl5A26L.neo virions that sediment with the same density as IMV are 
not true IMV, that is they have not differentiated as EV or IMV, and could be 
interpreted as a tissue culture artefact resulting from depletion of intracellular 
membranes that are required for EV wrapping (350). Therefore, it may be 
hypothesised that vl6A26L and vl5A26L.neo virions that do not either 1) become 
wrapped or 2) acquire IMV specific proteins such as A26, are less stable. Such an 
instability could account for the reduction of IMV, and the reduction in viral yields
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observed in one-step growth curves. It is difficult to explain the difference between 
the data reported in Chapter 3 and the data reported here. However, it is possible 
that minor variation in experimental conditions between Chapter 3 and the 
experiments described here may have influenced the stability of putative 
undifferentiated virions.
Interestingly, it is notable that in the experiments presented in this chapter, 
CsCI gradient analysis demonstrated reduced yields of both IMV and EV when 
A26L was deleted, suggesting a possible contraindication of deletion of A26L. This 
reduction in progeny was not the result of slower growth as it was evident in one- 
step growth curves that the growth rates for both A26L deletion mutants were 
similar to the wild-type and revertant viruses.
The quantities of EV produced by the deletion mutants were similar to the 
IHD-J and vl5A26L.rev strains by 24 and 30 hours p.i., suggesting that if deletion of 
A26L prevents maturation of particles as IMV, this does not result in a concomitant 
increase in EV. This suggests that if IMV production is controlled independently of 
EV production, so too EV production is limited by a mechanism independent of IMV 
production, possibly by the availability of intracellular membranes for wrapping 
(350).
The deletion of A26 in the WR strain has been reported by others and the 
effect of deletion on IMV and EEV production investigated (134;351). The results of 
these studies demonstrate no difference in IMV or EEV production in BSC40, 
RK13 and HeLa cells, although experiments performed in RK13 and HeLa cells 
used a low MOI of 0.1. The production of virus from an asynchronous infection will
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undoubtedly result in different kinetics of IMV and EEV synthesis, and is unlikely to 
be the best approach to study this compared to a synchronous infection where one 
cycle of replication would be observed. These studies also quantified EV in culture 
supernates and IMV from cell lysates by plaque titration as opposed to CsCI 
gradient purification of virus used in the current study to separate EV and IMV. The 
plaque titration method would quantify plaque forming units where the number of 
virions per plaque forming unit is different for IMV and EV (121) and could plausibly 
vary if the surface properties are altered by a mutation such as deletion of an IMV- 
specific protein. Quantification of virions by metabolic labelling of viral genomes 
has mitigated this in the current study. In addition, quantitation of crude culture 
extracts can result in false representation of the quantities of virus present as IMV 
may be found in infected cell culture supernates, and IEV and CEV may be present 
in the cellular fractions, although this can be mitigated by using IMV- and EV- 
neutralising antibodies in plaque titrations.
The increased quantities of IMV and reduced quantities of EV observed in 
COP cultures resulted in an increased ratio of IMV:EV compared to the IHD-J 
strain. The production of IMV in COP cultures was predicted to be reduced in these 
cultures as only a truncated version of A26 is synthesised. According to published 
reports, the final 73 residues of the A26L gene, which are absent in COP, are 
essential for attachment to the virion via an interaction with A27 (134;342;351). In 
light of this, the truncated A26 should not be able to bind to virions and therefore 
IMV would be expected to be reduced if A26 is a maturation marker for IMV. The 
inability of this strain to occlude IMVs within ATI bodies upon co-infection with
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CPXV Brighton Red (an ATI+ strain) further confirms that A26 is not present on the 
surface of COP IMV particles (188). The high levels of putative IMV produced by 
COP are at odds with our hypothesis, however it is possible that the apparent IMV 
produced by COP is in fact nascent, non-differentiated single-membraned virus, 
and that its abundance is due to an undescribed deficit in wrapping to make EV, or 
due to the exhaustion of intracellular membranes available for wrapping.
Quantitative RT-PCR suggested that A26L was transcribed in both the A26L 
deletion mutants. Following normalisation, levels of A26L expression were 
comparable to IHD-J and vl5A26L.rev. No transcripts were detected in VACV COP 
cultures across all time points, and so it was surprising that transcripts were 
detected in the A26L deletion mutants. This may suggest the presence of low 
quantities of wild-type virus in these cultures. It has been demonstrated in Chapter 
4 that wild-type virus can be present in recombinant virus preparations that have 
undergone multiple rounds of plaque purification. Contaminating wild-type virus 
was below the limits of detection for the A26L gene by PCR and for A26 by 
immunoblotting, however it could be amplified using reverse GPT selection when 
cultured in STO cells in the presence of 6-TG. Although the presence of the IHD-J 
parent is plausible and may account for detectable A26L transcripts, it is unlikely 
that enough A26 would be synthesised to complement the mutations in VI6A26L 
and vl5A26L.neo and indeed the absence of A26 on virions was confirmed in 
purified virus preparations of both vl5A26L and vl5A26L.neo. Additionally, it is 
likely that in vl5A26L.neo, the disrupted copy of A26L is transcribed as a result of 
read-through of the G418R gene expressed from its synthetic early/late promoter,
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as no transcriptional termination sequences were engineered to prevent this 
occurring during the early phase, and read-through transcription is a well described 
feature of late stage transcription in poxviruses. The mRNAs generated would be 
detected by RT-PCR, however due to the frameshift mutation and engineered stop 
codons throughout the sequence, these transcripts would not be translated. Levels 
of expression of the A27L and F13L genes in both A26L deletion mutants were 
also similar to their wild-type counterparts, and expression increased throughout 
the infectious cycle as expected. The data indicates that deletion of the A26L gene 
did not affect expression of the neighbouring A27L gene or the F13L gene.
To further confirm the role of A26 in IMV maturation, the ability of vlSA26L 
and vl5A26L.neo to recover EEV following inhibition of wrapping was assessed. In 
Chapter 3, vl6A26L was demonstrated to have increased ability to recover EEV 
when wrapping was inhibited beyond 10 hours p.i. (coinciding with detectable A26 
synthesis as reported by Ulaeto et al. (116)) using BFA, compared to the IHD-J 
strain. This suggests that in the absence of A26, virions were able to continue to 
become enveloped, even at very late times p.i., as the switch from EV to IMV 
maturation cannot occur. To build on this data, BFA and ST-246 were used to 
inhibit envelopment until late times p.i. when A26 production should be maximal, 
and the switch from EV to IMV predominance has occurred. No differences were 
observed in VI6A26L and vl5A26L.neo cultures when compared to the IHD-J and 
vl5A26L.rev strains, and recovery of EEV was minimal compared to previous 
findings in Chapter 3 (data not shown). This assay did not perform as in Chapter 3 
as very little recovery of EEV was achieved in BFA- and ST-246-treated cultures.
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One possible explanation for this is that the drugs were ineffectively washed out of 
cultures. Although the original data suggested that A26 was able to negatively 
regulate maturation of EEV thus acting as a differentiation switch, and that deletion 
of A26L resulted in increased secretion of EEV when cultures were treated with 
BFA, conclusions cannot be drawn from these experiments because of the lack of 
reproducibility reported here.
Increasing expression of A26L and generating increased quantities of A26 to 
direct maturation of particles to become IMV was intended when constructing 
vl5A26L.EL. Using CsCI gradients to examine the kinetics of IMV and EV 
production demonstrated an overall reduction in EV production, thus increasing the 
ratio of IMV:EV by 24 to 30 hours p.i. However, there was no increase in IMV 
formation in the early stages of the infectious cycle compared to vl5A26L.rev. 
Maximal expression from the early/late promoter used in this study may not be 
optimal to alter the fine kinetics of EV and IMV maturation, and it is possible that 
the early portion of the promoter was not sufficient to increase the quantities of A26 
available in the early stages. It is reported that A26 is attached to the virion via 
disulfide linkage with A27 (342), and in the absence of this association, A26 is 
degraded (351), therefore increased quantities of A26 prior to A27 production 
would not increase maturation as IMV. The late portion of the early/late promoter 
may not achieve maximal expression at a point that can markedly influence 
IMV.EV ratios. For example, if maximal A26L expression is only achieved 
subsequent to maximal expression of F13L (and other EV-associated genes), then 
EV production may peak or plateau before A26L expression reaches a level where
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A26 can effectively compete for attachment to virions. It is also possible in a 
competitive scenario that increased production of A26 might have to achieve a 
critical concentration before an increase in IMV maturation would be observed. 
This may also depend on the relative association constants of A26 with A27, and 
virions with wrapping membranes, and the ability of the late portion of the synthetic 
early/late promoter to tilt the competition in favour of A26-A27. This would be 
expected to result in the phenotype observed in this study.
The ability of A26 to act as a differentiation switch would depend on its 
attachment to the virion and it has been reported that A26 forms its association 
with A27 in solution before A27 itself associates with the virion (342;351). Thus a 
putative competition between IMV and EV maturation may be expected to manifest 
as a competition between non-differentiated virions and A26, for association with 
A27. This in turn may be expected to require that A27 and A27-A26 mutually 
exclude each other from non-differentiated virions upon forming the initial virion 
association. This is a complex scenario which merits substantial future 
investigation.
To further characterise the recombinant viruses the levels of transcription of 
A26L and A27L were examined in VI6A26L.EL and vl6A26L.rev cultures 
throughout the infectious cycle. It was predicted that A26L transcripts would be 
detected in the early stages (0-4 hours p.i.) of the replicative cycle compared to 
expression between 6 and 12 hours p.i. in vl6A26L.rev, and that A27L expression 
would occur from approximately 4 hours p.i. in both viruses (32). Interestingly, 
A26L transcription was detected from 1 hour p.i., in both vl6A26L.EL and
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vl6A26L.rev, much earlier than predicted. Expression of A27L was comparable in 
both viruses, indicating that in both viruses, levels of A27 would be sufficient for 
stability of A26. Expression of F13L was also unaffected in vl5A26L.EL suggesting 
that the reduction in EV was not due to a reduction in EV-specific proteins. This 
could suggest that the early portion of the promoter is ineffective and has failed to 
increase early expression over that seen in vl5A26L.rev, although this promoter is 
reported to have greater activity than other natural early VACV promoters such as 
P7.5K (327). However, vl6A26L.rev with which vl5A26L.EL is compared lacks an 
early termination sequence after the G418R gene, and transcriptional read-through 
of the A26L gene may give an apparent level of expression that is comparable to 
that in VI6A26L.EL, although it is unlikely that this is greater than in wild-type as 
vl5A26L.rev demonstrates the wild-type phenotype with respect to the kinetics 
experiments with CsCI gradients, and vl5A26L.EL does not. To further investigate 
the effects of overexpression of A26L throughout the replicative cycle, increased 
expression could be examined by engineering other natural VACV promoters or 
inducible promoters into the VACV genome, by expressing A26L in trans using 
transfected cell lines, or by inserting multiple copies of A26 in the genome.
The altered kinetics of IMV and EV maturation reported in this study for the 
IHD-J strain requires further investigation. It is apparent that variation in 
experimental conditions can affect the relative quantities of IMV and EV, where on 
occasion EV production was dominant even at late times p.i. Various studies have 
reported the majority of virions are found in the intracellular fraction at the final 
stages of the infectious cycle in the IHD-J, WR and MVA strains using plaque
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titration methods (361;362). Studies by Ulaeto et al. (116) have dissected this 
relationship further by separating virions through CsCI gradients, demonstrating EV 
is produced first in the replicative cycle, together with detectable F13, followed by a 
surge in IMV formation accompanied by the production of A26 in the IHD-J strain in 
RK13 cells. Contrary to this, examination of the different forms of particles 
associated with the cell by EM demonstrates the majority of virions are IEV and 
CEV, and IMV is the minority in the IHD-J strain in CEF Cells (362) and CsCI 
gradient density analysis of the WR strain demonstrates the majority of virions are 
wrapped particles in RK13 cells (361). In addition, Spehner et al. (2000) 
demonstrated the majority of virions mature as EEV by the MVA strain when 
cultured from low MOI in CEF cells, compared to COP strain that produced very 
little EEV, by separation through CsCI gradients (363). It would appear that there 
maybe differences in maturation of VACV when grown from different MOI or in 
different cell types, and the results may be dependent on the method by which 
virions are quantified. Using CsCI gradients to separate EV and IMV would appear 
to be the advantageous method to separate and quantify the different forms 
compared to plaque titration and EM methodology. Plaque titration of the culture 
medium and cellular fractions is a crude method particularly when IMV-neutralising 
antibodies are not used: IMV maybe released into the culture medium as a result of 
cell lysis at late times p.i., and plaque titration will only quantify plaque forming 
units as opposed to virus particles. EM methods can be subjective, as results may 
depend on the number of sections viewed and secreted virions will be lost. CsCI 
gradient analysis also has its limitations as i) CEV and EEV cannot be
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distinguished in culture extracts unless the culture medium and cellular fractions 
are analysed separately; and ii) the fragility of the EV membrane may affect the 
number of particles that sediment as EV (339).
It is plausible that the different maturation kinetics of IMV and EV are due to 
different kinetics of A26 and F13 production of the strains used in these studies. 
RT-PCR for the IHD-J strain demonstrated F13L expression was maximal at 12 
hours p.i. whereas A26L expression was still increasing from 12 hours p.i. and was 
not maximal until later in the infectious cycle, correlating with previous reports by 
Ulaeto et al. (1996). Transcription of these genes in vl5A26L.rev was observed 
from as early as 1 hour p.i., although the maximal fold change in F13L expression 
occurred earlier than the maximal fold change for A26L. For F13L, an exponential 
increase in transcription occurred between 1 and 6 hours p.i., whereas for A26L 
the exponential increase in transcription took place between 1 and 12 hours, with a 
much shallower curve.
The function of A26 has yet to be fully elucidated, however this data has 
provided further insight into the role of A26 in virion morphogenesis and has shown 
the variability of the kinetics of IMV and EV production by wild-type virus using 
CsCI gradients. This study has demonstrated that deletion of A26L in the IHD-J 
strain negatively affects virus growth. Although the deletion of A26L appears to 
negatively perturb levels of single-membraned virus, the effect is variable and may 
be influenced by host cell type, passage history, and possibly metabolic state. It 
may be suggested that in the absence of A26, single-membraned virus is not IMV 
and is not a mature, end-stage virion. Rather it is a nascent virion awaiting
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envelopment as EV. The differences observed would thus be due to variability in 
conditions that affect efficiency of wrapping. This bears further examination in the 
future, including studies to investigate more effective expression of A26L by VACV 
promoters to better define the role of the A26 protein.
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7 Effect of Antimicrobial Peptides on VACV
7.1 Introduction
The main focus of this thesis is to examine the hypothesis that IMV that 
does not undergo envelopment is a true end-stage product of OPV 
morphogenesis. It is likely that wrapping of virions to form EV is limited by the 
availability of required intracellular membranes in vitro and possibly in vivo, 
however, this does not preclude the possibility that some single-membraned virions 
mature in such a way that they cannot be wrapped, even if suitable intracellular 
membranes are available. The function(s) of IMV and its biological significance 
during infection and transmission have not fully been determined. As the more 
robust particle, IMV is likely to be involved in host-to-host transmission, and this 
would appear even more likely in OPVs such as cowpoxvirus and raccoonpox virus 
(185;222), that occlude IMVs within A-type inclusions (ATIs), which may protect 
virus particles in the environment. EV however, is known to promote virus spread 
both in vitro and in vivo, and aid virus evasion of antibody and complement 
(reviewed in (189)).
Antimicrobial peptides (AMPs) such as cathelicidins and defensins are 
essential components of the innate immune system and have wide-spectrum 
activity against bacteria, fungi and enveloped viruses, and even cancerous cells 
(reviewed in ((364)). In addition, AMPs have also been shown to have 
immunomodulatory functions resulting in activation of the adaptive immune 
response (reviewed in (365)). They are produced by a range of organisms across 
the animal kingdoms including mammals, insects, plants and amphibians.
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AMPs have been classed according to their structure and amino acid 
composition. They are generally between 12-50 amino acids in length containing 2 
or more positively charged amino acids, usually arginine, lysine or histidine, and a 
large proportion of hydrophobic residues (366). AMPs are mostly unstructured 
when free in solution, however, they form secondary structures such as a-helical, 
linear or disulfide-bonded to give regions of polar and non-polar domains that are 
required for their activity (reviewed in (364);(366)).
Unlike antibiotics which usually interact with specific target molecules in a 
bacterial cell, AMPs usually interact specifically with the cell membrane although 
the mechanisms of action of these peptides are not fully understood. The 
selectivity of AMPs between prokaryotic and eukaryotic membranes is probably 
due to variations in the composition of the cell membrane. In the case of eukaryotic 
cells, the membrane is predominantly neutral in charge and contains cholesterol, 
which may act to stabilise the membrane. In contrast, bacterial membranes are 
negatively charged and lack cholesterol. The selectivity of AMPs is due to the 
cationic nature of AMPs at physiological pH, resulting in an electrostatic attraction 
with anionic bacterial membranes; AMPs are less likely to associate with 
zwitterionic mammalian membranes. Once associated with a membrane, their 
hydrophobic domain and amphipathic structure allows AMPs to disrupt the 
biological membrane. Two major models of action have been proposed: i) barrel- 
stave, and ii) the carpet model. In the barrel-stave model, peptides insert into the 
membrane in an orientation perpendicular to the plane of the lipid bilayer to form 
“staves” in a barrel-shaped cluster, where the hydrophilic regions of the peptides
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face inwards and the hydrophobic regions interact with the bilayer, forming a pore 
and thus depolarising the membrane. The carpet model suggests peptides 
aggregate parallel to the surface of the lipid bilayer, coating the membrane with 
peptide molecules. The activity of peptides in this model is concentration- 
dependent leading to disruption and disintegration of the membrane when a 
threshold concentration is reached (reviewed in (364)).
The varying activity of AMPs against prokaryotic and eukaryotic membranes 
suggests potential therapeutic applications of AMPs against bacterial pathogens, 
yet some AMPs have activity against enveloped viruses such as HIV-1, HSV types 
1 and 2, cytomegalovirus, vesicular stomatitis virus and influenza virus that utilise 
host-derived membranes (reviewed in (364;367)). It may be therefore assumed 
that the mechanism of action of AMPs against viruses differs to that observed in 
bacteria, due to the difference in properties of the mammalian-derived envelope 
and bacterial outer membranes.
LL-37 of the cathelicidin family of AMPs has recently been shown to have 
activity against VACV (368), and is thought to cause disruption of the viral 
membrane as treatment of cell-associated virus demonstrated a loss of integrity of 
the viral membranes and of the internal structure (368). More recent studies in our 
laboratory have demonstrated a differential effect on the enveloped and non­
enveloped forms of VACV. LL-37 was specifically active against EEV and its 
activity was enhanced by the addition of the non-ionic detergent Tween-20 (Dean 
et al., in preparation). In contrast, the Xenopws-derived AMP magainin-ll had no 
virucidal activity against either form of VACV, although it acquired significant
248
virucidal activity against EV in the presence of Tween-20 (Dean et al., in 
preparation). Interestingly, infectivity of EV could be further decreased using IMV- 
neutralising antibodies following AMP treatment, suggesting that the envelope had 
been disrupted to expose antigens on the inner membrane. Treatment of EEV with 
Tween-20 alone resulted in increased infectivity over a 60 minute incubation 
period, but when the incubation period was increased to 90 minutes, a significant 
decrease in infectivity was observed (Dean etal., in preparation).
7.1.1 Aims of This Study
The effect of the AMPs LL-37 and magainin-ll, and Tween-20 on viral 
membranes was investigated in this chapter using CsCI density gradient analysis 
to allow separation of virions according to their difference in buoyant densities. 
Removal of the outer membrane of EV would result in an increase in density of 
treated virions. This chapter will determine if AMPs unwrap EV, and if unwrapped 
EV is equivalent to IMV. This may also provide evidence for a mechanism for the 
activity of AMPs against VACV consistent with existing models of action.
7.2 Results
7.2.2 Effect of AMPs on EEV Membrane
The activity of AMPs on VACV has previously been reported, and more 
recently the activities of LL-37 and magainin-ll have been reported to be almost 
exclusively against enveloped particles (Dean et al., in preparation). To understand 
this activity further, the effects on the EEV membrane, if any, of these two AMPs
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were investigated using CsCI density gradients. Disruption of the viral envelope 
would result in a change in buoyant density of the virus particle and cause a shift in 
the density at which the virus particles sediment within the CsCI gradient.
Tritium-labelled EEV-enriched virus preparations were treated with 100 
pg/ml LL-37 or magainin-ll, or PBS in triplicate for 90 minutes at 37 °C (section 
2.5.7). Two out of three of the treated cultures were separated through CsCI 
density gradients (section 2.5.2 and 2.5.4) and the density was determined by 
weighing 100 pi of each fraction (Figures 7.1 and 7.2). When EEV preparations 
were treated with magainin-ll, two distinct similarly-sized peaks were seen, one 
with a density expected for EEV and one with a density expected for IMV. 
Treatment with LL-37 caused a shift in density of the majority of virus particles, to a 
higher density similar to that expected of IMV. Interestingly, there was no evidence 
of particles sedimenting with an intermediate density between the two peaks. The 
remaining cultures were titrated on RK13 cells (section 2.5.3) in the presence of 
neutralising-IMV antibodies, as a control to confirm the activity of each of the 
peptides on the infectivity of EEV (Figure 7.3).
7.2.3 Effect of Detergent on the EEV Membrane
The activity of magainin-ll on the EEV membrane has previously been 
shown to be enhanced in the presence of the non-ionic detergent Tween-20 (Dean 
et al., in preparation), suggesting a synergy between the two compounds. To 
dissect the effect of Tween-20 alone on the EEV membrane further, EEV-enriched
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Figure 7.1 Effect of AMPs on the EEV Membrane (I)
Freshly harvested EEV from VACV IHD-J cultures supplemented with 3H thymidine were treated in 
duplicate with PBS (A and B), magainin-ll (C and D) or LL-37 (E and F) for 90 minutes at 37 °C. 
Virions were separated by ultracentrifugation through CsCI gradients. The density (♦) of each 
fraction was determined using a fine balance and fractions were subjected to scintillation counting 
to determine the CPM (■) per fraction. The average densities of each peak were calculated for each 
trace and are indicated by asterisks.
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Figure 7.2 Effect of AMPs on the EEV Membrane (II)
Freshly harvested EEV from VACV IHD-J cultures supplemented with 3H thymidine were treated in 
duplicate with PBS (A and B), magainin-ll (C and D) or LL-37 (E and F) for 90 minutes at 37 °C. 
Virions were separated by ultracentrifugation through CsCI gradients. The density (♦) of each 
fraction was determined using a fine balance and fractions were subjected to scintillation counting 
to determine the CPM (■) per fraction. Fractions were normalised to 100. The average densities of 
each peak were calculated for each trace and are indicated by asterisks.
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Figure 7.3 Effect of AMPs on EEV-enriched Cultures
Freshly harvested EEV from VACV IHD-J cultures supplemented with 3H thymidine were treated 
with PBS (■), magainin-ll (■) or LL-37 (■), in triplicate, for 90 minutes at 37 °C. The quantity of 
recovered virus in one replicate was determined by Reed-Muench limiting dilution analysis in the 
presence of IMV-neutralising antibody. A and B are each representative of two experiments. Virions 
in the remaining replicates were separated by ultracentrifugation through CsCI gradients where A 
corresponds with Figure 7.1 and B corresponds with Figure 7.2.
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cultures were treated with Tween-20 (0.5 % v/v) for 90 minutes or 180 minutes, or 
with PBS for 180 minutes in triplicate at 37 °C (section 2.5.7). Two out of three of 
the treated cultures were separated through CsCI density gradients (section 2.5.2 
and 2.5.4) and the density was determined by weighing 100 pi of each fraction 
(Figures 7.4 and 7.5). Tween-20 treatment resulted in a shift in the density of virus 
particles, although the peaks were not well defined. Treatment for 90 minutes 
appeared to show three rather than two peaks and the peaks were not well 
separated, suggesting that intermediate density particles were present. The 
putative third peak was of higher density than expected for IMV, and may represent 
particles where both the inner and outer membranes had been wholly or partially 
removed. Treatment with Tween-20 for 180 minutes removed most of the lowest 
density peak observed after 90 minute treatment, and again the remaining peaks 
were not well separated. The remaining cultures were titrated on RK13 cells 
(section 2.5.3) in the absence or presence of neutralising-IMV antibodies, as a 
control to confirm the activity of Tween-20 treatment on the infectivity of EEV 
(Figure 7.6). Treatment of cultures with Tween-20 resulted in a reduction in virus 
titre as expected, and this was further reduced in the presence of IMV-neutralising 
antibodies. A slight reduction in titre was also observed in the PBS treated cultures 
when quantified in the presence of IMV-neutralising antibodies and this was likely 
due to a small amount of IMV, as observed in these preparations following CsCI 
density gradient analysis (Figure 7.6B).
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Figure 7.4 Effect of Tween-20 on the EEV Membrane (I)
Freshly harvested EEV from VACV IHD-J cultures supplemented with 3H thymidine were treated 
with PBS (A and B) or Tween-20 for 90 minutes (C and D) or 180 minutes (E and F) at 37 °C. 
Virions were separated by ultracentrifugation through CsCI gradients. The density (♦) of each 
fraction was determined using a fine balance and fractions were subjected to scintillation counting 
to determine the CPM (■) per fraction. Fractions were normalised to 100. The average density of 
each peak was calculated for each trace and is indicated by asterisks.
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Figure 7.5 Effect of Tween-20 on the EEV Membrane (II)
Freshly harvested EEV from VACV IHD-J cultures supplemented with 3H thymidine were treated 
with PBS (A and B) or Tween-20 for 90 minutes (C and D) or 180 minutes (E and F) at 37 °C. 
Virions were separated by ultracentrifugation through CsCI gradients. The density (♦) of each 
fraction was determined using a fine balance and fractions were subjected to scintillation counting 
to determine the CPM (■) per fraction. Fractions were normalised to 100. The average density of 
each peak was calculated for each trace and is indicated by asterisks.
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Figure 7.6 Effect of Tween-20 on EEV-enriched Cultures
Freshly harvested EEV from VACV IHD-J cultures supplemented with 3H thymidine were treated 
with PBS (■), Tween-20 for 90 minutes (■) or 180 minutes (■), in triplicate, at 37 °C. The quantity of 
virus in one replicate was determined by Reed-Muench limiting dilution analysis in the absence 
(solid bars) or presence (hatched bars) of IMV-neutralising antibodies. A and B are representative 
of two experiments. Virions in the remaining replicates were separated by ultracentrifugation 
through CsCI gradients where A corresponds with Figure 7.4 and B corresponds with Figure 7.5.
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7.2.4 Effect of Detergent on the IMV Membrane
LL-37 and magainin-ll have been shown to have no effect on infectivity of 
IMV, although they acquired slight activity in the presence of Tween-20 (Dean et 
al., in preparation). To investigate the effect of Tween-20 on the IMV membrane 
further, IMV-enriched cultures were treated with Tween-20 for 90 minutes or 180 
minutes, or with PBS for 180 minutes at 37 °C, in triplicate (section 2.5.7). Two out 
of three of the treated cultures were separated through CsCI density gradients 
(section 2.5.2 and 2.5.4) and the density was determined by weighing 100 pi of 
each fraction (Figures 7.7 and 7.8). The majority of particles sedimented with a 
density expected of IMV following treatment with Tween-20. A lower density peak 
was observed in PBS treated cultures, with a density lower than that found for EEV 
in this study. This peak was likely to be IEV, and appeared to be susceptible to 
Tween-20 treatment resulting in a shift to sediment at a higher density. The 
remaining cultures were titrated on RK13 cells (section 2.5.3) as a control to 
determine the activity of Tween-20 treatment on the infectivity of IMV (Figure 7.9). 
A small reduction in virus titre was observed in cultures treated with Tween-20 and 
might be due to the inactivation of contaminating IEV in the cultures. It is possible, 
indeed likely, that single-membraned virus that has not acquired A26 and is 
destined for envelopment is present in the samples and would be susceptible to 
inactivation by 90 or 180 minute incubations with Tween-20.
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Figure 7.7 Effect of Tween-20 on the IMV Membrane (I)
Freshly harvested IMV from VACV IHD-J cultures supplemented with 3H thymidine were treated 
with PBS (A and B), Tween-20 for 90 minutes (C and D) or Tween-20 for 180 minutes (E and F) at 
37 °C. Virions were separated by ultracentrifugation through CsCI gradients. The density (♦) of each 
fraction was determined using a fine balance and fractions were subjected to scintillation counting 
to determine the CPM (■) per fraction. Fractions were normalised to 100. The average density of 
each peak was calculated for each trace and is indicated by asterisks. Note: f  represents “spikes” 
that are presumed to be due to a fault that occurred during scintillation counting.
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Figure 7.8 Effect of Tween-20 on the IMV Membrane (II)
Freshly harvested IMV from VACV IHD-J cultures supplemented with H thymidine were treated
with PBS (A and B), Tween-20 for 90 minutes (C and D) or Tween-20 for 180 minutes (E and F) at 
37 °C. Virions were separated by ultracentrifugation through CsCI gradients. The density (♦) of each 
fraction was determined using a fine balance and fractions were subjected to scintillation counting 
to determine the CPM (■) per fraction. Fractions were normalised to 100. The average density of 
each peak was calculated for each trace and is indicated by asterisks. Note: t  represents “spikes” 
that are presumed to be due to a fault that occurred during scintillation counting.
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Figure 7.9 Effect of Tween-20 on IMV-enriched Cultures
Freshly harvested IMV from VACV IHD-J cultures supplemented with 3H thymidine were treated
with PBS (■), Tween-20 for 90 minutes (■) or 180 minutes (■) in triplicate at 37 °C. The quantity of
virus in one replicate was determined by Reed-Muench limiting dilution analysis. A and B are
representative of two experiments. Virions in the remaining replicates were separated by
ultracentrifugation through CsCI gradients where A corresponds with Figure 7.7 and B corresponds
with Figure 7.8.
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7.2.5 Stability of VACV When A26 is Deleted
Removal of the outer membrane of EEV using AMPs or detergents appears 
to have varying effects on infectivity, and can render the virus particle susceptible 
to neutralisation with IMV-neutralising antibodies. A key difference in the surface 
properties of EEV that has been stripped of its outer membrane compared to IMV 
is the absence of IMV-specific proteins such as A26, which may contribute to the 
increased resistance of IMV to the effects of these compounds. Treatment of IMV- 
enriched cultures of wild-type VACV IHD-J, vl5A26L.rev, VI6A26L and vl5A26L.neo 
with Tween-20, Triton X-100, LL-37 or PBS for 180 minutes at 37 °C was 
investigated to determine the effect of alteration of the surface properties of IMV 
particles by deletion of A26 (Figure 7.10). Treatment with LL-37 had no discernible
effect on infectivity of wild-type or mutant IMV, however an increased reduction in
r
virus titre was observed after treatment with Tween-20 for IMV cultures of VI5A26L 
when compared to IHD-J (p<0.01) and for vl5A26L.neo when compared to 
vl6A26L.rev (p<0.05), using a repeated measures ANOVA with Bonferroni’s post­
tests. Treatment with Triton X-100 almost completely inactivated virions to less 
than 100 TCID5o/ml.
7.3 Discussion
During this study, the activity of both LL-37 and magainin-ll has been 
demonstrated to be restricted to the enveloped form of VACV, where the activity of 
LL-37 is greater. This differential activity may be due to the reported stability of the 
a-helical structure of LL-37 in solution which may increase its potency, whereas
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Figure 7.10 Effect of LL-37 and Detergents on Infectivity of IMV-enriched Cultures of 
Recombinant VACV
IMVs isolated from wild-type IHD-J (■), VI5A26L (■), vl5A26L.rev (■) and v vl5A26L.neo (■) cultures 
were treated for 180 minutes with LL-37 (A), or the detergents Tween-20 or Triton X-100 (B) then 
quantitated in RK13 cells as described in section 2.5.3. Data is presented as the mean and SEM of 
the percentage reduction in infectivity compared to PBS treated cultures. The experiment was 
performed with duplicate cultures on three separate occasions (n=6) and the combined data for 
each virus subjected to a two-way ANOVA (** p<0.001; * p<0.05).
t  due to low numbers of virus remaining in these cultures and the limits of detection of the virus 
titration method numbers of virus was deemed as <100 TCID50/ml.
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magainin-ll is unstructured in solution and has been shown to require the presence 
of lipids for this conformational change in structure (369); this usually provides the 
driving force for binding to and disruption of the membrane (370). This would also 
suggest that interaction of LL-37 with the membrane may have a different energetic 
basis as it does not undergo a structural change.
Howell et al. (2004) reported activity of LL-37 against VACV and suggested 
that the activity was directed against the IMV form on the basis that their virus was 
isolated from cell lysates following infection with the Wyeth strain (368). 
Propagation of the Wyeth strain would be expected to result in retention of EV on 
the cell surface, as opposed to its release as EEV. This is because the Wyeth 
strain of VACV, unlike the IHD-J strain, has an A34R gene that is similar to that of 
the WR strain which has been shown to mediate the over-production of CEV 
relative to EEV (180). In addition, their virus was prepared from 3-day bulk cultures 
infected at low multiplicity. With cells at different stages of the infectious cycle it is 
not possible to be certain that IMV or EV would be the predominant virus form at 
the time of harvest. It is thus not possible to determine whether the inactivation 
reported by Howell et al. (2004) is of EV or IMV. More recent data (Dean et al., in 
preparation) indicate clearly that the EV form is the target of AMP activity, and that 
the IMV form is resistant. The combination of the IHD-J strain and RK13 host cells 
in high multiplicity synchronous infections used in this study yield dependable 
quantities of EV in the form of EEV, therefore it is possible to enrich for either EEV 
or IMV in the culture supernate or cellular fraction, respectively.
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Using CsCI density gradient centrifugation to determine the effect of these 
AMPs on the viral envelope suggests that the membrane is stripped from the virus 
particle in one event, as treatment of samples resulted in distinct peaks, with no 
intermediate signal. If the membrane was partially lost in increments a broad peak 
would be expected where the density of virus particles comprised a continuous 
range from low-density EV peaks to high-density IMV-like peaks. These results are 
consistent with the carpet model where the membrane disintegrates when a 
threshold level of peptide molecules is reached on the membrane surface. In 
further support of this model, the activity of the non-ionic detergent Tween-20 also 
demonstrates disruption of the outer membrane when treated EEV particles were 
separated by CsCI density gradient centrifugation, although stripping of the 
membranes appears to be consistent with incremental removal of the inner and 
outer membranes as demonstrated by poorly defined peaks. Neutralisation of 
stripped virions by IMV-neutralising antibodies following AMP treatment or Tween- 
20 treatment also confirmed that the outer membrane had been disrupted to reveal 
neutralising epitopes below.
Treatment of EEV with Tween-20 resulted in a peak that had a greater 
density than that expected of IMV which suggests that the inner membrane has 
also been disrupted. This higher density peak was not evident in EEV preparations 
treated with LL-37 or magainin-ll suggesting that both peptides are only able to 
remove the outer membrane, yet it is unclear why this results in inactivation by LL- 
37 but not magainin-ll. One possible explanation is that LL-37 inactivates 
unwrapped EEV by disturbing the inner membrane but without removing it,
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possibly by perturbing or displacing surface proteins that are essential for 
infectivity, and that magainin-ll is unable to mediate this additional interaction 
unaided.
The resistance of IMV to LL-37 and magainin-ll may be in part due to the 
presence of IMV-specific surface proteins which may affect the ability of peptides 
to associate with the virion surface. Previous studies have demonstrated that their 
activity can be enhanced in the presence of Tween-20, although the possibility that 
this is due to inactivation of IEV present in the IMV-enriched cultures cannot be 
excluded (Dean et al., in preparation). In this study, CsCI density gradient analysis 
demonstrated no effect on the IMV membrane following treatment with Tween-20, 
although a minimal reduction in infectivity was observed. Resistance of the IMV 
membrane may be due to the presence of IMV-specific surface proteins, which are 
not found on EEV that has been stripped of its outer membrane.
To investigate this further, recombinant VACVs were used as a tool where 
the surface of IMV had been modified by deletion of the A26L ORF. A26 
represents 2.8 % of total protein of IMV (240) and has been shown to attach to the 
surface of the virion via disulphide linkage with A27 (351). Association of A25 (ATI) 
is mediated by A26 (351), representing a further 3.4 % of total protein of IMV (240). 
Therefore the surfaces of IMV and stripped EV are distinctly different. Infectivity 
following LL-37 treatment was unaffected in the mutants indicating that the 
resistance of IMV to LL-37 was not mediated by A26 or, by extrapolation, by A25. 
However, treatment with Tween-20 resulted in a significant reduction in infectivity 
of IMV from both A26 deletion mutants relative to wild-type and revertant viruses.
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This demonstrates an observable difference between IMV and unwrapped EEV 
that is attributable to the presence of the A26 protein on IMV, and is a strong 
indication that IMV (as defined by the presence of surface A26 and thus the ability 
to be incorporated into OPV A-type inclusions) is distinct from nascent single- 
membraned particles destined to be wrapped as EEV.
This study has demonstrated that AMPs are able to strip the outer 
membrane from EEV particles, but not the inner membrane and that this is 
sufficient for the human LL-37 AMP to inactivate EEV. This provides a rationale for 
the future investigation of AMPs as potential therapeutics for OPV infections, in 
particular for complications of vaccination such as eczema vaccinatum where 
topical application of therapeutics might significantly affect the course of disease. 
The presence of two distinct peaks in CsCI gradients representative of enveloped 
and stripped particles and the absence of intermediate density particles suggests 
the outer membrane is removed in a single event and is supportive of the carpet 
model of AMP activity.
Interestingly, AMPs alone appear to have no effect on IMV even when the 
IMV-specific A26 protein is absent, indicating the peptides are unable to associate 
effectively with the IMV membrane to cause membrane disruption or reduce 
infectivity. A26 mediates association of IMV with the only other known IMV-specific 
protein, the ATI protein A25. Thus by extrapolation, A25 is unlikely to be the 
mediator of differential susceptibility of IMV and unwrapped EEV to LL-37. Whilst it 
is possible that additional IMV-specific proteins are yet to be discovered, there are 
other possible mechanisms for this differential sensitivity, perhaps involving the
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association of proteins such as A27 with the EV membrane-associated protein 
F13. Plausibly, removal of F13 along with the outer membrane of EEV may disrupt 
the association of a protein such as A27, with the unwrapped particle. Such 
hypotheses would require further investigation. However, the data presented here 
provide further evidence that IMV is a true end-stage product of VACV 
morphogenesis, rather than an EV pre-cursor.
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8 Final Discussion
8.1 VACV as a Live Smallpox Vaccine
Although smallpox was eradicated nearly 30 years ago, there are concerns 
over the safety and efficacy of current vaccines and antiviral therapies that are 
available in the event of an accidental or deliberate release of VARV, or a fully 
emergent human MPXV outbreak. The increased understanding of poxvirus 
biology, in particular from studying the prototypical OPV VACV, paves the way to 
improving current smallpox vaccines and developing new strategies for antiviral 
therapies.
Most, if not all, OPVs produce two types of mature virion: EV and IMV. EV is 
produced first in conjunction with F13 production (116), accounting for up to 25 % 
of the total virus and is required for dissemination throughout the host 
(117;118;338). IMV is produced later in the infectious cycle when A26 production is 
maximal (116), and is the more robust particle. Although the exact role of IMV has 
not been fully defined, it is likely that the production of each particle type provides 
some advantages for virus replication. Due to the difference in antigenicity of the 
enveloped and non-enveloped forms, and the importance that each form of the 
virus plays in inducing protective immunity (300;302;303;305), a vaccine strain 
would ideally be required to produce both EV and IMV.
One approach taken elsewhere has been to abrogate EV production by the 
disruption of genes essential for EV maturation (117-119). This would reduce viral 
dissemination and hence reduce virulence to create a safer live vaccine (120). 
Unfortunately, although these EV knockout mutants had an attenuated phenotype,
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the production of large quantities of virus was inherently difficult due to the reduced 
ability to spread in tissue culture.
An alternative strategy would be to increase the quantities of virions that 
mature as IMV, which would result in reduced EV production as the quantities of 
virions available for envelopment would be reduced. Directing morphogenesis 
towards IMV production has the potential to avoid total abrogation of EV production 
and therefore both forms of the virus could be presented to the immune system. If 
successful, a significant but not total reduction in the quantities of EV produced 
might attenuate the virus in vivo but still allow an economically acceptable rate of 
virus propagation in tissue culture-based vaccine production. To achieve this, the 
mechanism by which maturation of virions switches from EV to IMV during the 
infectious cycle would need to be understood. This has led to the role of the IMV- 
specific protein, A26, in IMV morphogenesis being investigated in this study, and 
the impact of overproduction of A26 on the maturation of EV and IMV examined, as 
a potential strategy to generate a next generation live smallpox vaccine.
8.2 Role of A26 in IMV Maturation
Prior to this study, the role of A26 in VACV was largely undefined: previous 
studies had proposed that A26 was a component of surface tubules, although 
strains that did not have A26 also produced surface tubules (238;239). Another 
study demonstrated that A26 was an occlusion factor to aid trafficking of IMV into 
ATI bodies (188). Occlusion of IMVs does not occur in all poxviruses and yet 
interestingly the A26 ORF, or at least a portion of the ORF, is highly conserved in
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OPVs and orthologues are found in other poxviruses (371-374). A26 has also been 
identified as unique to IMV, where the synthesis of A26 is concurrent with 
maturation of IMV (116). From this, the hypothesis that A26 acts as a differentiation 
switch causing maturation to switch from EV to IMV was proposed. More recent 
studies have demonstrated the association of A26 with A27 (342;351), and this 
would support the hypothesis where A26 acts to negatively regulate wrapping, as 
binding of A26 to the virion via A27, could plausibly cause EV maturation to cease 
and IMV maturation to predominate.
In the study presented here, the A26L deletion mutant strain, VI6A26L, was 
produced. Initial experiments demonstrated a reduction in virus titres from one-step 
growth curves that could be attributed to a dramatic reduction in IMV production 
when examined by CsCI density gradient analysis compared with the IHD-J parent 
strain. Experiments with a second deletion mutant in the same gene, vl5A26L.neo, 
demonstrated a similar reduction in virus titres in one-step growth curves 
compared to a revertant strain, however, the same reduction in IMV was not 
observed by CsCI density gradient analysis. The reproducibility of the kinetic 
assays was brought into question in these studies which may have been affected 
by the host cell type, the passage history and the metabolic state of the cells. 
Deletion of A26 however, does appear to perturb the production of single- 
membraned virus, and it could be suggested that single-membraned virions that do 
not acquire A26 are not a mature end-stage product of virion morphogenesis but 
are nascent virions awaiting envelopment. This was not observed in other studies 
that have also used A26L deletion mutant strains to quantify the IMV and EV
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produced in culture, although the different quantification methods and culture 
conditions may contribute to this (134;351). The increased production of IMV in 
VACV COP does not fit with our hypothesis, and the non-enveloped intracellular 
virus observed may be in fact nascent virions that cannot be wrapped, for a reason 
not associated with a lack of A26. The conservation of part of the A26 coding 
sequence in the COP strain is interesting as the final 73 amino acids are 
demonstrated to be required for association with A27, and therefore attachment to 
virions via A27 (342;351): this region is absent in COP. The truncated A26 is not 
attached to the virion (Dr D. Pickup, personal communication) and the truncated 
A26 cannot complement occlusion negative strains of CPXV (188). During the 
course of this study, several researchers reported further roles for A26 in cell 
attachment by binding IMV to cell surface laminin (134) and the suppression of 
GAG-mediated cell fusion (342). For these roles, attachment of A26 to the virion 
surface is likely to be necessary, therefore the function of unbound A26 in COP 
remains unsolved.
Although the evidence from this study suggests that A26 is not a 
differentiation switch controlling maturation of IMV, it may still be a marker of fully 
differentiated, non-enveloped mature virus that can no longer mature as EV.
8.3 IMV as a True End-stage Product of VACV Morphogenesis
It is generally accepted that IMV are precursors of EV where IMV are the 
kernels that are wrapped to become EV, and that the accumulation of IMV within a 
cell is a tissue culture artefact that results from limiting quantities of intracellular
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membranes used for wrapping. Membrane perturbing agents demonstrated that 
stripping the outer membrane from EV inactivated the virion but IMV were not 
inactivated when subjected to the same treatment (Dean et al., in preparation). 
This suggests that the single-membraned EV pre-cursor and mature IMV are 
different particles. Modification of the IMV surface by deletion of A26 demonstrated 
that the intracellular non-enveloped form of the mutant strains had an increased 
sensitivity to Tween-20, behaving similarly to stripped EV, compared to wild-type 
intracellular non-enveloped virus. The relative resistance of wild-type IMV to 
inactivation by Tween-20 might be attributable to the presence of IMV-specific 
proteins that are not found on stripped EV, such as A26 and by extrapolation, A25 
(ATI).
This provides evidence that IMV is a true end-stage product of VACV 
morphogenesis, and that a mechanism exists by which OPVs actively differentiate 
particles towards IMV, thus preventing the maturation of a subset of virions as EV. 
Therefore, it is proposed that in addition to EV and IMV, the term “nascent virus” 
(NV) be used to describe a third virion form that is non-differentiated but is able to 
mature as either EV or IMV via two independent maturation pathways (Figure 8.1).
8.4 Active Differentiation of Virions in OPVs
This study presents evidence that IMV is a true-end stage product of OPV 
morphogenesis, and that OPVs differentiate to produce two mutually non- 
interchangeable co-existing isoforms of mature infectious virion. Thus OPVs 
appear to differentiate in a manner that is not known in other virus families.
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Figure 8.1 Proposed VACV Morphogenesis where Two Non-lnterchangeable Isoforms of 
Infectious Virus are Produced
1 EV or IMV bind to the cell and enter following the loss of one or more membranes. The naked 
viral core is released into the cytoplasm. 2 The core is transported via microtubules (MT) where the 
formation of viral factories occurs within the cell. 3 Transcription of the early gene leads to core 
uncoating. DNA replication and viral crescent formation begins. 4 DNA is packaged and immature 
virions (IV) assemble. Concomitant with proteolytic cleavage of viral core proteins IV are processed 
to form single-membraned nascent virus (NV). 5 Some virions are transported via microtubules to 
intracellular membranes for envelopment. 6 NV particles are wrapped by a Golgi or TGN-derived 
double membrane to form triple-membraned IEV and are then transported to the cell surface via 
microtubules. 7 To exit the cell, the outer IEV membrane fuses with the cell membrane to expose a 
CEV at the cell surface. Actin polymerisation beneath the CEV occurs to drive the virus into a 
neighbouring cell, or the virus is released as an EEV. 8 In the later stages of the infectious cycle, 
wrapping of virions decreases and some NV acquire A26 and remain within the cell until lysis. 
These virions cannot become wrapped.
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The herpesviruses and papillomaviruses provide examples of viruses whose 
genomes are able to replicate in non-encapsidated states through manipulation of 
the host cell and as a result produce two different types of infection: latent and lytic 
(375;376). Latent infections are an important feature of many viral infections to 
ensure maintenance of the viral genome within the host indefinitely, where it may 
be reactivated periodically to produce new progeny and subsequently infect new 
hosts. During latency, infectious virus is not produced and the virus is maintained 
as non-encapsidated nucleic acid with only minimal viral gene expression, usually 
only to prevent apoptosis therefore maintaining viability of the host cell (377-379). 
The “duality of infection states” exhibited by these viruses is achieved by 
manipulation of the differentiation state of the host cell to maintain and replicate 
non-encapsidated viral nucleic acid, and is not indicative of differentiation of the 
viruses in a manner that is analogous to differentiation in metazoan life-forms.
Bacteriophages are also able to produce either latent or lytic infections in 
their prokaryotic hosts. Some bacteriophage genomes integrate into the host 
genome (lysogeny) where the bacteriophage DNA is replicated along with the host 
chromosome as the bacterial host cell divides (380). This maintains the genetic 
material in all progeny cells, essentially acting to delay lytic infection until the 
environmental conditions favour the lytic cycle as the optimal replication strategy. 
Although bacteriophage lysogeny is analogous to latency in herpesvirus and 
papillomavirus infections, it cannot be truly be regarded as manipulating the host­
cell differentiation state. The “duality of infection states” described for 
bacteriophages and the eukaryotic viruses aforementioned are examples of viruses
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that produce two interchangeable phases of infection that occur sequentially: both 
infection states cannot co-exist in the same cell and infection produces only one 
type of viron with one set of functions. This is quite different to what we describe 
here as OPV differentiation, and is not functionally analogous to differentiation as 
we understand it in metazoan eukaryotes.
True differentiation is demonstrated in metazoan and some protozoan 
eukaryotes. In the protozoan Dictyostelium discoideum, or cellular slime mould, the 
organism(s) remain in their single-celled state when nutrients are available. 
However, when nutrients are depleted, signals are released from the individual 
cells and they form swarms. The cells join to form a slug-like creature behaving as 
a multi-cellular organism and the slug migrates towards an open space where a 
fruiting body develops. The cells differentiate so that some become spores to begin 
the next generation and others become the basal cells and stalk, sacrificing 
themselves for the sake of the “organism”. The specialist spores will form a new 
generation, while the specialist basal and stalk cells will not, and the differentiation, 
once complete, is largely irreversible (381 ;382).
Eukaryotic differentiation usually begins from a totipotent cell population 
whose progeny become specialised for their particular task: in metazoans a single 
zygote is able to differentiate into a complex system of tissues and cell types to 
construct a complete and viable organism. Cellular differentiation occurs in 
response to a stimulus and is also controlled at the genetic level. Changes in gene 
expression usually result from signal molecules such as hormones and growth 
factors which induce cell-to-cell signalling. This cascade results in the activation of
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transcription factors and thus a change in gene expression that will result in cell 
differentiation (383). Often differentiation is terminal, and cells cannot normally “de­
differentiate”.
OPVs appear to differentiate in a manner more similar to that of eukaryotic 
organisms rather than the “duality of infection states” described above for other 
viruses that can replicate in non-encapsidated states as their host cell divides. Two 
morphologically distinct forms are produced in OPV infection: EV for virus 
dissemination in the infected host, and IMV for host-to-host transmission. It is often 
assumed that the production of EV is limited by the quantities of intracellular 
membranes that are available for wrapping during the infectious cycle, resulting in 
an accumulation of IMV by default. However, the presence of the IMV-restricted 
protein A26, would suggest OPVs actively differentiate particles towards IMV, thus 
actively preventing the maturation of a subset of virions as EV, resulting in two 
mutually non-interchangeable co-existing isoforms of mature infectious virion. As 
an adaptation this would ensure that both forms of virion are produced to perform 
their individual functions in the virus life-cycle in a manner highly analogous to 
cellular differentiation in higher eukaryotes. This is the first description of such a 
process in the virus kingdom.
8.5 Future Work
Examining the kinetics of EV and IMV production has proven to be a difficult 
task, and a challenge to obtain reproducible results. During the course of these 
experiments both A26L deletion mutants produced virions that sedimented with the
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same density as IMV in wild-type cultures. Although structurally similar to wild-type 
IMV, these virions do not possess A26 and have increased sensitivity to a non­
ionic detergent. Conceivably, if intracellular membranes for virion wrapping are 
limiting in tissue culture systems, the single-membraned intracellular virus that is 
produced in wild-type cultures may be a heterogeneous population of virus: a 
mixture of A26+ (fully differentiated) and A26' (nascent) virions. It is also 
conceivable that the quantities of A26+ and A26~ virions in such a situation may 
differ depending on the cell line used. This could make future studies in this area 
technically challenging, but might be addressed by limiting virus assembly (e.g. by 
addition of rifampicin) to a level where wrapping membranes themselves cease to 
be limiting.
The potential use of a recombinant VACV as a vaccine strain, where the 
A26L gene was modulated to overproduce A26, was not investigated as set out in 
the original aims of this project as expression from a synthetic early/late promoter 
did not appear to increase expression of A26, relative to a revertant. It may be that 
the early portion of the promoter was not efficient. However, during the course of 
this project other researchers have found that A26 is not stable in the absence of 
A27 and is rapidly degraded, which indicates that the approach of controlling A26L 
with a synthetic early/late promoter could not have achieved the objective. Other 
approaches could be taken to try to increase the levels of expression of A26 in 
cultures. This could involve additional transient expression of A26 under a vaccinia 
promoter in a cultured cell line that was used to propagate VACV, although this 
would be complicated by the additional production of A26 away from the virus
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factories where virions are assembled. Alternatively, different promoters that have 
been proven to give increased levels of expression such as the T7 bacteriophage 
promoter system could be engineered into VACV (384), or multiple copies of A26L 
could be engineered into the VACV genome.
There is no simple explanation for the lack of activity of AMPs on the 
intracellular virus of the A26L deletion mutant viruses, when the peptides have 
clear activity against EEV but not against IMV of wild-type IHD-J, and there is a 
clear difference in susceptibility to Tween-20. Plausibly, there may be additional 
differences between IMV and unwrapped EV. To try to unravel the reasons for the 
differential effect of AMPs and Tween-20 on single-membraned intracellular virus 
from A26L deletion mutants, future analyses could be performed to examine the 
effect on the virion membrane by CsCI density gradient centrifugation of treated 
virions, or visualising the effects by electron microscopy.
Ultimately, the goal of this project was to generate a defined VACV strain 
that could be used as a safer alternative to current licensed smallpox vaccines. 
This study used the IHD-J strain for proof of principle, as this strain produces 
increased quantities of EEV when cultured in RK13 cells compared to other 
laboratory strains such as WR (181). However, such laboratory strains would not 
be used in the development of a vaccine; a strain with a better safety and efficacy 
profile such as Lister would be more appropriate. Deletion of A26 in the IHD-J 
strain in this study resulted in only a mild effect on virus replication, and no effect 
was observed by other researchers in the WR strain in vitro (134;188;342;351). 
However, the effect in vivo has not yet been examined, and as A26 has been
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demonstrated to play a role in cell binding and cell-to-cell fusion, it is possible that 
this protein may yet prove to affect VACV virulence.
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT  
T T G a a t tg g a  t c a g c t t t t t  t t t t t t t t t t  t t t g g c a t a t  a a a t a a g g t c  g a c a a a a a t t  
g a a a a a c t a t  t c t a a t t t a t  tg c a c g g A T G  AGCGAAAAAT ACATCGTCAC CTGGGACATG
TTGCAGATCC ATGCACGTAA ACTCGCAAGC CGACTGATGC CTTCTGAACA ATGGAAAGGC
ATTATTGCCG TAAGCCGTGG CGGTCTGGTA CCGGGTGCGT TACTGGCGCG TGAACTGGGT
ATTCGTCATG TCGATACCGT TTGTATTTCC AGCTACGATC ACGACAACCA GCGCGAGCTT
AAAGTGCTGA AACGCGCAGA AGGCGATGGC GAAGGCTTCA TCGTTATTGA TGACCTGGTG
GATACCGGTG GTACTGCGGT TGCGATTCGT GAAATGTATC CAAAAGCGCA CTTTGTCACC
ATCTTCGCAA AACCGGCTGG TCGTCCGCTG GTTGATGACT ATGTTGTTGA TATCCCGCAA
GATACCTGGA TTGAACAGCC GTGGGATATG GGGGTCGTAT TCGTCCCGCC AATCTCCGGT
CGCTAATTAC CCGATTGTAG TTAAGTTTTG AATAAAATTT TTTATAATAA ATGGAGGTCA
CGAACCTTAT TGAAAAATGT ACCAAGCACT CCAAA
Figure A1 vl6A26L Recombination Cassette Sequence
Cassette used to construct vl6A26L virus by replacing A26L with EcoGPT (black) expressed from a 
synthetic early/late promoter (purple). Upstream and downstream flanking regions of A26L are 
highlighted in red and were included to facilitate homologous recombination.
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT
TTGTTAATTA AAAGTATATT CAAAAAATGA GTTATATAAA TGGCGAACAT TATAAATTTA
TGGAACGGAA TTGTACCAAC GGTTCAAGAT GTTAATGTTG CGAGCATTAC TGCGTTTAAA
TCTATGATAG ATGAAACATG GGATAAAAAA ATCGAAGCAA ATACATGCAT CAGTAGAAAA
CATAGAAACA TTATTCACGA AGTTATTAGG GACTTTATGA AAGCCTATCC TAAAATGGAT
GAGAATAAAA AATCTCCATT AGGAGCCCCA ATGCAATGGC TAACACAATA TTATA TTTTA
AAGAATGAAT ATCATAAGAC CATGCTAGCG TATGATAATG GATCATTGAA TACAAAATTT
AAAACGTTAA ACATTTATAT GATTACTAAC GTTGGTCAAT ATATTTTATA TATAGTATTT
TGTATAATAT CTGGTAAGAA TCACGATGGT ACTCCTTATA TATACGATTC TGAGATAACG
AGCAATGATA AAAATTTTAT TAATGAGCGT ATCAAGTATG CATGTAAGCA AATATTACAC
GGTCAATTAA CTATAGCTCT GAGAATTAGA AATAAATTCA TGTTTATAGG ATCACCCATG
TATTTATGGT TTAACGTAAA CGGATCACAG GTATATCACG ACATATATGA TCGTAATGCC
GGTTTTCATA ATAAAGAGAT AGGTAGACTA CTATACGCAT TTATGTACTA TCTATCTATA
AGTGGTAGAT TTTTGAATGA TTTCGCACTA TTAAAGTTTA CGTATTTAGG AGAATCCTGG
ACATTTAGTT TGAGTGTCCC TGAATATATA TTATATGGTT TAGGATATTC TGTTTTCGAT
ACTATTGAAA AATTTAGCAA TGATGCTATA CTCGTTTATA TTAGAACAAA CAATAGAAAT
GGATATGATT ATGTAGAGTT TAATAAAAAA GGAATTGCTA AGGTGACAGA AGATAAACCC
GATAACGATA AGCGAATTCA TGCTATAAGA CTCATCAACG ATAGTACTGA TGTTCAACAC
ATACATTTTG GGTTTAGAAA TATGGTAATA ATAGACAATG AATGCGCTAA TATTCAGTCG
AGTGCTGAAA ATGCAACTGA TACAGGACAT CATCAAGATA GCAAAATAAA TATCGAAGTC
GAAGATGATG TCATAGACGA TGATGATTAT AATCCAAAAC CCACTCCGAT ACCGGAGCCT
CACCCTAGAC CACCGTTTCC CAGACATGAA TATCATAAGA GGCCGAAACT TCTTCCTGTA
GAAGAACCTG ATCCTGTCAA AAAAGACGCG GATCGTATAA GACTTGATAA TCATATATTA
AACACATTGG ATCATAATCT TAATTTCATC GGACACTATT GTTGTGATAC AGCGGCAGTT
GATAGGTTAG AACATCACAT CGAAACATTG GGACAATATG CAGTAATACT GGCAAGAAAG
ATAAATATGC AAACATTACT GTTCCCATGG CCATTACCTA CTGTCCATCC ACATGCGATA
GATGGTAGTA TTCCACCACA TGGGAGATCT ACGATTTTAT ATGGAGGTCA CGAACCTTAT
TGAAAAATGT ACCAAGCACT CCAAA
Figure A2 Revertant Construct for Reverse GPT Selection
A26L DNA sequence plus upstream and downstream flanking regions of VACV WR (GenBank 
Accession Number AY243312, position 138371-140062). The predicted native promoter sequence 
is highlighted in red; the flanking regions are highlighted in blue.
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT
TTGAATTGGA TCAGCTTTTT T T T T T T T T T T  TTTGGCATAT AAATAACGTC GACAAAAATT
GAAAAACTAT TCTAATTTAT TGCACGGATG GCGAACATTA TAAATTTATG GAACGGAATT
GTACCAACGG TTCAAGATGT TAATGTTGCG AGCATTACTG CGTTTAAATC TATGATAGAT
GAAACATGGG ATAAAAAAAT CGAAGCAAAT ACATGCATCA GTAGAAAACA TAGAAACATT
ATTCACGAAG TTATTAGGGA CTTTATGAAA GCCTATCCTA AAATGGATGA GAATAAAAAA
TCTCCATTAG GAGCCCCAAT GCAATGGCTA ACACAATATT ATATTTTAAA GAATGAATAT
CATAAGACCA TGCTAGCGTA TGATAATGGA TCATTGAATA CAAAATTTAA AACGTTAAAC
ATTTATATGA TTACTAACGT TGGTCAATAT ATTTTATATA TAGTATTTTG TATAATATCT
GGTAAGAATC ACGATGGTAC TCCTTATATA TACGATTCTG AGATAACGAG CAATGATAAA
AA TTTTATTA ATGAGCGTAT CAAGTATGCA TGTAAGCAAA TATTACACGG TCAATTAACT
ATAGCTCTGA GAATTAGAAA TAAATTCATG TTTATAGGAT CACCCATGTA TTTATGGTTT
AACGTAAACG GATCACAGGT ATATCACGAC ATATATGATC GTAATGCCGG TTTTCATAAT
AAAGAGATAG GTAGACTACT ATACGCATTT ATGTACTATC TATCTATAAG TGGTAGATTT
TTGAATGATT TCGCACTATT AAAGTTTACG TATTTAGGAG AATCCTGGAC ATTTAGTTTG
AGTGTCCCTG AATATATATT ATATGGTTTA GGATATTCTG TTTTCGATAC TATTGAAAAA
TTTAGCAATG ATGCTATACT CGTTTATATT AGAACAAACA ATAGAAATGG ATATGATTAT
GTAGAGTTTA ATAAAAAAGG AATTGCTAAG GTGACAGAAG ATAAACCCGA TAACGATAAG
CGAATTCATG CTATAAGACT CATCAACGAT AGTACTGATG TTCAACACAT ACATTTTGGG
TTTAGAAATA TGGTAATAAT AGACAATGAA TGCGCTAATA TTCAGTCGAG TGCTGAAAAT
GCAACTGATA CAGGACATCA TCAAGATAGC AAAATAAATA TCGAAGTCGA AGATGATGTC
ATAGACGATG ATGATTATAA TCCAAAACCC ACTCCGATAC CGGAGCCTCA CCCTAGACCA
CCGTTTCCCA GACATGAATA TCATAAGAGG CCGAAACTTC TTCCTGTAGA AGAACCTGAT
CCTGTCAAAA AAGACGCGGA TCGTATAAGA CTTGATAATC ATATATTAAA CACATTGGAT
CATAATCTTA ATTTCATCGG ACACTATTGT TGTGATACAG CGGCAGTTGA TAGGTTAGAA
CATCACATCG AAACATTGGG ACAATATGCA GTAATACTGG CAAGAAAGAT AAATATGCAA
ACATTACTGT TCCCATGGCC ATTACCTACT GTCCATCCAC ATGCGATAGA TGGTAGTATT
CCACCACATG GGAGATCTAC GATTTTATAA ATGGAGGTCA CGAACCTTAT TGAAAAATGT
ACCAAGCACT CCAAA
Figure A3 EL construct for Reverse GPT Selection
A26L DNA sequence plus upstream and downstream flanking regions of VACV WR (GenBank 
Accession Number AY243312, position 138371-140062). The synthetic early/late promoter 
sequence is highlighted in red (327); the flanking regions are highlighted in blue.
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT  
TGTTACCCGA TTGTAGTTAA GTTTTGAATA AAATTATTTT TTATAATAAA TGGAGGTCAC 
GAACC
Figure A4 Null Construct for Reverse GPT Selection
Upstream (blue) and downstream (black) flanking regions of VACV WR A26L sequence (GenBank 
Accession Number AY243312, position 138371-140062).
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT
TTGCAAAAAT TGAAAAACTA TTCTAATTTA TTGCACGGAT GGCGAACATT ATAAATTTAT
GGAACGGAAT TGTACCAACG GTTCAAGATG TTAATGTTGC GAGCATTACT GCGTTTAAAT
CTATGATAGA TGAAACATGG GATAAAAAAA TCGAAGCAAA TACATGCATC AGTAGAAAAC
ATAGAAACAT TATTCACGAA GTTATTAGGG ACTTTATGAA AGCCTATCCT AAAATGGATG
AGAATAAAAA ATCTCCATTA GGAGCCCCAA TGCAATGGCT AACACAATAT TATATTTTAA
AGAATGAATA TCATAAGACC ATGCTAGCGT ATGATAATGG ATCATTGAAT ACAAAATTTA
AAACGTTAAA CATTTATATG ATTACTAACG TTGGTCAATA TATTTTATAT ATAGTATTTT
GTATAATATC TGGTAAGAAT CACGATGGTA CTCCTTATAT ATACGATTCT GAGATAACGA
GCAATGATAA AAATTTTATT AATGAGCGTA TCAAGTATGC ATGTAAGCAA ATATTACACG
GTCAATTAAC TATAGCTCTG AGAATTAGAA ATAAATTCAT GTTTATAGGA TCACCCATGT
ATTTATGGTT TAACGTAAAC GGATCACAGG TATATCACGA CATATATGAT CGTAATGCCG
GTTTTCATAA TAAAGAGATA GGTAGACTAC TATACGCATT TATGTACTAT CTATCTATAA
GTGGTAGATT TTTGAATGAT TTCGCACTAT TAAAGTTTAC GTATTTAGGA GAATCCTGGA
CATTTAGTTT GAGTGTCCCT GAATATATAT TATATGGTTT AGGATATTCT GTTTTCGATA
CTATTGAAAA ATTTAGCAAT GATGCTATAC TCGTTTATAT TAGAACAAAC AATAGAAATG
GATATGATTA TGTAGAGTTT AATAAAAAAG GAATTGCTAA GGTGACAGAA GATAAACCCG
ATAACGATAA GCGAATTCAT GCTATAAGAC TCATCAACGA TAGTACTGAT GTTCAACACA
TACATTTTGG GTTTAGAAAT ATGGTAATAA TAGACAATGA ATGCGCTAAT ATTCAGTCGA
GTGCTGAAAA TGCAACTGAT ACAGGACATC ATCAAGATAG CAAAATAAAT ATCGAAGTCG
AAGATGATGT CATAGACGAT GATGATTATA ATCCAAAACC CACTCCGATA CCGGAGCCTC
ACCCTAGACC ACCGTTTCCC AGACATGAAT ATCATAAGAG GCCGAAACTT CTTCCTGTAG
AAGAACCTGA TCCTGTCAAA AAAGACGCGG ATCGTATAAG ACTTGATAAT CATATATTAA
ACACATTGGA TCATAATCTT AATTTCATCG GACACTATTG TTGTGATACA GCGGCAGTTG
ATAGGTTAGA ACATCACATC GAAACATTGG GACAATATGC AGTAATACTG GCAAGAAAGA
TAAATATGCA AACATTACTG TTCCCATGGC CATTACCTAC TGTCCATCCA CATGCGATAG
ATGGTAGTAT TCCACCACAT GGGAGATCTA CGATTTTATA AATGGAGGTC ACGAACCTTA
TTGAAAAATG TACCAAGCAC TCCAAA
Figure A5 Early Construct for Reverse GPT Selection
A26L DNA sequence plus upstream and downstream flanking regions of VACV WR (GenBank 
Accession Number AY243312, position 138371-140062). The early promoter sequence is 
highlighted in red (327); the flanking regions are highlighted in blue.
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT
TTGATTTGGA TCAGCTTTTT T TT T T T T T T T  TTTGGCATAT AAATGGCGAA CATTATAAAT
TTATGGAACG GAATTGTACC AACGGTTCAA GATGTTAATG TTGCGAGCAT TACTGCGTTT
AAATCTATGA TAGATGAAAC ATGGGATAAA AAAATCGAAG CAAATACATG CATCAGTAGA
AAACATAGAA ACATTATTCA CGAAGTTATT AGGGACTTTA TGAAAGCCTA TCCTAAAATG
GATGAGAATA AAAAATCTCC ATTAGGAGCC CCAATGCAAT GGCTAACACA ATATTATATT
TTAAAGAATG AATATCATAA GACCATGCTA GCGTATGATA ATGGATCATT GAATACAAAA
TTTAAAACGT TAAACATTTA TATGATTACT AACGTTGGTC AATATATTTT ATATATAGTA
TTTTGTATAA TATCTGGTAA GAATCACGAT GGTACTCCTT ATATATACGA TTCTGAGATA
ACGAGCAATG ATAAAAATTT TATTAATGAG CGTATCAAGT ATGCATGTAA GCAAATATTA
CACGGTCAAT TAACTATAGC TCTGAGAATT AGAAATAAAT TCATGTTTAT AGGATCACCC
ATG TATTTAT GGTTTAACGT AAACGGATCA CAGGTATATC ACGACATATA TGATCGTAAT
GCCGGTTTTC ATAATAAAGA GATAGGTAGA CTACTATACG CATTTATGTA CTATCTATCT
ATAAGTGGTA GATTTTTGAA TGATTTCGCA CTATTAAAGT TTACGTATTT AGGAGAATCC
TGGACATTTA GTTTGAGTGT CCCTGAATAT ATATTATATG GTTTAGGATA TTCTG TTTTC
GATACTATTG AAAAATTTAG CAATGATGCT ATACTCGTTT ATATTAGAAC AAACAATAGA
AATGGATATG ATTATGTAGA GTTTAATAAA AAAGGAATTG CTAAGGTGAC AGAAGATAAA
CCCGATAACG ATAAGCGAAT TCATGCTATA AGACTCATCA ACGATAGTAC TGATGTTCAA
CACATACATT TTGGGTTTAG AAATATGGTA ATAATAGACA ATGAATGCGC TAATATTCAG
TCGAGTGCTG AAAATGCAAC TGATACAGGA CATCATCAAG ATAGCAAAAT AAATATCGAA
GTCGAAGATG ATGTCATAGA CGATGATGAT TATAATCCAA AACCCACTCC GATACCGGAG
CCTCACCCTA GACCACCGTT TCCCAGACAT GAATATCATA AGAGGCCGAA ACTTCTTCCT
GTAGAAGAAC CTGATCCTGT CAAAAAAGAC GCGGATCGTA TAAGACTTGA TAATCATATA
TTAAACACAT TGGATCATAA TCTTAATTTC ATCGGACACT ATTGTTGTGA TACAGCGGCA
GTTGATAGGT TAGAACATCA CATCGAAACA TTGGGACAAT ATGCAGTAAT ACTGGCAAGA
AAGATAAATA TGCAAACATT ACTGTTCCCA TGGCCATTAC CTACTGTCCA TCCACATGCG
ATAGATGGTA GTATTCCACC ACATGGGAGA TCTACGATTT TATAAATGGA GGTCACGAAC
CTTATTGAAA AATGTACCAA GCACTCCAAA
Figure A6 Late Construct for Reverse GPT Selection
A26L DNA sequence plus upstream and downstream flanking regions of VACV WR (GenBank 
Accession Number AY243312, position 138371-140062). The late promoter sequence is highlighted 
in red (327); the flanking regions are highlighted in blue.
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CTCTGGCTAA AAAGATTGAT GTTCAGACTG GACGGCGCCC ATATGAGTAA CTTAACTCTT
TTGGGATGTA TAAG TTTTTA TGTTAACTAA ATGGCGAACA TTATAAATTT ATGGAACGGA
ATTGTACCAA CGGTTCAAGA TGTTAATGTT GCGAGCATTA CTGCGTTTAA ATCTATGATA
GATGAAACAT GGGATAAAAA AATCGAAGCA AATACATGCA TCAGTAGAAA ACATAGAAAC
ATTATTCACG AAGTTATTAG GGACTTTATG AAAGCCTATC CTAAAATGGA TGAGAATAAA
AAATCTCCAT TAGGAGCCCC AATGCAATGG CTAACACAAT ATTA TA TTTT AAAGAATGAA
TATCATAAGA CCATGCTAGC GTATGATAAT GGATCATTGA ATACAAAATT TAAAACGTTA
AACATTTATA TGATTACTAA CGTTGGTCAA TATATTTTAT ATATAGTATT TTGTATAATA
TCTGGTAAGA ATCACGATGG TACTCCTTAT ATATACGATT CTGAGATAAC GAGCAATGAT
AAAAATTTTA TTAATGAGCG TATCAAGTAT GCATGTAAGC AAATATTACA CGGTCAATTA
ACTATAGCTC TGAGAATTAG AAATAAATTC ATGTTTATAG GATCACCCAT GTATTTATGG
TTTAACGTAA ACGGATCACA GGTATATCAC GACATATATG ATCGTAATGC CGGTTTTCAT
AATAAAGAGA TAGGTAGACT ACTATACGCA TTTATGTACT ATCTATCTAT AAGTGGTAGA
TTTTTGAATG ATTTCGCACT ATTAAAGTTT ACGTATTTAG GAGAATCCTG GACATTTAGT
TTGAGTGTCC CTGAATATAT ATTATATGGT TTAGGATATT CTGTTTTCGA TACTATTGAA
AAATTTAGCA ATGATGCTAT ACTCGTTTAT ATTAGAACAA ACAATAGAAA TGGATATGAT
TATGTAGAGT TTAATAAAAA AGGAATTGCT AAGGTGACAG AAGATAAACC CGATAACGAT
AAGCGAATTC ATGCTATAAG ACTCATCAAC GATAGTACTG ATGTTCAACA CATACATTTT
GGGTTTAGAA ATATGGTAAT AATAGACAAT GAATGCGCTA ATATTCAGTC GAGTGCTGAA
AATGCAACTG ATACAGGACA TCATCAAGAT AGCAAAATAA ATATCGAAGT CGAAGATGAT
GTCATAGACG ATGATGATTA TAATCCAAAA CCCACTCCGA TACCGGAGCC TCACCCTAGA
CCACCGTTTC CCAGACATGA ATATCATAAG AGGCCGAAAC TTCTTCCTGT AGAAGAACCT
GATCCTGTCA AAAAAGACGC GGATCGTATA AGACTTGATA ATCATATATT AAACACATTG
GATCATAATC TTAATTTCAT CGGACACTAT TGTTGTGATA CAGCGGCAGT TGATAGGTTA
GAACATCACA TCGAAACATT GGGACAATAT GCAGTAATAC TGGCAAGAAA GATAAATATG
CAAACATTAC TGTTCCCATG GCCATTACCT ACTGTCCATC CACATGCGAT AGATGGTAGT
ATTCCACCAC ATGGGAGATC TACGATTTTA TAAATGGAGG TCACGAACCT TATTGAAAAA
TGTACCAAGC ACTCCAAA
Figure A7 F13L Construct for Reverse GPT Selection
A26L DNA sequence plus upstream and downstream flanking regions of VACV WR (GenBank 
Accession Number AY243312, position 138371-140062). The predicted F13L promoter sequence is 
highlighted in red; the flanking regions are highlighted in blue.
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CCCGGGa t g a  g c g a a a a a t a  c a t c g t c a c c  t g g g a c a t g t  t g c a g a t c c a  t g c a c GCGGC
CGCa a t t g g a  t c a g c t t t t t  t t t t t t t t t t  t t t g g c a t a t  a a a t a a g g t c  g a c a a a a a t t
g a a a a a c t a t  t c t a a t t t a t  tg c a c g g A T G  ATCGAGCAGG ACGGCCTGCA CGCCGGCTCC
CCCGCCGCCT GGGTGGAGCG CCTGTTCGGC TACGACTGGG CCCAGCAGAC CATCGGCTGC
TCCGACGCCG CCGTGTTCCG CCTGTCCGCC CAGGGCCGCC CCGTGCTGTT CGTGAAGACC
GACCTGTCCG GCGCCCTGAA CGAGCTGCAG GACGAGGCCG CCCGCCTGTC CTGGCTGGCC
ACCACCGGCG TGCCCTGCGC CGCCGTGCTG GACGTGGTGA CCGAGGCCGG CCGCGACTGG
CTGCTGCTGG GCGAGGTGCC CGGCCAGGAC CTGCTGTCCT CCCACCTGGC CCCCGCCGAG
AAGGTGTCCA TCATGGCCGA CGCCATGCGC CGCCTGCACA CCCTGGACCC CGCCACCTGC
CCCTTCGACC ACCAGGCCAA GCACCGCATC GAGCGCGCCC GCACCCGCAT GGAGGCCGGC
CTGGTGGACC AGGACGACCT GGACGAGGAG CACCAGGGCC TGGCCCCCGC CGAGCTGTTC
GCCCGCCTGA AGGCCCGCAT GCCCGACGGC GAGGACCTGG TGGTGACCCA CGGCGACGCC
TGCCTGCCCA ACATCATGGT GGAGAACGGC CGCTTCTCCG GCTTCATCGA CTGCGGCCGC
CTGGGCGTGG CCGACCGCTA CCAGGACATC GCCCTGGCCA CCCGCGACAT CGCCGAGGAG
CTGGGCGGCG AGTGGGCCGA CCGCTTCCTG GTGCTGTACG GCATCGCCGC CCCCGACTCC
CAGCGCATCG CCTTCTACCG CCTGCTGGAC GAGTTCTTCT A A t a a c t t a a  c t c t t t t g t t
a a t t a a a a g t  a t a t t c a a a a  a a t g a g t t a t  ataaATGGCG AACATTATAA ATTTATGGAA
CGGAATTGTA CCAACGGTTC AAGATGTTAA TGTTGCGAGC ATTACTGCGT TTAAATCTAT
GATAGATGAA ACATGGGATA AAAAAATCGA AGCAAATACA TGCATCAGTA GAAAACATAG
AAACATTATT CACGAAGTTA TTAGGGACTT TATGAAAGCC TATCCTAAAA TGGATGAGAA
TAAAAAATCT CCATTAGGAG CCCCAATGCA ATGGCTAACA CAATATTATA TTTTAAAGAA
TGAATATCAT AAGACCATGC TAGCGTATGA TAATGGATCA TTGAATACAA AATTTAAAAC
GTTAAACATT TATATGATTA CTAACGTTGG TCAATATATT TTATATATAG TATTTTGTAT
AATATCTGGT AAGAATCACG ATGGTACTCC TTATATATAC GATTCTGAGA TAACGAGCAA
TGATAAAAAT TTTATTAATG AGCGTATCAA GTATGCATGT AAGCAAATAT TACACGGTCA
ATTAACTATA GCTCTGAGAA TTAGAAATAA ATTCATGTTT ATAGGATCAC CCATGTATTT
ATGGTTTAAC GTAAACGGAT CACAGGTATA TCACGACATA TATGATCGTA ATGCCGGTTT
TCATAATAAA GAGATAGGTA GACTACTATA CGCATTTATG TACTATCTAT CTATAAGTGG
TAGATTTTTG AATGATTTCG CACTATTAAA GTTTACGTAT TTAGGAGAAT CCTGGACATT
TAGTTTGAGT GTCCCTGAAT ATATATTATA TGGTTTAGGA TATTCTGTTT TCGATACTAT
TGAAAAATTT AGCAATGATG CTATACTCGT TTATATTAGA ACAAACAATA GAAATGGATA
TGATTATGTA GAGTTTAATA AAAAAGGAAT TGCTAAGGTG ACAGAAGATA AACCCGATAA
CGATAAGCGA ATTCATGCTA TAAGACTCAT CAACGATAGT ACTGATGTTC AACACATACA
TTTTGGGTTT AGAAATATGG TAATAATAGA CAATGAATGC GCTAATATTC AGTCGAGTGC
TGAAAATGCA ACTGATACAG GACATCATCA AGATAGCAAA ATAAATATCG AAGTCGAAGA
TGATGTCATA GACGATGATG ATTATAATCC AAAACCCACT CCGATACCGG AGCCTCACCC
TAGACCACCG TTTCCCAGAC ATGAATATCA TAAGAGGCCG AAACTTCTTC CTGTAGAAGA
ACCTGATCCT GTCAAAAAAG ACGCGGATCG TATAAGACTT GATAATCATA TATTAAACAC
ATTGGATCAT AATCTTAATT TCATCGGACA CTATTGTTGT GATACAGCGG CAGTTGATAG
GTTAGAACAT CACATCGAAA CATTGGGACA ATATGCAGTA ATACTGGCAA GAAAGATAAA
TATGCAAACA TTACTGTTCC CATGGCCATT ACCTACTGTC CATCCACATG CGATAGATGG
TAGTATTCCA CCACATGGGA GATCTACGAT TTTATAAagc c g t g g g a t a t  g g g c g t c g t a
t t c g t c c c g c  c a a t c t c c g g  t c g c t a a CCC GGG
Figure A8 Revertant Recombination Cassette Sequence
Cassette used to construct vl5A26L.rev the revertant virus by replacing EcoGPT (green) with 
G148r (black) expressed from a synthetic early/late promoter (purple), followed by A26L (blue) 
expressed from its predicted natural promoter (red). Cassette contains Smal restriction sites at each 
end of the construct to allow excision from plasmid vector. Not\ restriction sites were included to 
allow inactivation of G418 R at a later stage if preferred.
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CCCGGG i -i  
C G C a a t t g g a  
g a a a a a c t a t  
CCCGCCGCCT 
TCCGACGCCG 
GACCTGTCCG 
ACCACCGGCG 
CTGCTGCTGG 
AAGGTGTCCA 
CCCTTCGACC 
CTGGTGGACC 
GCCCGCCTGA 
TGCCTGCCCA 
CTGGGCGTGG 
CTGGGCGGCG 
CAGCGCATCG 
t g g a a c g g a a  
t c t a t g a t a g  
c a t a g a a a c a  
g a g a a t a a a a  
a a g a a t g a a t  
a a a a c g t t a a  
t g t a t a a t a t  
a g c a a t g a t a  
g g t c a a t t a a  
t a t t t a t g g t  
g g t t t t c a t a  
a g t g g t a g a t  
a c a t t t a g t t  
a c t a t t g a a a  
g g a t a t g a t t  
g a t a a c g a t a  
a t a c a t t t t g  
a g t g c t g a a a  
g a a g a t g a t g  
c a c c c t a g a c  
g a a g a a c c t g  
a a c a c a t t g g  
g a t a g g t t a g  
a t a a a t a t g c  
g a t g g t a g t a  
TCGTATTCGT
g c g a a a a a t a  
t c a g c t t t t t  
t c t a a t t t a t  
GGGTGGAGCG 
CCGTGTTCCG 
GCGCCCTGAA 
TGCCCTGCGC 
GCGAGGTGCC 
TCATGGCCGA 
ACCAGGCCAA 
AGGACGACCT 
AGGCCCGCAT 
ACATCATGGT 
CCGACCGCTA 
AGTGGGCCGA 
CCTTCTACCG  
t t g t a c c a a c  
a t g a a a c a t g  
t t a t t c a c g a  
a a t c t c c a t t  
a t c a t a a g a c  
a c a t t t a t a t  
c t g g t a a g a a  
a a a a t t t t a t  
c t a t a g c t c t  
t t a a c g t a a a  
a t a a a g a g a t  
t t t t g a a t g a  
t g a g t g t c c c  
a a t t t a g c a a  
a t g t a g a g t t  
a g c g a a t t c a  
g g t t t a g a a a  
a t g c a a c t g a  
t c a t a g a c g a  
c a c c g t t t c c  
a t c c t g t c a a  
a t c a t a a t c t  
a a c a t c a c a t  
a a a c a t t a c t  
t t c c a c c a c a  
CCCGCCAATC
c a t c g t c a c c  
t t t t t t t t t t  
tg c a c g g A T G  
CCTGTTCGGC 
CCTGTCCGCC 
CGAGCTGCAG 
CGCCGTGCTG 
CGGCCAGGAC 
CGCCATGCGC 
GCACCGCATC 
GGACGAGGAG 
GCCCGACGGC 
GGAGAACGGC 
CCAGGACATC 
CCGCTTCCTG 
CCTGCTGGAC 
g g t t c a a g a t  
g g a t a a a a a a  
a g t t a t t a g g  
ag g a T A A c c a  
c a t g c t a g c g  
g a t t a c t a a c  
t c a c g a t g g t  
t a a t g a g c g t  
g a g a a t t a g a  
c g g a t c a c a g  
a g g t a g a c t a  
t t t c g c a c t a  
t g a a t a t a t a  
t g a t g c t a t a  
t a a t a a a a a a  
t g c t a t a a g a  
t a t g g t a a t a  
t a c a g g a T A A  
t g a t g a t t a t  
c a g a c a t g a a  
a a a a g a c g c g  
t a a t t t c a t c  
c g a a a c a t t g  
g t t c c c a t g g  
t g g g a g a t c t  
TCCGGTCGCT
t g g g a c a t g t
t t t g g c a t a t
ATCGAGCAGG
TACGACTGGG
CAGGGCCGCC
GACGAGGCCG
GACGTGGTGA
CTGCTGTCCT
CGCCTGCACA
GAGCGCGCCC
CACCAGGGCC
GAGGACCTGG
CGCTTCTCCG
GCCCTGGCCA
GTGCTGTACG
GAGTTCTTCT
g t t a a t g t t g
a t c g a a g c a a
g a c t t t a t g a
a t g c a a t g g c
t a t g a t a a t g
g t t g g t c a a t
a c t c c t t a t a
a t c a a g t a t g
a a t a a a t t c a
g t a t a t c a c g
c t a t a c g c a t
t t a a a g t t t a
t t a t a t g g t t
T A A g t t t a t a
g g a a t t g c t a
c t c a t c a a c g
a t a g a c a a t g
c a t c a a g a t a
a a t c c a a a a c
t a t c a t a a g a
g a t c g t a t a a
g g a c a c t a t t
g g a c a a t a t g
c c a t t a c c t a
a c g a t t t t a t
AAc c c g g g
t g c a g a t c c a
a a a t a a g g t c
ACGGCCTGCA
CCCAGCAGAC
CCGTGCTGTT
CCCGCCTGTC
CCGAGGCCGG
CCCACCTGGC
CCCTGGACCC
GCACCCGCAT
TGGCCCCCGC
TGGTGACCCA
GCTTCATCGA
CCCGCGACAT
GCATCGCCGC
a t G c g a a c a t
c g a g c a t t a c
a t a c a t g c a t
a a g c c t a t c c
t a a c a c a a t a
g a t c a t t g a a
a t a t t t t a t a
t a t a c g a t t c
c a T A A a a g c a
t g t t t a t a g g
a c a t a t a t g a
t t a t g t a c t a
c g t a t t t a g g
t a g g a t a t t c
t t a g a a c a a a
a g g t g a c a g a
a t a g t a c t g a
a a t g c g c t a a
g c a a a a t a a a
c c a c t c c g a t
g g c c g a a a c t
g a c t t g a t a a
g t T A A g a t a c
c a g t a a t a c t
c t g t c c a t c c
aaAGCCGTGG
tgcacGCGGC  
g a c a a a a a t t  
CGCCGGCTCC 
CATCGGCTGC 
CGTGAAGACC 
CTGGCTGGCC 
CCGCGACTGG 
CCCCGCCGAG 
CGCCACCTGC 
GGAGGCCGGC 
CGAGCTGTTC 
CGGCGACGCC 
CTGCGGCCGC 
CGCCGAGGAG 
CCCCGACTCC 
t a t a a a t t t a  
t g c g t t t a a a  
c a g t a g a a a a  
t a a a a t g g a t  
t t a t a t t t t a  
t a c a a a a t t t  
t a t a g t a t t t  
t g a g a t a a c g  
a a t a t t a c a c  
a t c a c c c a t g  
t c g t a a t g c c  
t c t a t c t a t a  
a g a a t c c t g g  
t g t t t t c g a t  
c a a t a g a a a t  
a g a t a a a c c c  
t g t t c a a c a c  
t a t t c a g t c g  
t a t c g a a g t c  
a c c g g a g c c t  
t c t t c c t g t a  
t c a t a t a t t a  
a g c g g c a g t t  
g g c a a g a a a g  
a c a t g c g a t a  
GATATGGGCG
Figure A9 vl6A26L.neo Recombination Cassette Sequence
Cassette used to construct vl5A26L.neo virus by replacing EcoGPT (green) with G148R (black) 
expressed from a synthetic early/late promoter (purple), followed by a non-functional A26L (blue). 
Mutations within A26L are highlighted as block capitals. Cassette contains Sma\ restriction sites at 
each end of the construct to allow excision from plasmid vector. Not\ restriction sites were included 
to allow inactivation of G418 R at a later stage if preferred.
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CCCGGGa t g a  g c g a a a a a t a  c a t c g t c a c c  t g g g a c a t g t  t g c a g a t c c a  t g c a c GCGGC
CGCa a t t g g a  t c a g c t t t t t  t t t t t t t t t t  t t t g g c a t a t  a a a t a a g g t c  g a c a a a a a t t
g a a a a a c t a t  t c t a a t t t a t  tg c a c g g A T G  ATCGAGCAGG ACGGCCTGCA CGCCGGCTCC
CCCGCCGCCT GGGTGGAGCG CCTGTTCGGC TACGACTGGG CCCAGCAGAC CATCGGCTGC
TCCGACGCCG CCGTGTTCCG CCTGTCCGCC CAGGGCCGCC CCGTGCTGTT CGTGAAGACC
GACCTGTCCG GCGCCCTGAA CGAGCTGCAG GACGAGGCCG CCCGCCTGTC CTGGCTGGCC
ACCACCGGCG TGCCCTGCGC CGCCGTGCTG GACGTGGTGA CCGAGGCCGG CCGCGACTGG
CTGCTGCTGG GCGAGGTGCC CGGCCAGGAC CTGCTGTCCT CCCACCTGGC CCCCGCCGAG
AAGGTGTCCA TCATGGCCGA CGCCATGCGC CGCCTGCACA CCCTGGACCC CGCCACCTGC
CCCTTCGACC ACCAGGCCAA GCACCGCATC GAGCGCGCCC GCACCCGCAT GGAGGCCGGC
CTGGTGGACC AGGACGACCT GGACGAGGAG CACCAGGGCC TGGCCCCCGC CGAGCTGTTC
GCCCGCCTGA AGGCCCGCAT GCCCGACGGC GAGGACCTGG TGGTGACCCA CGGCGACGCC
TGCCTGCCCA ACATCATGGT GGAGAACGGC CGCTTCTCCG GCTTCATCGA CTGCGGCCGC
CTGGGCGTGG CCGACCGCTA CCAGGACATC GCCCTGGCCA CCCGCGACAT CGCCGAGGAG
CTGGGCGGCG AGTGGGCCGA CCGCTTCCTG GTGCTGTACG GCATCGCCGC CCCCGACTCC
CAGCGCATCG CCTTCTACCG CCTGCTGGAC GAGTTCTTCT A A a a t t g g a t  c a g c t t t t t t
t t t t t t t t t t  t t g g c a t a t a  a a t a a g g t c g  a c a a a a a t t g  a a a a a c t a t t  c t a a t t t a t t
gcacggATG G  CGAACATTAT AAATTTATGG AACGGAATTG TACCAACGGT TCAAGATGTT
AATGTTGCGA GCATTACTGC GTTTAAATCT ATGATAGATG AAACATGGGA TAAAAAAATC
GAAGCAAATA CATGCATCAG TAGAAAACAT AGAAACATTA TTCACGAAGT TATTAGGGAC
TTTATGAAAG CCTATCCTAA AATGGATGAG AATAAAAAAT CTCCATTAGG AGCCCCAATG
CAATGGCTAA CACAATATTA TATTTTAAAG AATGAATATC ATAAGACCAT GCTAGCGTAT
GATAATGGAT CATTGAATAC AAAATTTAAA ACGTTAAACA TTTATATGAT TACTAACGTT
GGTCAATATA TTTTATATAT AGTATTTTGT ATAATATCTG GTAAGAATCA CGATGGTACT
CCTTATATAT ACGATTCTGA GATAACGAGC AATGATAAAA ATTTTATTAA TGAGCGTATC
AAGTATGCAT GTAAGCAAAT ATTACACGGT CAATTAACTA TAGCTCTGAG AATTAGAAAT
AAATTCATGT TTATAGGATC ACCCATGTAT TTATGGTTTA ACGTAAACGG ATCACAGGTA
TATCACGACA TATATGATCG TAATGCCGGT TTTCATAATA AAGAGATAGG TAGACTACTA
TACGCATTTA TGTACTATCT ATCTATAAGT GGTAGATTTT TGAATGATTT CGCACTATTA
AAGTTTACGT ATTTAGGAGA ATCCTGGACA TTTAGTTTGA GTGTCCCTGA ATATATATTA
TATGGTTTAG GATATTCTGT TTTCGATACT ATTGAAAAAT TTAGCAATGA TGCTATACTC
GTTTATATTA GAACAAACAA TAGAAATGGA TATGATTATG TAGAGTTTAA TAAAAAAGGA
ATTGCTAAGG TGACAGAAGA TAAACCCGAT AACGATAAGC GAATTCATGC TATAAGACTC
ATCAACGATA GTACTGATGT TCAACACATA CATTTTGGGT TTAGAAATAT GGTAATAATA
GACAATGAAT GCGCTAATAT TCAGTCGAGT GCTGAAAATG CAACTGATAC AGGACATCAT
CAAGATAGCA AAATAAATAT CGAAGTCGAA GATGATGTCA TAGACGATGA TGATTATAAT
CCAAAACCCA CTCCGATACC GGAGCCTCAC CCTAGACCAC CGTTTCCCAG ACATGAATAT
CATAAGAGGC CGAAACTTCT TCCTGTAGAA GAACCTGATC CTGTCAAAAA AGACGCGGAT
CGTATAAGAC TTGATAATCA TATATTAAAC ACATTGGATC ATAATCTTAA TTTCATCGGA
CACTATTGTT GTGATACAGC GGCAGTTGAT AGGTTAGAAC ATCACATCGA AACATTGGGA
CAATATGCAG TAATACTGGC AAGAAAGATA AATATGCAAA CATTACTGTT CCCATGGCCA
TTACCTACTG TCCATCCACA TGCGATAGAT GGTAGTATTC CACCACATGG GAGATCTACG
ATTTTATAAa g c c g t g g g a t  a t g g g c g t c g  t a t t c g t c c c  g c c a a t c t c c  g g t c g c t a a C
CCGGG
Figure A10 vl5A26L.EL Recombination Cassette Sequence
Cassette used to construct vl5A26L.EL by replacing EcoGPT (green) with G148R (black) expressed 
from a synthetic early/late promoter (purple), followed by A26L (blue) expressed from a synthetic 
early/late promoter (purple). Cassette contains Sma\ restriction sites at each end of the construct to 
allow excision from plasmid vector. Not\ restriction sites were included to allow inactivation of G418 
R at a later stage if preferred.
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